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ABSTRACT 
A vaccine capable of preventing or therapeutically limiting human immunodeficiency 
virus (HIV) pathogenesis is urgently needed to contain the acquired immunodeficiency 
syndrome (AIDS) pandemic.  Recombinant adenovirus (Ad)-based vectors are being explored as 
vaccine candidates due to their potent induction of cell-mediated immunity.  To circumvent the 
limitations of vector-specific humoral immunity, novel Ad serotypes impervious to pre-existing 
immunity against conventional vectors have been developed.  Utilizing the nonhuman primate 
model of HIV infection, we evaluated the immunogenicity of conventional Ad serotype 5- (Ad5) 
and novel serotype 35- (Ad35) based vaccinations against simian immunodeficiency virus (SIV) 
infection.  In a preventative, proof-of-concept vaccination regimen, immunization against the 
SIV Gag protein proved highly efficacious, demonstrating robust boosting of Ad5-based 
vaccine-induced cellular immunity by Ad35-based vectors.  Ad5/Ad35-based vaccination 
induced durable, high-frequency effector T cell responses that were later recalled upon 
heterologous SIV challenge.  Vaccination resulted in modest reductions in SIV viremia, notable 
given the limited scope of immunization.  We then tested the capacity of Ad5/Ad35-based 
vaccination targeting the SIV Gag, Env, and Nef proteins, with or without IL-15 augmentation, 
to promote cellular immunity during antiretroviral-treated chronic SIV infection with the goal of 
limiting rebound viremia following cessation of antiretroviral therapy (ART).  Vaccination 
enhanced both systemic and mucosal antigen-specific cell-mediated immunity, increasing the 
breadth and strength over innate response to infection.  Ad-induced immunity consisted of CD4+ 
and CD8+ T lymphocyte TH1 cytokine production of a predominantly monofunctional nature.  
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Furthermore, vaccination enhanced both central and effector memory CD4+ and CD8+ T cell 
populations without augmenting naive T cell responses.  Although Ad-based immunotherapy 
transiently restored the systemic central memory CD4+ T cell compartment, vaccination failed to 
salvage effector memory or mucosal CD4+ T cells.  Therapeutic intervention was associated with 
transient containment of rebound viremia upon ART cessation which vaccination failed to 
augment.  An effective vaccination against HIV represents the most efficient method to end the 
AIDS pandemic, and is of considerable public health significance.  The findings presented herein 
provide evidence to support the continued evaluation of Ad-based vectors in novel treatment 
strategies against HIV infection, representing an incremental advancement in the field of HIV 
vaccine development.                   
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1.0  INTRODUCTION 
Throughout human history, the struggle for survival has been intertwined with the battle 
against infectious diseases.  For the vast majority of human existence, this battle was fought 
blindly against an unidentified assailant until a technological breakthrough, unheralded initially, 
lead Antony van Leeuwenhoek to examine the nature of the microbial world.  Still unaware of 
the microscopic enemy, Edward Jenner combined astute observation with cultural traditions to 
administer the first effective vaccination, inoculating patients with the related cowpox virus to 
confer protection against lethal smallpox.  These simple experiments would prove to be a 
milestone of modern medicine, providing the first instance of human intervention affecting the 
course of infectious illness through directly targeting the pathogen responsible.  With 
microbiology still in its infancy, Louis Pasteur excited the world with his miraculous protection 
of cattle from anthrax, chickens from cholera, and most dramatically, the treatment of a young 
boy with rabies utilizing attenuated organisms for vaccination.  Yet, for as spectacular a 
showman as Pasteur had become, it was the methodic and dedicated examination of Robert Koch 
that would finally demonstrate the role of microbes as the causative agents of disease.  Through 
formulating the Koch’s postulates, medical science had now identified its enemy.   
 Well over 300 years since the recognition of microbes, much of modern medicine is still 
focused on preventing their deleterious effects upon mankind.  Whether they are established, 
historical diseases such as tuberculosis, emerging infectious diseases such as the SARS-
coronavirus or zoonotic influenza infections, or re-emerging diseases as is the case with 
antibiotic resistant bacterial infections, microbial pathogens remain one of the most significant 
threats to global health.  In this context, human immunodeficiency virus type 1 has become 
known as arguably the most elusive and deadly pathogenic agent in history.  In as much, the 
study of the HIV has pushed the fields of virology and immunology to greater heights, and 
spawned a new generation of researchers, clinicians, and activists in an attempt to curtail the 
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massive social and physical destruction caused by disease.  With no cure in site, the fight against 
HIV infection is one of the preeminent battle grounds of modern medical science, whose 
outcome will influence all aspects of human society on a global scale.                             
1.1 HIV AND SIV 
The human immunodeficiency virus type 1 (herein referred to as HIV) is a member of the 
Retroviridae family of the Lentivirus genus.  Nucleotide sequence comparisons allow for 
distinction of three groups of HIV isolates differing between 15-20%, consisting of the M (most) 
group, further divided into eleven clades (subtypes A-D, F-H, J, and K), group O (outlier) and 
group N [1].  HIV is an enveloped virus of roughly 110 to 146 nm in length [2].  The HIV 
genome is composed of two positive single-stranded RNA molecules 9747 base pairs in length 
containing nine open reading frames coding for structural (Gag, Pol, Env), regulatory (Tat and 
Rev), and accessory (Vpu, Vpr, Vif, and Nef) proteins.  The defining characteristic of HIV is its 
remarkably error-prone reverse transcriptase, which in conjunction with the influences of 
immune and drug pressure, as well as host genetics, leads to exceptionally rapid viral evolution.     
The HIV lifecycle begins with viral adhesion to its cellular target, with subsequent 
receptor-mediated entry into the cellular cytoplasm facilitated by recognition of the viral gp120 
envelope trimer with the cellular primary and co-receptors, CD4+ and CCR5+/CXCR4+, 
respectively [3].  Upon viral entry, the HIV virion is uncoated allowing for the reverse 
transcription of its RNA genome into linear double-stranded DNA before translocating to the 
nucleus and becoming permanently integrated into the genome of its host cell, a hallmark of 
retroviruses.  Integrated proviral DNA establishes latent viral reservoirs which may lay dormant 
for years before the host cell becomes activated, initiating transcription and replicating the viral 
genes necessary for HIV reproduction [4, 5].  Although viral reproduction occurs primarily in 
activated CD4+ T cells, resting host cells have been shown to continually produce low levels of 
progeny virus.  Proviral DNA is transcribed, exported to the cytoplasm, and subsequently 
translated by host cellular mechanisms.  Viral proteins congregate at the cellular membrane, 
where they undergo virion assembly and proteolytic cleavage, allowing for the budding release 
of infectious progeny.      
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The simian immunodeficiency virus (SIV), first discovered in 1985 [6], has been shown 
to infect over 30 species of nonhuman primates [7], and is divided into six major lineages 
representing genetic variation and host origin [8].  Infection by species-adapted SIV in its natural 
host is nonpathogenic due to prolonged host-dependant evolution, resulting in sustained 
moderate SIV viremia with low level immune induction without disease progression [8].  
Conversely, host infection by SIV strains of divergent evolution, such as inoculation of Asian 
macaques with established African SIVmac, closely mimics human HIV infection, resulting in 
acute and chronic pathogenesis, progression to AIDS, and the development of opportunistic 
infections [8].  Recently, it has been shown that human HIV infection resulted from three distinct 
incidences of zoonotic transmission of SIVcpzPtt from the chimpanzee species Pan troglodytes 
troglodytes in western central Africa leading to the emergence of the pandemic M, and non-
pandemic O and N clades of HIV [9, 10].  The emergence of SIVcpzPtt itself resulted from 
cross-species super-infection of chimpanzees with SIVrcm and SIVgsn from red-capped 
mangabeys and greater spot-nosed monkeys, respectively, allowing for viral recombination and 
presumably genetic speciation [11, 12].  Speculatively, HIV acquisition by humans and 
SIVcpzPtt acquisition by chimpanzee occurred through cross-species blood-borne transmission 
from hunting and preying upon monkeys naturally infected with species-adapted SIV.  For these 
reasons, non-adapted SIV infection of nonhuman primates is currently the most suitable model of 
HIV infection and intervention [6, 13, 14].          
1.2 THE HIV PANDEMIC 
1.2.1 History 
The HIV pandemic likely originated in western central Africa [15], as it is the only 
known region where HIV clades M, N, and O, as well as SIVcpzPtt infection of humans and 
chimpanzees, respectively, are found to coexist [9, 16, 17].  The oldest known HIV isolate, found 
to be clade M, was derived from a 1959 plasma sample from a man in what is now the 
Democratic Republic of Congo [18], and evolutionary modeling has estimated the emergence of 
HIV clade M at around 1930 ± 20 years [19].  In the summer of 1981, a mysterious and 
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horrifying rash of premature deaths caused by unusually rare diseases was first observed in the 
United States [20].  In September of 1982, the U.S. Centers for Disease Control and Prevention 
dubbed this mysterious plague acquired immunodeficiency syndrome (AIDS) due to the 
progressive loss of immunity seen in effected patients.  The following year, independent groups 
lead by Luc Montagnier, Robert Gallo, and Jay Levy isolated the HIV virus and identified it as 
the etiologic agent leading to the development AIDS [21-25].  HIV pathogenicity was quickly 
recognized to include severe depletion of CD4+ T lymphocytes, heightened susceptibility to 
opportunistic pathogens, and increased incidences of lymphoma and Kaposi’s sarcoma [26].     
1.2.2 Current Status  
As of 2007, there were an estimated 2.5 million new HIV infections and 2.1 million 
deaths due to HIV, accounting for 33.2 (30.6-36.1) million people living with HIV/AIDS 
worldwide [27].  No country has been spared by the HIV pandemic, which effects regions 
through either concentrated epidemics in which pockets of high-risk individuals such as 
intravenous drug users, sex workers, and men who have sex with men are affected, or as 
generalized epidemics involving heterosexual transmission which become self-sustaining 
through high national incidence rates.  The highest HIV incident rates are in sub-Saharan Africa, 
accounting for roughly 68% of people living with HIV/AIDS worldwide, including 90% of child 
infections and 76% of HIV-associated deaths [27].  HIV transmission is dependent upon the 
infectiousness of the index case, determined through concentration of cell-associated and cell-
free virus transmitted in body fluids, along with the susceptibility of the naïve host [28].  
Notably, the susceptibility of each individual to infection varies dramatically and is influenced 
by genetic factors, such as the presence of specific human leukocyte antigen (HLA) types or 
mutations within the cellular HIV coreceptor CCR5Δ32 [29, 30], by the presence of sexually 
transmitted infections which increase skin lesions and HIV target cell numbers in the genital 
mucosa, and by the presence of physical barriers such as foreskin [28, 31].  HIV infection is 
predominantly spread through heterosexual intercourse (~80%), with intravenous drug use, 
unprotected anal intercourse, and mother to child transmission pre- or post-partum remaining 
significant methods of viral transfer.  
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1.3 HIV/SIV PATHOGENESIS 
1.3.1 Acute Destruction 
The preeminent mechanism of HIV pathogenesis is the viral-mediated elimination of 
CD4+-expressing T helper lymphocytes responsible for providing the cytokine support necessary 
for the induction and propagation of antiviral cellular and humoral immunity.  Within days 
following the establishment of HIV infection, virus disseminates throughout receptive cellular 
targets of the body residing predominantly in the genital, intestinal, and respiratory mucosal 
tracts, as well as the lymph nodes, thymus, and spleen [32-36] primarily via cell-to-cell 
transmission [37, 38].  Specifically, the majority of viral strains deplete activated, HIV-specific 
CD4+ effector memory T cells (Tem) bearing the tissue directing CCR5 chemokine receptor [39-
42] found in the lamina propria of the mucosal tissues [33, 43, 44].  Yet, this effect is not 
exclusive, as HIV-mediated depletion of resting CD4+ T lymphocytes has been well documented 
[34, 45].  The loss of CD4+ Tem cells is highly correlated to immunodeficiency, as they provide 
antigen (Ag)-specific anamnestic clearance of HIV/SIV, as well as defense against opportunistic 
infections.  Concurrently, HIV-mediated elimination of CD4+ central memory T cells (Tcm) 
further disrupts T cell homeostasis, as the Tcm population is responsible for CD4+ T cell 
memory regeneration through clonal expansion and differentiation.  In addition, HIV/SIV 
disease control has been associated with the ability of systemic CD4+ Tcm cells to replenish 
depleted CD4+ Tem populations systemically and at the mucosa [46].  Traditionally, CD4+ T cell 
depletion has been monitored in the peripheral blood, yet only 2-5% of total lymphocytes reside 
there, with the majority of these cells harbored in the gut-associated lymphoid tissue (GALT), 
estimated at 60%, and subsequent mucosal tissues [47].  Recent studies have demonstrated that 
the viral-mediated destruction of CD4+ Tem at sites of the mucosa occurs almost immediately, 
leading to greater than 90% elimination of the mucosal CD4+ Tem population by 14 days post-
infection, and is not reflected in the peripheral blood until chronic stages of disease [33, 48-51].  
The pathogenesis of acute mucosal CD4+ T cell loss is exemplified by the fact that restoration, 
either naturally or following ART, of GALT CD4+ Tem cells has been identified in long-term 
non-progressor macaques [52, 53].  The primary burst of acute HIV viremia is thought to be 
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sequestered by the virally-reduced frequency of available cellular targets in conjunction with the 
development of adaptive antiviral immunity.   
1.3.2 Viral Latency 
Immediately upon HIV infection, proviral integration into host DNA establishes a 
permanent reservoir in all anatomic locations capable of extended latency.  Due to dependence 
on cellular transcriptional machinery, 99% of viral replication occurs in activated productively 
infected CD4+ T cells.  HIV infected memory T cells which return to a resting state may stably 
preserve the viral reservoir for the life of the cell, potentially decades [54, 55].  Monocytes, 
macrophages, and dendritic cells (DC) may contribute to HIV latency through trafficking 
associated viral particles and nominal productive infection, but these cells contribute minimally 
to long-term latency [56, 57].  Even as ART is capable of restricting viral replication to 
undetectable levels, individuals harbor an estimated latent pool of roughly 106-107 cells, or 0.1-1 
HIV infected cells per million T lymphocytes [58-61].  Furthermore, the establishment of the 
viral reservoir seems unavoidable, as studies have found that ART given before seroconversion 
fails to prevent latent infection [62].  Mathematical models of viral reservoir decay kinetics have 
postulated that a current ART regimen would need to be sustained for 60 years to provide 
potential eradication of the latent pool [63].  Immune activation therapy, aimed at activating 
latent proviral replication under the protection of ART, would allow for the clearance of latently 
infected cells through viral cytopathic effects or immune targeting [64].  To this end, studies 
have employed the cytokines Interleukin-2 (IL-2), IL-6, interferon-γ (IFN-γ), and tumor necrosis 
factor-α (TNF-α), the anti-CD3 mAb OKT3, and the chemical activators cyclophosphamide and 
valproic acid [65-69].  Immune activation therapy utilizing IL-2 alone or with other agents 
during ART was found to reduce the number of resting CD4+ T cells containing latent virus and 
increase proliferation, but failed to lower rebound viremia upon cessation of ART [67-69].  As 
the presence of the HIV reservoir prohibits viral clearance, novel therapeutic interventions must 
be combined with ART to inhibit disease progression.   
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1.3.3 Cellular Pathogenesis: AIDS 
1.3.3.1 Regenerative Exhaustion  
When compared with nonpathogenic species-adapted SIV infection, the 
immunopathology of HIV is a consequence of chronic activation [70-74].  Remarkably, 
measurements of T lymphocyte activation are more precise indicators of disease progression than 
plasma viral loads [75].  While continual HIV and SIV cytotoxicity eliminates CD4+ T cells and 
receptive targets, it creates a prolonged inflammatory environment capable of bystander cellular 
destruction and permanent restructuring of lymphoid and mucosal tissues negatively impacting 
cellular homeostasis [76-78].  Chronic CD4+ T cell destruction consists of the gradual decline in 
remaining CD4+ targets characterized by impaired regenerative capacity, draining of the naïve T 
cell pool, activation-induced cell death, as well as continual viral-mediated killing seen during 
prolonged infection [36].  Labeling studies utilizing 5-bromo-2-deoxyuridine (BrdU), Ki-67 
staining, or 2H-glucose in vivo in humans and nonhuman primates have demonstrated 
disproportionate loss of proliferating CD4+ memory T cells, due to the intrinsic brief life 
expectancy of activated memory cells in addition to viral cytopathicity and elimination by Ag-
specific CD8+ T cells [36, 79-82].  Furthermore, memory CD4+ T cells are inherently more 
susceptible to apoptosis via activation-induced cell death, Fas-Fas-ligand interactions, and other 
apoptotic signals present during systemic inflammation [83-85].  Rapid cellular turnover occurs 
in conjunction with limited repopulation of CD4+ T cells due to age-dependent declines in 
thymopoiesis [86], suggested to be a key factor in cellular reconstitution during ART or 
controlled HIV infection [87-92].  Ag-driven expansion of memory CD4+ T cells is limited 
compared to memory CD8+ T cells [93-95], with fewer activated CD4+ T cells standing-down 
and returning to long-lived resting states [96-98].  Additionally, acute pathogenesis to GALT 
immunity and the breach of structural integrity at the intestinal epithelium allow for microbial 
translocation, further exacerbating chronic immune activation [99, 100].  Generalized activation 
affects CD4+ T lymphocyte homing and recirculation from the peripheral blood, lymphoid, and 
extralymphoid effector sites, likely inducing redistribution to areas containing a high 
concentration of virally infected cells such as the GALT or lung mucosa, creating a positive 
feedback loop of expansion, recruitment, and local viral-mediated elimination of memory CD4+ 
T cells [101-103].  Thus, limitations in the generation of CD4+ T cells through age-attenuated 
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thymic output and Ag-driven peripheral expansion are concurrent with rapid CD4+ T cell loss 
which progressively exhausts the body’s regenerative capacity, removing CD4+ T helper 
function and promoting the collapse of CD8+ cytotoxic T lymphocyte (CTL) containment of 
chronic, set-point viremia.   
1.3.3.2 Dysfunctional Cellular Immunity 
Establishment of chronic, set-point viremia is a consequence of the rapid elimination of 
available CD4+ T cell substrates for HIV [104] in conjunction with the development of effective 
T cell-mediated immunity [105-107].  HIV-specific CD4+ and CD8+ T cells become refractory to 
Ag-specific proliferative induction due to their post-activation state and continual stimulation by 
chronic viremia [108, 109].  During progressive HIV and SIV infection, the ability of effector T 
lymphocytes to recognize viral Ag decreases as CD8+ T cells frequently contain T cell receptors 
(TCR) of low functional avidity and disruptions in signal transduction that together can lead to 
gaps in the immune repertoire with clonal deletion or exhaustion [110-114].  In addition, 
dysfunctional HIV-specific CTLs have been shown to lack efficient perforin and granzyme B 
production, inhibiting cytolytic functions [115, 116].  Notably, CTL-mediated killing and 
antiviral restriction governed through cytokine production are dramatically diminished or 
dysfunctional during progressive disease.  Rapid dysfunction of CD4+ T lymphocyte production 
of IL-2, IFN-γ, and TNF-α occurs during SIVmac251 infection in as early as ten days [117].  In 
addition, skewed maturation of CD8+ T cell populations results in an overabundance of CD8+ 
Tem cells, often with limited expression of effector molecules such as CD27 and CD28, as well 
as homing receptors necessary for proper function [118-120].  Furthermore, Ag-specific CTLs 
over-express the negative regulatory molecule PD-1 during progressive HIV infection, 
associated with T cell exhaustion, compounding immune dysfunction through both lack of 
appropriate Ag-specific reaction as well as negative regulatory inhibition of responses [121-123].  
The viral-induced disruption of the cellular immune compartment during chronic infection 
prevents effective clearance of latent cell associated viral reservoirs.   
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1.4 ANTIRETROVIRAL THERAPY 
The utilization of ART has transformed HIV infection into a chronic illness, capable of 
extending a patient’s life expectancy and reducing disease associated morbidity [124].  The 
restriction of viral replication by ART provides immediate physical benefit, allowing for the 
replenishment of CD4+ T cell numbers, reduced immune activation, and restoration of Ag-
specific cellular immunity and proliferative capacity [125, 126].  Although ART may reduce 
plasma viral concentrations to undetectable levels, ART is insufficient to provide sterilizing 
immunity, as latent viral reservoirs are unaffected by current pharmacologic interventions 
providing continual low-level, cryptic viral replication [127].  In rare instances when ART is 
initiated early during acute HIV or experimental SIV infection, acute pathogenesis is inhibited, 
establishing a diminished rate of viral destruction and disease course [128].  Combinations of 
antiretroviral drugs targeting multiple stages of the HIV lifecycle including entry into host cells, 
reverse transcription of the RNA genome to DNA, integration of proviral DNA into the host 
genome, and maturation of formed virions, have enhanced the duration of therapeutic efficacy 
[129].  Unfortunately, the extraordinarily high rate of HIV replication and genomic error 
incorporation allow for the development of drug resistant and multi-drug resistant quasispecies to 
all known inhibitors available [130].  In conjunction, the associated toxicity and financial burden 
of ART make therapeutic intervention either unavailable or unsustainable for the vast majority of 
persons living with HIV worldwide.   
Early attempts to alleviate drug toxicity and side effects while promoting HIV-specific 
immunity were performed through structured treatment interruptions (STI) of ART.  Therapeutic 
re-exposure to HIV Ag through STI allowed for contained viremia if ART was initiated during 
early infection prior to irreparable immunologic damage [131].  Unfortunately, viral rebound and 
subsequent expansion of the cell-associated viral reservoir during STI nullifies the potential 
benefit of stimulating naïve and functional cellular memory [132].  Notably, reduced viremia 
following STI was consistently associated with the functional capacity of CD4+ Tcm cells to 
produce IL-2 and IFN-γ, of CD4+ and CD8+ Tem cells to produce IFN-γ, and the 
lymphoproliferative response to recall antigens in all existing therapeutic strategies [40, 133-
135].  These findings suggested that therapeutic augmentation of HIV-specific cellular immunity 
may potentially contain chronic viremia in the absence of life-long ART.      
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1.5 INTERLEUKIN-15 
1.5.1 Biologic Function 
Inerleukin-15 (IL-15) is a pleiotropic, immunoregulatory cytokine belonging to the 
common cytokine receptor γ-chain family with profound influence on innate and adaptive 
immunity against intracellular pathogens [136].  IL-15 protein production is strictly regulated 
through translational inhibition via the inclusion of 12 upstream AUG start codons in the 5’ UTR 
of IL-15 mRNA and by secondary RNA structures of the C-terminus, as well as trafficking and 
translocation restrictions mediated by the presence of distinct long and short signaling peptides 
encoding for secreted and intracellular cytokine localization, respectively [137-140].  Secreted at 
times, IL-15 is most frequently membrane-bound in association with the IL-15-specific IL-15Rα, 
allowing for endosomal recycling and trans presentation of the IL-15 complex to neighboring 
cells following production by DCs, monocytes, and macrophages [141, 142].  The membrane-
associated IL-15 presentation from antigen presenting cells (APCs) allows for B and T cell Ag 
recognition and stimulation in the context of IL-15 co-expressed with co-stimulatory molecules 
and activation factors, modifying the adaptive TH1-biased immune response following cell-to-
cell activation [141].  As a member of the common cytokine receptor γ-chain family, IL-15 
induces some redundant actions with IL-2, IL-21, and others due to shared elements of receptor-
mediated signaling through the common family γc receptor and IL-2/15Rβ chain subunit leading 
to Janus kinase (JAK) and signal transducer and activator of transcription systems (STAT) 
activation [143].  Signaling through its high-affinity heterotrimeric receptor including the IL-15-
specific IL-15Rα component activates pathways specialized for stimulating the proliferation of 
activated CD4+ and CD8+ T cells through FKBP12-mediated activation of p70 S6 kinase, 
generation of memory CD8+ CTLs, synthesis of immuonoglobulin from B cells, expansion of 
natural killer (NK) cells, and importantly, the formation and maintenance of cellular memory 
populations [144-150].  Notably, IL-15 induces the proliferative expansion of CD4+ and CD8+ 
Tem cells, of virus-specific CD8+ Tcm cells necessary for long-lived immunologic memory, as 
well as the Ag-independent expansion and differentiation of naive CD8+ T cells [149, 151-153].  
Interestingly, IL-15Rα expression is found in a wide variety of cells and tissues, with associated 
affects ranging from anabolic stimulation of skeletal muscle, growth of mast cells, to microglial 
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maintenance, illustrating the broad systemic influences of the cytokine [143, 154].  IL-15 
promotes survival and inhibits apoptosis of CD4+ and CD8+ T cells induced via cytokine-
deprivation, TNF-, and Fas-mediated pathways through the production of the anti-apoptotic 
proteins Bcl-2, Bcl-XL, and c-FLIP [155-160].  In addition, IL-15 is a chemoattractant for T 
lymphocytes, but not B cells, monocytes, or neutrophils [161, 162].  It should be noted that due 
to its potency as a pro-inflammatory mediator, IL-15 has been associated with autoimmune 
disorders and T cell-mediated alveolitis in AIDS patients, and should be carefully evaluated in 
nonhuman primate models [163, 164].   
1.5.2 Immunotherapeutic Application 
IL-15 is strongly implicated in HIV pathogenesis as IL-15 deficiencies have been 
identified in patients with progressive infection [165], while IL-15 maintenance is associated 
with viral containment both during and without ART intervention [166], and high plasma IL-15 
levels are associated with viral containment during STI from ART [167].  PBMC from HIV-
infected individuals fail to produce adequate amounts of IL-15 upon ex vivo stimulation with 
herpes simplex virus-1 or Staphylococcus aureus compared to healthy donors [165, 168].  
Monocyte-derived DCs harvested from progressive AIDS patients have been shown to be 
severely compromised in their ability to produce IL-15 in response to bacterial 
lipopolysaccharide (LPS) or Candida albicans [169].  In the context of these findings, IL-15 is 
uniquely suited as a therapeutic agent for HIV due to its limited mitogenic effects on CD4+ T 
cells compared to IL-2 treatment, minimizing de novo viral synthesis from activated 
lymphocytes [166, 170, 171].  Furthermore, IL-15 induces Ag-specific expansion and Ag-
independent propagation and maintenance of memory CD8+ T cells in the absence of CD4+ T 
cell help, a valuable characteristic given the profound CD4+ T cell depletion throughout HIV 
infection [172-174].  Treatment of CD8+ T cells from HIV infected individuals with exogenous 
IL-15 restored defects in activation, IFN-γ production, and direct cytotoxicity in HIV-specific 
memory CTLs [171, 175].  Addition of IL-15 to PBMC ex vivo modulates the production of the 
β-chemokines RANTES, MIP-1α, and MIP-1β from CD4+ and CD8+ T cells in HIV infected 
treatment-naïve, ART responding, and ART failing individuals [176].  Exogenous IL-15 has 
been shown to salvage fragile lymphocyte populations during HIV infection, enhancing 
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prolonged survival in culture [175].  Treatment of chronic SIV infected macaques with systemic 
IL-15 enhanced CD4+ Tem cell function and proliferation, and promoted extralymphoid tissue 
emigration of T lymphocytes [177].  In conjunction with restoring function, systemic IL-15 
treatment during chronic SIV infection bolsters CD8+ Tem and NK cell populations, without 
affecting CD4+ T cell or macrophage numbers or increasing viral loads [178].   
The ability of IL-15 to promote the development of cellular memory and TH1 immunity 
makes it an ideal adjuvant for vaccination against intracellular pathogens.  Immunization studies 
in the murine model have demonstrated that co-immunization of plasmid DNA encoding HIV 
gag with an optimized IL-15 construct enhanced the magnitude of the Ag-specific IFN-γ 
response over that seen with Ag alone [172].  Additionally, use of IL-15 as an adjuvant promoted 
superior Ag-specific immunity when compared to IL-2, inducing a more potent and durable Ag-
specific CD4+ and CD8+ T cell responses in both murine and nonhuman primate immunization 
models [179, 180].  Recent studies have demonstrated that delivery of plasmid encoding an 
optimized IL-15 in conjunction with a DNA-based multigene SIV vaccine in macaques induced 
robust antiviral IFN-γ production from CD4+ and CD8+ T cells, enhanced proliferative 
responses, and provided more rapid control and protection from a SIV/HIV-hybrid virus, 
SHIV89.6P, challenge over animals receiving SIV vaccination alone [181].  Interestingly, 
immunization utilizing plasmid SIV gag DNA alone in conjunction with plasmid IL-15 co-
immunization failed to contain viral SHIV89.6P challenge due to minimal development of 
cellular and humoral immunity [182].  Finally, recent findings have demonstrated that sequential 
administration of IL-12 followed by IL-15 plasmid DNA enhanced dual-functional antiviral 
cytokine responses induced through multigene plasmid DNA immunization during ART-treated, 
chronic SIVmac251 infection [183].       
1.6 ADAPTIVE IMMUNITY TO HIV INFECTION 
1.6.1 Humoral Immunity 
The humoral immune response to HIV infection is marked by the gradual development of 
highly functional antibodies (Ab) in conjunction with ongoing mutation and sophisticated viral 
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escape mechanisms limiting immunologic control.  Conventional models have suggested that 
upon HIV exposure, naïve B cells will take up to four months of maturation and IgG receptor 
mutation in lymph node germinal centers to develop into plasma cells capable of high avidity Ab 
production.  Recent studies have demonstrated the presence of functional neutralizing antibody 
(NAb) early during acute HIV infection, dispelling conventional thought that immune control of 
acute viremia is exclusively based upon cellular immunity [184-186].  Free virion neutralization 
occurs through Ab-mediated interference with viral fusion and subsequent cellular entry, or by 
blocking viral uncoating and subsequent replication [187].  HIV-specific NAbs function through 
binding viral elements necessary for association with the CD4 receptor, the cellular coreceptors 
CCR5 and CXCR4, or cell-virion fusion domains exposed during conformational shifts 
necessary for membrane fusion [188].  Within weeks, humoral responses directed against viral 
structural proteins develop, primarily targeting the gp120 surface unit and gp41 transmembrane 
region of HIV envelope.  Paradoxically, only a small fraction of Ab epitopes in exposed 
envelope trimers elicit potent neutralization, with conformational and glycosylation-based 
shielding of functionally optimal epitopes evading immune recognition [189].  Ultimately, the 
magnitude and breadth of NAb activity increases over time, with robust responses acquired only 
during chronic infection.  Furthermore, immunologic pressure from NAbs drives viral evolution, 
as NAbs preferentially recognize viral strains preceding their development, but are less effective 
at targeting contemporary viral isolates [190].  Passive administration of broadly NAbs either 
systemically or at the vaginal mucosa has been shown to prevent infection of nonhuman primates 
with a SHIV virus containing the HIV envelope upon an SIV backbone [191-194].  Although 
viral immune evasion due to selective NAb pressure serves as the most conclusive evidence for 
the protective role of humoral immunity, studies utilizing passive NAb immunization early, 
during acute HIV infected humans and nonhuman primates infected with pathogenic SIV strains 
have demonstrated modest reductions in plasma viremia and rapid viral mutation, further 
illustrating the utility of focusing NAb responses [192, 195, 196].  By contrast, passive 
immunization utilizing NAb fails to reduce established, chronic infection, rapidly selecting for 
viral escape variants [194].  Taken together, these findings illustrate that although the humoral 
immune response plays a key role in viral suppression during acute and choric HIV/SIV 
infection, Ab-mediated immunity alone is insufficient to contain viremia during established 
infection.           
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1.6.2 Cellular Immunity 
Despite massive efforts, the precise correlates of protective immunity against HIV 
infection remain elusive.  While merely one component of the complex and coordinated response 
that will be necessary to contain HIV infection, the ability of cellular immunity to ameliorate 
HIV/SIV infection has been well documented.  Early findings demonstrated that the reduction in 
acute HIV viremia is temporally associated with the appearance of antiviral CD8+ T cell-
mediated immunity [105, 106].  Studies depleting CD8+ T cells in the rhesus macaque model 
have correlated the development and maintenance of an adaptive CTL response with control of 
acute SIV viremia [107, 197, 198] and containment of chronic set point viral loads [199].  
Furthermore, containment of rebound SIV viremia following cessation of ART during STI has 
been associated with robust sustained SIV-specific cellular immunity induced through 
therapeutic immunization [200, 201].  The protective role of cellular immunity during HIV 
infection is further supported by the finding that HIV-infected individuals homologous at any of 
three different loci in human leukocyte antigens (HLA) alleles, limiting T cell repertoire and 
viral epitope recognition, undergo accelerated disease progression [202].  Interestingly, HLA 
diversity by itself does not account for virologic control, as qualitative distinctions have been 
made between long-term non-progressors carrying the HLA-B57, HLA-B27, and HLA-B51 
alleles and rapid progressors presenting HLA-B35, illustrating inherent qualitative differences in 
the ability of epitope-specific T cell responses to contain viremia [203-205].   
T cell-dependant restriction of viral infection occurs through the production of soluble 
mediators, such as inhibitory β-chemokines and cytokines, as well as the direct cell-mediated 
lysis and induced apoptosis of viral infected cells [206, 207].  Detection of an infected cell 
through the recognition of major histocompatibility complex (MHC) class I-bound viral peptide 
by the specialized TCR and co-stimulation signals of an activated CTL initiates the vectorial 
release of perforin and granzymes A and B to initiate target cell apoptosis [206].  TCR ligation 
subsequently induces the release of IFN-γ and TNF-α, TH1 cytokines with broad spectrum 
antiviral activity including: recruitment of macrophages, NK cells, and T cells, polarization of T 
cell responses to TH1 antiviral cytokine profiles, and the upregulation of MHC class I molecules, 
Ag processing, and Ag transport within locally infected cells [208].  Cellular cytokine-mediated 
viral clearance is facilitated by the activation of host cellular mechanisms to interrupt viral 
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replication, such as activation of the RNAse L or PKR pathways to degrade single and double-
stranded viral RNA, respectively [208].  Additionally, activated T cells contribute to bystander 
killing through the production and upregulation of Fas-ligand, allowing for the induction of 
apoptosis through contact-dependant Fas-FasL-mediated signaling of both infected cells and 
those in the local vicinity [209].  Generally, MHC class I-restricted CTLs kill predominantly 
through the perforin/granzyme pathway, whereas CD4+ T cells rely primarily on Fas-FasL-
dependant apoptosis due to the limited target cell expression of MHC class II molecules [209].  
Additionally, CD4+ T helper function is essential in the propagation and maintenance of both 
central and effector memory lymphocyte compartments.               
  HIV/SIV containment has traditionally been associated with the overall magnitude of 
the Ag-specific CD8+ CTL and CD4+ T helper response, conventionally measured through IFN-γ 
production and target cell lysis [210-212].  Additionally, increased breadth of CD8+ T cell-
restricted epitopes targeted has been associated with viral control at all stages of infection [213].  
Recently, our understanding of the composition of T cell-mediated immunity has expanded, as 
Ag-specific responses from CD4+ Tcm cells were shown to have dramatic influence over 
HIV/SIV disease progression during natural infection, therapeutic intervention, and vaccine-
mediated protection [46, 214].  Concurrently, the ability of memory CD4+ and CD8+ T cells to 
proliferate upon HIV/SIV stimulation, allowing for repopulation of effector T cells and 
regeneration of CD4+ T helper support, is associated with reduced viremia [46, 215].  These 
factors are intrinsically linked to the ability of CD4+ Tcm cells to differentiate, expand, and 
produce IL-2, regenerating the CD4+ Tem and sustaining memory CD8+ T cell levels [46, 215, 
216].  Yet, these factors alone are insufficient for viral containment, as individuals with 
progressive AIDS have been identified with potent and broad T cell-mediated immune 
responses.  Detailed evaluation of cellular immunity has revealed that not all responses are 
created equal.  Studies involving treatment-naïve HIV-positive individuals have associated Gag-
specific CD8+ T cell-mediated IFN-γ production with superior control of plasma viral load, and 
Env-specific responses with lack of virologic containment, suggesting an immunologic 
advantage in targeting evolutionarily constrained viral epitopes [217].  Similarly, CTL responses 
mediated by the rare HLA-B*1503 allele were found to control HIV clade B infection when 
subdominant epitopes were presented, but failed to control clade C infection in the absence of 
subdominant epitope presentation [218].  Furthermore, the diversity of the antiviral effector 
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cytokine profile has been implicated in HIV elite controllers, individuals who innately control 
HIV viremia, and ART responders, with heterogeneic polyfunctional profiles including IL-2, 
IFN-γ, TNF-α, CD107, MIP-1α, and MIP-1β associated with superior viral restriction [219-222].  
Taken together, these findings suggest that the qualitative natural of the cellular immune 
responses against HIV is equal to, if not more important than its magnitude.            
1.7 HIV IMMUNE EVASION  
HIV replication results in roughly 109 new virions produced each day, with an estimated 
viral mutation rate of approximately one nucleotide alteration in every 105 bases due to the lack 
of proofreading activity by the reverse transcriptase enzyme [223].  Containing a viral genome of 
104 bases, a mutation may be expected to occur at least once at every possible location in the 
HIV genome each day.  With such extreme evolutionary flexibility, HIV rapidly evolves to 
escape selective immunologic pressure.  Viral escape from CTL-mediated elimination occurs 
through mutations in epitope sequences, ablating peptide presentation, antigenic processing, and 
subsequent recognition by CD8+ T cells [224].  CTL escape has been shown to occur rapidly 
during acute infection, as well as continually throughout progressive disease in both chronic HIV 
and SIV infection [225-228].  Following SIV infection of five sibling macaques, animals capable 
of specific Env and Nef CTL epitope recognition had potent immunologic responses to infection 
with concomitant CTL escape mutations, but prolonged survival, whereas related animals 
lacking effective CTL recognition profiles during primary infection progressed rapidly, 
illustrating the associated cost in viral fitness following CTL escape [226].  Similarly, rapid viral 
escape was observed in vivo following adoptive transfer of clonally expanded Nef-specific CTLs 
into an HIV-infected patient, demonstrating the clinical relevance of the escape phenomenon 
[229].   
In contrast to the altered processing and presentation mechanisms seen in CTL escape, 
viral escape from Ab-mediated humoral immunity is predominantly facilitated by physical 
occlusion and changes in structural confirmation, ablating Ab epitope recognition [190].  Ab-
mediated selective pressure was demonstrated in vitro following growth of HIV in the presence 
of the gp120 targeting NAb G3-4, leading to rapid viral variants expressing single amino acid 
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substitutions ablating Ab epitope recognition [230].  Not surprisingly given the precise 
conformational dependence of Ab epitope recognition, single amino acid changes in gp41 were 
shown to alter the exposure of multiple NAb binding domains in gp120, and amino acid 
substitutions in envelope have been shown to cooperate in reducing the overall sensitivity to 
neutralization in the presence of neutralizing antiserum [231-233].  Escape of the molecular 
clone SIVmac239 was demonstrated in vivo following the development of strong Ab-mediated 
selective pressure, leading to a heightened rate of nonsynonomous substitutions within the 
variable regions of the envelope protein [234].  Finally, numerous reports of HIV escape 
following selective humoral immune pressure have been noted clinically.  Dramatic evidence of 
successful viral evasion was demonstrated by the reduced ability of antiserum from the latter 
stages of infection to neutralize contemporary viral isolates, suggesting ineffective humoral 
immunity [184, 186, 235-237].  Concurrent with immune evasion, escape mutations incur a cost 
on the collective evolutionary fitness of the viral isolate, reducing replicative capacity and 
quickly reverting in the absence of immunologic pressure [238-240].  Although epitope escape 
undermines immunologic control of viral replication, the associated reduction in viral fitness 
may balance the overall pathologic detriment to the individual. 
1.8 HIV VACCINES 
1.8.1 Traditional Vaccine Limitations 
The goal of a conventional vaccine is to present innate, unaltered Ag from the pathogen 
of interest in a manner that promotes local immunity and subsequently establishes durable 
humoral and cellular memory responses capable of preventing disease pathogenesis.  The most 
effective vaccines to date have been comprised of live, attenuated pathogens as used in the oral 
polio, BCG tuberculosis, and yellow fever vaccines, along with chemically inactivated organisms 
utilized in vaccines against influenza, cholera, and hepatitis A.  Immunization utilizing protein 
subunits of target Ag, such as the hepatitis B surface Ag, have also proven effective, albeit with 
reduced immunogenicity, necessitating multiple rounds of vaccine boosting.  Regrettably, these 
approaches have largely failed against –immunodeficiency virus infections.  Over fifteen years 
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ago, researchers demonstrated that nonhuman primates immunized with a live attenuated form of 
pathogenic SIVmac239 containing a largely deleted nef gene were capable of resisting infection 
from homologous wild-type SIVmac239 as well as heterologous SIVmac251 [241].  Although 
initial findings suggested that live attenuated SIV vaccines were well tolerated, further 
vaccination studies in infant and adult nonhuman primates demonstrated that attenuated viruses 
retained virulence, with progressive disease associated with continuous low-level viremia [242-
244].  These findings were corroborated clinically after a small cohort of individuals in Australia 
developed progressive disease following transfusion-borne infection with a nef-deficient HIV 
strain [245, 246].  Similarly, immunization utilizing the virulence-attenuated SIVmac-1A11 strain 
was shown to prevent early disease but not infection from a pathogenic SIV strain [247].  
Formalin-inactivated whole virus immunogens have provided effective immunity in the SIV 
model of nonhuman primate infection, but protection was restricted to near homologous 
challenge strains [248].  Nearly a decade later, the first phase III HIV vaccine trial advanced the 
bivalent recombinant gp120 subunit protein immunization into clinical evaluation [249].  
Although initially touted as a success after conferring a level of protection upon chimpanzees 
infected with HIV-IIIB [250], VaxGen’s subunit protein immunization provided no significant 
protection from HIV infection in clinical trials [251, 252].  Failure to induce protective immunity 
was due to the inability of subunit protein gp120-based immunization to induce high-titer Ab, 
relevant NAb responses, or effective antiviral cellular immunity.  The inherent flaws of 
conventional vaccine modalities necessitate the creation and testing of novel immunization 
strategies against HIV infection. 
1.8.2 Novel Vaccine Strategies 
1.8.2.1 DNA Vaccines 
DNA vaccines consist of a foreign pathogen-associated gene of interest, often optimized 
for expression in eukaryotic cells, which is cloned into a bacterial plasmid [253].  Advancements 
in DNA vaccine delivery, including liposome-mediated, electroporation, and gene guns systems, 
in conjunction with affordable production and stable room temperature storage make DNA 
vaccines attractive candidates for the treatment of HIV.  Furthermore, DNA vaccination is 
capable of inducing both humoral and cellular Ag-specific immunity, largely due to potent 
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transfection of APCs and subsequent stimulation of both CD4+ and CD8+ T cells.  Unfortunately, 
naked DNA has limited immunogenicity.  The innate unmethylated cytidine-phosphate-
guanosine (CpG) dinucleotide motifs of the plasmid vector may be augmented through inclusion 
of additional toll-like receptor agonists, cytokines, co-stimulatory molecules, and classical 
vaccine adjuvants to increase DNA vaccine immunogenicity [254].  As DNA vaccines fail to 
elicit vector-specific immunity, multiple booster immunizations may be delivered to further 
enhance immunity.  DNA immunization in nonhuman primates elicited robust immunity.  IL-2 
cytokine augmented DNA-based vaccination expressing SIV gag and HIV env was able to 
protect monkeys against a minimally pathogenic, less stringent SHIV89.6 challenge, associated 
with the induction of Ag-specific CTL expansion and proliferation along with NAb responses 
[210].  In contrast, DNA vaccination has shown limited efficacy against pathogenic SIVmac251, 
SIVsmE660, or SIVmac239 infection, in light of substantial immune induction [255, 256].  
Clinical trials utilizing multiclade DNA immunization targeting the HIV gag, pol, nef, and env 
genes have demonstrated the induction of mediocre antiviral CTL responses (~50%), but strong 
lymphoproliferative responses against HIV Gag protein (~93) [257].              
1.8.2.2 Poxvirus-Based Vectors 
Recombinant poxvirus-based vectors confer the ability to efficiently infect a wide variety 
of host cells, possess ample room for transgenic inserts, and elicit natural innate and adaptive 
immune response against an intracellular viral pathogen.  To avoid safety concerns associated 
with replicating vaccinia vectors in potentially immunocompromised populations, poxvirus 
vectors such as MVA and the avian canarypox (ALVAC) and fowlopx have been engineered to 
undergo an abortive replication cycle in human cells.  Problematic in all recombinant viral 
systems, host cell infection by poxvirus-based vectors produces both viral and transgenic 
proteins, leading to the development of vector-specific immunity capable of inhibiting 
immunogenicity upon homologous boosting.  Initial immunization studies in chimpanzees and 
macaques demonstrated the ability of poxvirus-based vectors, particularly MVA, to induce 
potent CD4+ and CD8+ T cell-mediated immunity, as well as NAb responses to SIV proteins 
[258-260].  Yet, similar to other vaccine modalities, poxvirus-based vaccination has proven 
effective in protecting against the virulence attenuated SHIV89.6 strain only [261], while they 
failed to provide prolonged containment of pathogenic SIV species such as SIVsmE660, even 
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when administered to Mamu-A*01-expressing animals prone to viral control [262-264].  
Notably, recent immunization studies have suggested the MVA and NYVAC vectors may be 
superior in the induction of qualitatively advantageous, polyfunctional cellular immune 
responses consisting of perforin and granzyme expression, production of IL-2, IFN-γ, TNF-α, 
and MIP-1β, and the marker for degranulation, CD107a [265].  Currently, poxvirus-based 
vaccines are being evaluated in clinical efficacy trials against HIV, but have demonstrated lower 
immunogenicity than expected with ALVAC-induced Gag-, Pol-, and Env-specific CTL 
responses seen in roughly 50% of vaccinees [266, 267].                        
1.8.2.3 Virus-Like Particle Vaccines 
As HIV/SIV-specific cellular immunity can ameliorate but not prevent infection, a 
putative AIDS vaccine will optimally promote strong humoral immunity in conjunction with T 
cell-mediated responses.  Virus-like particles (VLPs) are uniquely suited for the induction of 
humoral immunity, as they present functional, conformationally relevant virion-associated viral 
envelope and structurally proteins in a safe context devoid of the viral RNA genome [268].  HIV 
and SIV VLPs self-assemble following expression of gag and env genes in permissive cell lines, 
creating mature particles expressing high levels of viral Env and capable of budding at the cell 
surface [269, 270].  In addition, VPLs bind cellular receptors facilitating virion fusion and entry 
into host cells expressing CD4+ and the appropriately matched CXCR4 or CCR5 coreceptor for 
the particular VLP Env [271].  Intranasal immunization of mice with SIV VLPs was shown to 
induce mucosal IgA and systemic IgG responses, as well as T cell-mediated release of IFN-γ and 
IL-4 in cervical lymphocytes and splenocytes, which were enhanced through the addition of a 
cholera toxin adjuvant [272].  Incorporation of HIV Env proteins with reduced glycosylation and 
selective deletions in the variable loops has lead to enhanced immunogenicity of these vectors 
[273].  Immunization with DNA plasmids sufficient for VLP formation in vivo induced strong 
NAb responses and CTL-mediated killing of target cells in Macaca fascicularis, leading to 
partial control of SIVmne challenge as seen by reduced cell free and cell-associated virus 
detection and inhibition of CD4+ T cell loss [274].  Given their likeness to the highly effective 
live-attenuated or inactivated particle vaccines for SIV, VLPs contain great potential as HIV 
immunogens [275].   
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1.8.2.4 Heterologous Prime-Boost Immunizations   
Plasmid DNA, VLPs, and recombinant viral vectors are each associated with unique 
profiles of immune induction, as well as limitations for clinical use.  Combining heterologous 
vaccination systems allows for induction of tailored and often superior immune responses while 
circumventing restrictions such as vector-specific immunity and lack of immunogenicity.  
Currently, DNA priming in conjunction with viral vector boosting has shown promise.  The 
DNA priming component of this regimen is capable of establishing more robust humoral 
immune responses, both NAb and quantitative Ab titer, then viral vector priming, and provides 
more even expansion of CD4+ and CD8+ T cell responses to Ag.  The limited immunogenicity of 
DNA vaccines can be combated with multiple boosts, adjuvants, and cytokine but will provide 
only modest cellular immunity.  In contrast, viral vector priming, most commonly with Ad or 
MVA, establishes broad and potent T cell-mediated immunity, but rarely induces strong antiviral 
humoral immunity due to predominant intracellular delivery and production of vector-associated 
transgenes.  Although numerous vaccination regimens have protected against inadequately 
pathogenic SHIV89.6P challenge, a finding skewed by overrepresentation of Mamu-A*01-
expressing animals in immunization groups, a study comparing vaccination utilizing DNA, 
MVA, or Ad5 either alone or in combinations, demonstrated a roughly 5 fold enhancement of 
Ag-specific tetramer positive CD8+ T cells in DNA primed/Ad5 boosted groups as compared to 
other regimens [211].  Follow up investigations correcting for macaque genetic variability found 
that homologous Ad5 immunization was superior at increasing the magnitude of Ag-specific 
tetramer positive and IFN-γ production, but did not control pathogenic intrarectal SIVmac239 
challenge to the extent of DNA/Ad5 regimen, suggesting a qualitative immunologic advantage of 
the heterologous prime-boost regimen [276].  Similar studies demonstrated that DNA/Ad5 
prime-boost regimens could mitigate acute and chronic infection upon low-dose SIVmac239 
challenge through Ag-specific cellular immunity and retention of T cell memory and CD4+ T cell 
populations alone in Mamu-A*01-expressing macaques [277].  Furthermore, DNA/Ad5 prime-
boost regimens have been shown to preserve memory CD4+ Tcm populations in macaques 
following pathogenic SIVmac251 infection, correlated with prolonged survival [278].  Similarly, 
studies evaluating DNA/poxvirus prime-boost strategies have demonstrated increased peak 
frequencies of Ag-specific tetramer positive and IFN-γ producing T cells in animals receiving 
DNA priming followed by MVA, fowlpox, or recombinant vaccinia boosting, but control of the 
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virulence attenuated SHIV89.6P was achieved following either homologous DNA alone or in 
conjunction with viral vector boosting [279]. 
1.8.3 Therapeutic Vaccination 
As a preventive vaccine is currently unavailable, diverse therapeutic strategies aimed at 
prolonging asymptomatic HIV infection and optimally inducing sterilizing host immunity are 
being pursued.  The most successful therapeutic vaccination studies to date have demonstrated a 
one thousand fold decreases in chronic SIV plasma RNA and reductions in cell associated DNA 
through repeated immunization of macaques with aldrithiol-2 inactivated, SIV-pulsed autologous 
DCs in the absence of ART [280].  Preliminary human immunization trials utilizing DCs loaded 
with aldrithiol-2 inactivated autologous virus achieved an 80% median reduction among all 
recipients for roughly four months, with 8 of 18 subjects containing plasma viremia for greater 
than one year post-vaccination without ART [281].  This study suggests that the nature of 
antigenic presentation to the immune system may dramatically influence the host’s ability to 
respond to HIV/SIV infection.  Practical application of a therapeutic HIV vaccination will occur 
during ART suppressed viremia, commonly after acute infection has impaired host immunity.  
During ART intervention, studies have demonstrated that poxvirus-based therapeutic vaccination 
of macaques during chronic SIVmac251 infection restores broad Ag-specific CTL and 
lymphoproliferative responses, absent during ART alone [201, 282, 283].  Furthermore, transient 
SIVmac251 suppression was achieved in 75% of macaques upon STI following poxvirus-based 
therapeutic vaccination during a six month course of ART, associated with enhanced Ag-specific 
lymphoproliferation and CTL target lysis [200]. 
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1.9 ADENOVIRAL VECTORS 
1.9.1 Adenovirus-Based Vaccination 
Adenoviruses are medium sized (90-100nm), non-enveloped, icosohedral viruses 
containing a linear, non-segmented, double-stranded DNA genome of roughly 35 kilobase pairs.  
There are 51 serologically distinct types of human-associated adenovirus, falling into six 
subgenera (A-F), with several serotypes capable of causing respiratory illness, gastroenteritis, or 
conjunctivitis.  Adenoviruses infect a broad range of both resting and dividing cell types, 
including potent APCs such as myeloid and plasmacytoid DCs [284].  Deletion of the adenoviral 
E1 and E3 genes eliminates replication capacity and MHC downregulation, respectively, and 
provides room to insert a foreign transgene of interest, such as a vaccine Ag.  Codon 
optimization of transgenic inserts and inclusion of heterologous regulatory elements such as the 
high-output CMV immediate/early promoter increase transgenic protein production [285, 286].  
Recombinant infectious adenovirus is then created by co-transfecting a packaging cell line 
engineered to express Cre recombinase with the adenoviral backbone (Adψ) DNA and a plasmid 
containing the nonviral transgene of interest (pAdlox) [287].  Cre recombinase can catalyze 
recombination between the Adψ containing E1 flanking loxP sites and pAdlox containing 
transgene flanking loxP sites in a two step process, removing the packaging site from Adψ then 
transferring the recombinant genes from pAdlox, creating E1-substituded Ad vectors [287].  
Additionally, Cre-lox recombination supplies negative selection pressure on non-recombinant 
viruses, allowing for rapid outgrown of desirable recombinants [287].  Recombinant adenovirus 
is easily grown and purified from cell culture, allowing for rapid and affordable mass production.                
1.9.2 Immunogenicity of Ad-Based Vaccines       
The utility of Ad-based vectors as HIV vaccines lies largely in their ability to induce TH1 
cellular immune responses, paramount in protection from intracellular pathogens.  
Immunogenicity studies in nonhuman primates have demonstrated the efficiency of recombinant 
Ad-based vectors to induce robust INF-γ ELISPOT responses and target cell lysis, as well as 
modest NAb titers in an escalating dose-dependent manner [288].  Comparative analysis of 
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DNA, MVA, and Ad-based immunizations against the SIV Gag protein found that Ad-based 
vectors promoted the highest quantitative IFN-γ production from Ag-specific T cells amongst the 
regimens tested [288].  Ad-based vaccination against the SIVmac239 Gag protein induced high-
frequency CD4+ and CD8+ T cell-mediated IFN-γ responses against both dominant and 
subdominant epitopes that were later recalled upon heterologous challenge with pathogenic 
SIV/DeltaB670 [289].  Although arguably superior in promoting the overall magnitude of TH1 
cellular immunity, Ad5-based vaccination has been shown to preferentially elicit CD8+ T cell-
mediated production of IFN-γ and TNF-α, either individually or combined, potentially due to 
high-dose vector-driven terminal differentiation of both Ag-specific CD4+ and CD8+ T cells 
[290-293].  In contrast, recent studies providing detailed characterization of the cytokine profiles 
elicited by the rare serotype Ad26- and Ad48-based vectors in rhesus macaques demonstrated a 
significant enhancement of polyfunctional IFN-γ+TNF-α+IL-2+ and overall IL-2 production from 
both CD4+ and CD8+ memory T cell populations as compared to immunization utilizing Ad5-
based vectors [294].  Given that DCs have been shown to express CD46, the receptor facilitating 
entry of subgroup B and D Ad, but not the coxsackievirus and adenovirus receptor (CAR) 
utilized by Ad5, suggests distinct biologic pathways of Ad infection which may potentially 
influence the dynamics and character of immune induction [295-297].  As recent findings have 
implicated polyfunctional cellular immune responses in vaccine efficacy and HIV disease 
control, methods to improve on the potency of Ad-based immunization must be explored [292].               
1.9.3 Limitations of Adenoviral Vectors 
Inherent in the use of viral vectors as immunogens are the natural humoral and cellular 
antiviral immune responses directed against the vector virions and derived proteins.  Ad-specific 
immune responses are manifested by an initial Ab-mediated clearance targeting the capsid 
hexon, fiber, and penton base proteins, followed by T cell-mediated elimination of cells 
expressing Ad proteins prior to and following novel Ad protein synthesis [298-301].  As 
expected, NAb responses are generally serotype specific, whereas CD4+ and CD8+ T cell-
mediated immunity targeting homologous sequences in structural proteins can be cross-reactive, 
with subgroup C primed CD4+ T cell-clones proliferating in responses to subgroup A, B, and C 
exposure [302].  In as much, the presence of pre-existing Ad-specific immunity dramatically 
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reduces the immunogenicity of the vaccine vector, attenuating its efficacy [288, 303].  Therefore, 
the prevalence of pre-existing vector-specific immunity in various populations will determine the 
potential utility for serotype-specific Ad-based vaccination regionally [304].  Pre-existing NAb 
responses against the common Ad5, subgroup C, were found in over 80% and 35% of adults in 
Africa and the United States, respectively, whereas NAb titers against rare Ad35, subgroup B, 
were present in roughly 2.5% and 6% of these same populations, respectively, with similar 
seroprevalence among HIV infected and uninfected individuals [298, 305, 306].  Ad-specific 
NAb responses were shown to develop rapidly, with infants in Sub-Saharan Africa developing an 
80% seroprevalence of Ad5-specific Abs by 18 months of age [307].  Given these limitations, 
novel approaches at circumventing pre-existing anti-Ad immunity, such as vaccination with Ad 
transduced DCs, are being evaluated [308].                                 
1.9.4 Heterologous Adenoviral Immunization 
To circumvent the limitations of pre-existing vector-specific immunity, Ad vectors of 
rare prevalence in human populations with unrelated serology are being utilized in heterologous 
prime-boost regimens.  Development of novel, alternative vectors based on rare human Ad 
serotypes from subgroup B (Ad11, Ad34, Ad35, Ad50), subgroup C (Ad6), and subgroup D 
(Ad24, Ad26, Ad48, Ad49) and nonhuman ovine, bovine, porcine, and chimpanzee serotypes 
(AdC1, AdC6, AdC7, AdC32, AdC33, AdC68) have been established to compliment traditional 
Ad5-based vectors (subgroup C) [304, 309-317].  Early immunogenicity studies in mice 
demonstrated that rare serotyped vectors, specifically Ad35, AdC6, and AdC68 are capable of 
boosting transgene-specific immunity either in conjunction with Ad5 or as independent prime-
boost regimens in the presence of pre-existing Ad5-specific NAb titers [311, 318, 319].  It was 
later shown that even the rare serotyped Ad11- and Ad35-based vectors, both subgroup B, were 
susceptible to low-level cross-reactive vector-specific NAb targeting regions of homology in the 
hexon hypervariable regions [318].  Consistent with these findings, vaccination of mice with a 
subgroup B/D combination Ad35- and Ad49-based prime-boost regimen proved more 
immunogenic than utilizing multiple Ad vectors within the same subgroup, demonstrating that 
even rare vectors must be sufficiently distinct to avoid cross-reactive immunity and optimal 
immunogenicity [320].  Immunization studies against HCV in macaques utilizing heterologous 
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Ad6/AdC32 regimens provided durable CD4+ and CD8+ T cell-mediated immunity susceptible to 
alternative serotype boosting 2 years after primary vaccination [321].  However, recent 
immunogenicity studies in the nonhuman primate have demonstrated that Ad vectors based on 
serotype 5, 26, and 48 individually promote unique, vector-specific cellular immune induction 
profiles which influence the subsequent ability of heterologous Ad-based boosting [294].  
Notably, this report suggests that Ad5-based vectors promote restricted transgene-specific 
cellular immunity consisting of CD8+ T cell dominated responses devoid of IL-2 production 
which limit the capacity of heterologous Ad-based boosting to alter the functionality of Ag-
specific cellular immunity [294].  Combined, these findings illustrate the potential utility of 
heterologous Ad-based vaccination to optimally induce HIV-specific immunity, and are among 
the leading vaccine candidates for the induction of T cell-mediated immunity.          
1.10 PUBLIC HEALTH SIGNIFICANCE 
In the absence of a preventive vaccine for HIV infection, alternative methods for the 
treatment of HIV should be explored.  The prohibitive cost, development of drug-resistant virus, 
and inability to induce sterilizing immunity to HIV infection are limiting factors to continual 
ART.  Transient immune reconstitution and therapeutic vaccination during ART suppressed 
viremia may provide the necessary stimulation to eradicate the persistent viral reservoirs 
responsible for eventual treatment failure.  Our immunotherapy proposes a temporary treatment 
of –immunodeficiency virus infection, eliminating the cost and duration of current treatment 
models with the potential for persistent disease containment.  Therapeutic vaccine-mediated 
reductions in viremia would inhibit HIV pathogenesis, preventing disease progression while 
decreasing the potential for further viral transmission [322, 323].      
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2.0  HYPOTHESIS AND SPECIFIC AIMS 
The cellular immune response to HIV infection is implicated in controlling acute viremia, 
containing set-point chronic viral loads, and establishing durable suppression of disease 
associated pathogenesis allowing for long-term non-progressor status and extended survival 
without pharmacologic intervention.  Therefore, a prophylactic vaccine aimed at preventing HIV 
infection or a therapeutic vaccine used to inhibit disease progression and transmission should 
promote high frequency, qualitatively superior T cell-mediated antiviral immunity.  Recombinant 
Ad-based vectors are among the preeminent vehicles for the induction of transgene-specific 
cellular immunity, but have been limited by the development of vector-specific immunity.  
Utilizing novel Ad35-based vectors in conjunction with conventional Ad5-based vectors, we 
have examined the capacity of heterologous Ad-based immunization to induce efficacious 
antiviral cellular immunity in the nonhuman primate model of HIV infection.  We hypothesize 
that dual-serotype Ad-based vaccination will elicit superior cellular immune responses over 
those attained by homologous Ad-based vaccination, and that in a model of therapeutic 
intervention, heterologous vaccine induce immunity will be capable of controlling chronic 
viremia.  The specific aims of this project are: 
 
Aim 1:  To measure the potential for novel Ad35-based vectors to enhance transgene-
specific cellular immunity previously induced through conventional Ad5-based vaccination.  
Hypothesis:  Serologically distinct Ad35-based vectors will be capable of enhancing cellular 
immune responses induced through Ad5-based vaccination due to lack of vector-specific Ab-
mediated cross-neutralization.  In a proof-of-concept trial, rhesus macaques received four 
priming immunizations utilizing Ad5-based vectors encoding the SIVmac239 gag transgene, 
followed by boosting with either continual Ad5-based vaccination or Ad35-based vectors.  
Vaccinated and naïve control animals were then challenged with pathogenic SIV/DeltaB670.  To 
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evaluate the magnitude of vaccine-induced cellular immunity between groups, longitudinal IFN-
γ ELISPOT analysis was performed.  IFN-γ ELISPOT matrix analysis and fine epitope mapping 
were utilized to provide detailed characterization of the Ag-specific breadth elicited by 
vaccination and in responses to infection.  MHC restriction of identified epitopes was performed 
through IFN-γ ELISPOT following magnetic bead depletion of CD4+ and CD8+ T cells from 
peripheral blood mononuclear cells (PBMC).  Subsequently, SIV immune evasion from vaccine-
induced T cell-mediated responses was evaluated by comparison of sequence analysis from 
plasma viral isolates with known previously identified epitope targets.     
 
Aim 2:  To evaluate the efficacy of therapeutic dual-serotype Ad-based vaccination during 
ART-treated chronic SIV infection to limit rebound viremia following STI through the 
induction of antiviral cellular immunity.  Hypothesis:  Immunotherapeutic vaccination 
utilizing Ad5- then Ad35-based vectors during established SIV infection will augment antiviral T 
cell-mediated immunity capable of restricting rebound viremia following ART cessation.  
Building upon our previous trial, we next examined the potential of Ad5/Ad35-based delivery of 
the codon optimized SIVmac239 gag, env, and nef transgenes, with or without IL-15 
augmentation, to boost cellular immunity during ART-treated SIVmac251 infection.  Ag-specific 
cellular immune responses to Gag, Env, and Nef proteins in PMBC were longitudinally 
measured by IFN-γ ELISPOT.  Subsequently, multiparametric flow cytometry was utilized to 
measure production of the TH1 cytokines IFN-γ, TNF-α, and IL-2 in memory populations of 
CD4+ and CD8+ T lymphocytes from PBMC and bronchoalveolar lavage (BAL) samples at 
timepoints of peak response.  Fluorescence-activated cell sorting (FACS) analysis and cellular 
quantitation was performed to evaluate absolute memory CD4+ and CD8+ T cells in peripheral 
blood, and total percentages of CD4+ T cells in BAL throughout infection.  Plasma viral RNA 
levels were measured, and immune correlates of viral control were identified.        
 
Aim 3:  To assess the ability of immunotherapeutic vaccination with or without IL-15 
augmentation to effect the dynamics of T cell phenotype and proliferation systemically and 
at the lung mucosa.  Hypothesis: Administration of Ad-based immunotherapeutic vaccination 
will promote peripheral expansion and proliferation of CD4+ and CD8+ T cell memory 
populations that will be further enhanced upon IL-15 delivery.  Throughout therapeutic 
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intervention, we utilized multiparametric FACS analysis to longitudinally monitor alterations in 
CD4+ and CD8+ T cell memory phenotype and proliferation following SIVmac251 infection, 
ART treatment, and dual-serotype Ad-based immunization.  Cellular proliferation was 
determined by Ki-67 detection in PBMC and BAL samples, comparing immunized animals with 
mock vaccinated or non-infected controls, respectively.  Absolute cell enumeration was 
performed in PBMC and population percentages examined in BAL samples. 
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3.1 PREFACE 
The following chapter is in fulfillment of specific aim 1.  The described study was a large 
scale collaborative effort within the University of Pittsburgh involving the Barratt-Boyes lab for 
immunologic analysis, the Viral Vector Core for creation of adenoviral vectors, and the Primate 
Facility for Infectious Disease Research for animal procedures and maintenance.  Specifically, 
Adam C. Soloff performed all ELISPOT analysis subsequent to wk 22 post-vaccination, roughly 
100 wks, and assisted in the study design, analysis, and manuscript preparation.  This work 
included longitudinal determination of Ag-specific responses, evaluation of CD4+ and CD8+ T 
cell-mediated fractional response through T cell-specific Ab depletion, identification of epitope 
targets, and additional fine mapping of precise epitope sequences.  Kevin Brown performed 
partial Ag-specific ELISPOT analysis from study initiation to wk 22 post-vaccination.  
Xiangdong Liu carried out RT-PCR assays for viral sequencing.  Premeela A. Rajakumar and 
Michael Murphey-Corb provided viral load measurements.  Edward Nwanegbo preformed Ad-
specific NAb assays.  Richard D. Day ran statistical analysis on viral load measurements.  
Wentao Gao, Paul D. Robbins, and Andrea Gambotto manufactured all Ad vectors utilized in the 
study.  The published manuscript was authored primarily by Simon M. Barratt-Boyes, who 
conceived and designed the study.                
3.2 ABSTRACT 
The ability of Ad-based vaccines to induce potent T cell-mediated immunity to 
transgenes is limited by the immunogenicity of the vector, which induces serotype specific NAb 
responses.  We have examined the potential for a novel Ad35-based vaccine to boost cellular 
immunity to SIV Gag protein previously delivered by a conventional Ad5-based vaccine in 
rhesus macaques.  Eight animals received four immunizations each of Ad5 expressing the codon 
optimized SIVmac239 gag gene in two parts (Ad5-Gag), followed by two boosts utilizing either 
continued Ad5-Gag or alternative Ad35-Gag.  Subsequently, animals were challenged 
intrarectally with the heterologous primary isolate SIV/DeltaB670.  Initial immunizations with 
Ad5-Gag induced broad and potent T cell responses to SIV Gag protein measured by IFN-γ 
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ELISPOT.  Repeated Ad5-Gag immunization was ineffective in boosting T cell responses, 
associated with an elevated Ad5 NAb response.  In contrast, boosting with Ad35-Gag 
substantially increased the strength of T cell responses to Ag.  Vaccination induced CD4+ and 
CD8+ T cell responses to several previously unreported epitopes.  These responses were recalled 
upon heterologous viral challenge suggesting viral epitopes targeted by vaccination were 
conserved between distantly related SIV strains.  Notably, immunization provided reductions in 
post-challenge viral load demonstrating acute and chronic viral inhibition.  The capacity of dual-
serotype Ad-based vaccination to induce broad T cell-mediated immunity to multiple conserved 
epitopes illustrates the potential power of this vaccine regimen for HIV-1.           
3.3 INTRODUCTION 
Developing an effective HIV vaccine has been hindered by safety concerns involved with 
classical attenuated and inactivated virus, and the limited immunogenicity of subunit protein and 
plasmid DNA-based immunogens [324].  Live, recombinant viral vectors have received 
increased attention due to their innate ability to stimulate cellular immune responses.  Viral 
vector immunogens including MVA, poxvirus, vesicular stomatitis virus, Ad5 and others have 
shown promise in prophylactic vaccination models against SIV infection models in nonhuman 
primates [211, 212, 261, 325-327].  Furthermore, studies comparing plasmid DNA, MVA, and 
Ad5-based immunizations have demonstrated the superior ability of Ad vectors to induce Ag-
specific cellular immunity [211, 288], and are currently being advanced in clinical trials [328].  
Ad5-based vaccinations against such emerging pathogens as Ebola virus, the SARS-coronavirus, 
and H5N1 influenza are currently being explored [329-331].  Regrettably, repeated 
administration of Ad-based immunizations are limited by the induction of vector-specific cellular 
and humoral immunity, reducing the capacity for continual immune induction from homologous 
vectors [332-335].  In conjunction, a high prevalence of serum Ab titres to Ad5 have been 
demonstrated in the global human population due to previous naturally occurring adenoviral 
infections [297, 305, 306].     
To circumvent pre-existing vector specific immunity, development of alternative vectors 
based on rare human Ad serotypes (Ad35, Ad11, Ad24, Ad26, Ad4, Ad34) and chimpanzee 
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serotypes (AdC6, AdC7, AdC68) have been pursued [304, 310-313, 317].  Serial immunization 
regimens utilizing heterologous Ad vectors have demonstrated the ability of discordant Ad-based 
vaccination to boost transgene specific cellular immune responses in the presence of pre-existing 
Ad-specific immunity [312].  As natural, pre-existing immunity against Ad35 is found to a 
dramatically reduced extent compared to responses against Ad5, vectors based on an Ad35 
backbone would not experience the restrictions of vector-specific humoral immunity associated 
with high Ad5 seroprevalence [297, 305, 306, 336].  Additionally, previous studies have 
demonstrated that Ad5-specific Ab responses fail to cross-neutralize Ad35-based vectors, 
allowing for the combination of these vectors in prime-boost immunization regimens [297, 319].  
Findings in the murine model have supported this platform, demonstrated the potential utility of 
Ad35 immunization to boost SIV Gag-specific immunity in the presence of pre-existing Ad5-
specific humoral responses [319].   
In the presented study, we have evaluated the ability of Ad35-based vectors to enhance 
Gag-specific cellular immunity previously induced through Ad5-based vaccination in a 
sequential, heterologous immunization strategy against SIV in adult Indian rhesus macaques.  As 
macaques naturally lack pre-existing immunity to either Ad5 or Ad35, the nonhuman primate 
model of HIV infection provides on optimal situation to examine the immunogenicity of this 
vaccination platform.  To determine the extent of immune induction, we performed detailed 
characterization of the breadth and strength of transgene-specific cellular immunity following 
vaccination and upon subsequent viral challenge with the pathogenic biologic isolate SIV/Delta 
B670.  Intrarectal viral challenge with SIV/DeltaB670 provided a stringent and relevant model of 
mucosal HIV infection, consisting of a CCR5 tropic virus with a median time to death of 11 
months [337-339].  At its initiation, this study represented the first examination of the 
heterologous Ad5/Ad35-based immunization regimen in the nonhuman primate model of HIV 
infection.   
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3.4 MATERIALS AND METHODS 
3.4.1 Generation and expression of recombinant Ad vectors 
Replication-defective Ad5-based vectors excluding the E1/E3 genes were produced by Cre-lox 
recombination as described previously [287, 308].  Briefly, a SalI-NotI fragment containing the 
transgenic segment of interest was inserted into the pAdlox shuttle plasmid and subsequently 
cotransfected with the E1/E3 deleted Adψ5 helper virus into the Ad packaging cell line CRE8.  
Recombinant Ad was purified by cesium chloride density gradient centrifugation, dialyzed, and 
stored at -800C.  Vectors were constructed to include two codon-optimized fragments of the 
SIVman239 gag gene expressing the full-length protein as Ad5-p17 and Ad5-p45 (collectively, 
Ad5-Gag).  Segmented expression of the Gag protein allowed for potential presentation of 
subdominant epitopes that may otherwise be restricted by competition from regions containing 
immunodominant epitopes [340]. Construction of replication-competent Ad35-based vectors 
excluding the E3 gene alone was performed utilizing the loxP recombination method previously 
described to incorporate identical Gag transgenes as described above, creating Ad35-p17 and 
Ad35-p45 (Ad35-Gag) [310].  Briefly, SalI–NotI fragments of codon-optimized gag p17 or gag 
p45 were cloned into the Ad35 shuttle plasmid pAd35E3.  Plasmids were linearized with EcoRV 
and cotransfected with NotI-digested Ad35 helper virus Ad35E3/EYFP DNA into CRE8 cells.  
The resultant Ad35-based vectors were produced in HEK293 cells.  Western blot analysis 
utilizing the SIV p17- and p27-specific monoclonal Abs, KK59 and 2F12 was performed to 
confirm segmented Gag protein expression from lysates of HEK239 and 239T cells transfected 
with Ad5- and Ad35-based vectors [308] (Gao, W. unpublished data). 
3.4.2 Animals 
Eleven colony-bred, adult Indian rhesus macaques (Macaca mulatta) where housed at the 
University of Pittsburgh Primate Facility for Infectious Disease Research and maintained in 
accordance with Institutional Animal Care and Use Committee (IACUC) guidelines.  MHC 
determination was carried out via contract with the Wisconsin National Primate Research Center.  
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Molecular typing of the MHC class I Mamu-A*01, A*02, A*08, A*11, B*03, B*04, and B*17 
alleles was performed.   
3.4.3    Immunization and SIV challenge 
All Ad manipulation was performed at 4oC with minimization of vector disturbance.  Ad-based 
immunizations were rapidly thawed and resuspended in cold sterile saline at a concentration of 
1011 viral particles per 150 μl.  Immunization was administered in less than 1 h from viral 
thawing.  Ad5- and Ad35-based vectors containing p17 or p45 were delivered at separate sites by 
intramuscular (i.m.) injection in the lateral thigh or by intradermal (i.d.) injection in the inguinal 
region, respectively.  All animals were challenged through atraumatic inoculation of an undiluted 
stock of pathogenic SIV/DeltaB670 into the rectum as previously described [341].             
3.4.4 IFN-γ ELISPOT assays 
Effector T cell-mediated responses to SIV Gag were analyzed in previously frozen PBMC by 
IFN-γ ELISPOT assay as described [308].  Briefly, 96-well high protein binding membrane-
coated plates (Millipore, Bedford, MA) were incubated overnight with 10 μg/ml monoclonal 
IFN-γ capture Ab (MD-1) (U-Cytech, Utrecht, The Netherlands) in 0.1 M carbonate buffer at 
4oC.  Subsequently, cells were plated at 1x105 to 3x105 per well in the presence of peptide Ag, 
dimethyl sulfoxide (DMSO) negative control, or staphylococcal enterotoxin B (SEB) positive 
controls and incubated for 24 h, 37oC, at 5% CO2.  Following stimulation, cells were disposed of, 
and plates underwent successive overnight incubations at 4oC using biotinylated IFN-γ detection 
Ab at 10 μg/ml (U-Cytech) and streptavidin-alkaline phosphatase conjugate (Bio-Rad, Hercules, 
CA).  Spots were developed using chromogenic alkaline phosphatase substrate (Bio-Rad) and 
enumerated using an AID ELISPOT reader (Cell Technology, Columbia, MD).  Individual 15-
mer peptides at >80% purity representing the Gag, Pol, Env and Nef sequences of SIVmac239 
and overlapping by 11 amino acids (NIH AIDS Research & Reference Reagent Program, 
Bethesda, MD) were dissolved in DMSO and used as Ag.  Gag peptides were used in pools of 
eight peptides, 30-32 peptides (final concentration 3.1 – 3.9 μg/ml) or individually (5 μg/ml), as 
described (7).  Env and Nef peptides were used as single pools of 212 peptides (0.6 μg/ml) and 
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64 peptides (1.6 μg/ml), respectively.  Pol peptides were split into two pools of 131 and 132 
peptides (1 μg/ml).  For detailed epitope analysis of MHC class I and II responses respectively, 
9-mer and 15-mer peptides were synthesized and HPLC purified to >93% (Sigma Genosys, The 
Woodlands, TX).  Significant responses were three times that of background with a minimum 
number of 50 spots per 106 cells.  
3.4.5 NAb responses to Ad vectors 
Serum NAb responses to Ad5 and Ad35 vectors were detected through inhibition of infection by 
serotype matched reported viruses as previously demonstrated [305].  The human lung 
carcinoma cell line A549 (American Type Culture Collection, Manassas, VA) was cultured to 
confluence in 150- by 25-mm tissue culture dishes, harvested through trypsin disruption, washed, 
and counted utilizing trypan blue for apoptotic cell exclusion.  Cells were then seeded at 105 per 
well in a 96-well flat-bottom plate.  Four-fold serum dilutions from individual macaques (1:8, 
1:32, 1:128, and 1:512) were pre-incubated with 108 viral particles of either E1/E3-deleteed Ad5-
EGFP or E3-deleted Ad35-EYFP, expressing the fluorescent extra green or yellow fluorescent 
protein (EGFP/EYFP), respectively, for 1 h at 370C prior to combination with previously 
distributed A549 cells.  Plates were incubated for 24 h at 370C.  Cells were then harvested, 
washed, and EGFP or EYFP expression was analyzed using a FACScan flow cytometer and Cell 
Quest software (Becton Dickinson, Mountain View, CA).  A minimum of 1,000 events were 
collected.  The end-point titre was calculated as the highest serum dilution that inhibited >50% of 
infection.  Significance determined by Student’s t test.  A549 cell line was chosen for providing 
equivalent infection qualities and kinetics between Ad5 and Ad35 viral serotypes.   
3.4.6 Virus quantitation 
Quantitation of virion-associated RNA in plasma was determined through real-time PCR as 
described previously [341].  From 1 ml plasma, virions were pelleted, total RNA was extracted 
utilizing Trizol reagent (Life Technologies, Rockville, MD), and 20 μl per sample was analyzed 
in a 96-well plate.  cDNA synthesis was accomplished through the addition of 50 mM MgCl, 
1xPCR buffer II (50 mM KCl, 10 mM Tris-HCl, pH 8.3), 0.75 mM dGTP, 0.75 mM dATP, 0.75 
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mM dCTP, 0.75 mM dTTP, 1 U of RNase inhibitor, 1.2 U of murine leukemia virus reverse 
transcriptase (RT), 2.5 μM random hexamers, and 10% total viral RNA.  Following mixing and a 
10 min incubation at room temperature, PCR was initiated by the addition of RT and 30 μl 
master mix containing 1xPCR buffer A, 5.5 mM MgCl2, 2.5 U of Amplitaq Gold, 200 mM 
deoxyribonucleoside triphosphates (dNTPs), 450 nM each primer, and 200 nM probe. The 
primers used were 5’AGGCTGGCAGATTGAGCCCTGGGAGGTTTC3’ and 
5’CCAGGCGGCGACTAGGAGAGATGGGAACAC3’, and the probe used was 
5’TTCCCTGCTAGACTCTCACCAGCACTTGG3’.  The probe was labeled in the 5’ position 
with the fluorescent reporter dye 6-carboxyfluorescein and in the 3’ position with the quencher 
dye 6-carboxymethylrhodamine. Successive incubations as room temperature for 10 min, 42oC 
for 12 min, 99oC for 5 min, and 4oC for 5 min completed the reaction.  Amplification was 
performed on a Prism 7700 sequence detection system undergoing the following conditions: 
95oC for 10 min, 40 cycles of 95oC for 15 s, 55oC for 15 s, and 72oC for 30 s.  Standard curves 
were generated through serial dilutions of in vitro transcribed LTR-containing control plasmid 
ranging from 108 to 100 and run in triplicate.        
3.4.7 Viral sequencing 
To perform viral sequence analysis, cell-free plasma was obtained and viral RNA was isolated 
utilizing the viral RNA mini kit (Qiagen, Valencia, CA) as per company instructions.  To 
amplify the gag gene, first-strand cDNA synthesis was primed with random hexamers or the 
gag-specific primer BGAGR: 5’-GCGCTGCAGTGGGAGTTGCCCTGGTGTCAGT-3’ and 
reverse transcribed using Superscript II reverse transcriptase (Invitrogen, Carlsbad, CA).  PCR-
amplified fragments containing 90% of the gag gene were generated by using the primers 
BGAGF: 5’-GGCGAATTCATGGGCGTGAGAAACTCCGTCTTG-3’ and BGAGR with the 
Expanded High Fidelity PCR system (Roche Applied Science, Indianapolis, IN), as per 
manufacturer’s instructions, using an annealing temperature of 53oC.  For analysis of individual 
cloned viral cDNA sequences, amplicon DNA was purified from agarose gels and cloned into 
the pGEM-TA vector (Promega, Madison, WI) prior to transformation into bacteria.  Plasmid 
DNA was sequenced with a 3770 DNA analyzer (Applied Biosystems, Foster City, CA).  
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Sequence data were aligned with SIVmac239 (GenBank accession no. M33262) using 
CLUSTAL W. 
3.4.8 Statistical analyses  
Statistical comparisons of animal-specific cellular immunity were achieved through paired 
sample t tests while NAb determinations were measured using Student’s t Test.  Longitudinal 
evaluations of cellular immunity or viral load between immunized and control groups were 
attained by calculating the cumulative average response from the summed means of individual 
values per animals over a predetermined interval.  Mean values per immunized and control 
treatment groups were then compared over sequential time points using the non-parametric 
binomial (sign) test [342], examining the consistency of binary differences (±) between the two 
groups across time [343].     
3.5 RESULTS 
3.5.1 Study characteristics  
In a proof-of-concept study, eight adult, Indian rhesus macaques received four 
immunizations each of an Ad5-based vaccine encoding the SIVmac239 gag transgene in as p17 
and p45.  Segmentation of the Gag protein was performed to allow for the optimal expression 
and potential recognition of subdominant epitopes.  Vaccination was delivered at roughly wks 0, 
4, 16, and 26.  Subsequently, two animals received continued boosting with conventional Ad5-
based vectors, while the six remaining monkeys received heterologous boosting utilizing the 
novel Ad35-based vectors encoding identical gag transgenes (Table 1).  Eight immunized and 
three naïve control animals were then challenged through atraumatic inoculation with 
SIV/DeltaB670 at roughly three months following the final immunization.  Animals were 
monitored for disease progression, and followed to a study endpoint defined as greater than 20% 
 38 
 39 
weight loss or the development of non-treatable opportunistic infections.  Study animals were 
males of equivalent age, with one Mamu-A*01 expressing individual per treatment group.    
      
Table 1: Animal characteristics and immunization schedule. 
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3.5.2 Ad35-based booster vaccination enhances Ad5-based vaccine primed 
immunity to SIV Gag 
Upon immunization with Ad5-Gag, all animals demonstrated a rapid and potent Gag-
specific cellular immune response measured by IFN-γ ELISPOT assay (Fig. 1, left).  Peak 
responses following Ad5-Gag immunizations were identified following two to four 
immunizations, with frequencies of Gag-specific effector T cells in uncloned PBMC ranging 
from 1:1000 to 1:500 for most study animals.  We found no apparent differences in the 
development of cellular immunity following either i.m. or i.d. vaccination.  In agreement with 
previous studies, we observed the immediate induction of Ad5-specific NAb that were incapable 
of cross-neutralizing Ad35-based vectors (Fig. 1, right).  As expected, repeated Ad5-Gag 
immunization displayed reduced efficacy in the presence of high titre Ad5-specific NAb.  Upon 
continued boosting immunization with Ad5-Gag, animals M1501 and M1601 displayed 
dramatically inhibited expansion of Ag-specific immunity, representing roughly 30% and 50% of 
previously attained peak values.  Notably, the persistence of Ad5-specific NAb in serum 
decreased in the absence of Ad5 exposure following the fourth Ad5-Gag immunization, showing 
a 40 fold reduction in Ab titre in the 27.3±2.8 weeks between priming and boosting 
immunizations.  This decline in Ab titre potentially allowed for the measure of immune 
induction identified after continual Ad5-Gag booster vaccination.  By contrast, boosting using 
Ad35-Gag provided substantial immune enhancement, attaining higher frequency Gag-specific T 
cell responses in all vaccinees over those found following repeated Ad5-Gag alone.  
Interestingly, the development of Ad35-specific NAb titres were delayed and muted, with one 
third of the animals failing to mount a response until the second Ad35-Gag immunization.  
Additionally, Ad35 exposure produced weaker, transient NAb titres, with responses falling to 
undetectable levels between the first and second Ad35-Gag immunizations in 83% of animals.                     
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Figure 1:  Ad35 boosts SIV Gag-specific immunity induced by Ad5. 
Monkeys were immunized and boosted with replication-defective Ad5-p17 and Ad5-p45 alone (arrows, top panels)
or prior to boosting with replication-competent Ad35-p17 and Ad35-p45 (arrowheads, bottom panels).  Left, PBMC
were incubated with four pools of Gag peptides and IFN-γ-producing cells were quantified 24 h later.  Shown are
mean ± SEM of triplicate determinations for all pools combined after subtraction of background.  Thresholds for
significance are shown by horizontal lines denoting mean background responses over all time points for each
animal.  Right, Ad5- and Ad35-specific neutralizing Ab titres in serum.  
3.5.3 Dual-serotype Ad-based vaccination induced broad T cell responses to Gag 
We next sought to characterize the development of Gag-specific epitope recognition upon 
Ad5-Gag priming and subsequent Ad35-Gag boosting vaccinations.  This was achieved through 
IFN-γ ELISPOT analysis of overlapping peptide matrices.  Peptide matrix design provides that a 
specific peptide is contained in two discrete pools of eight peptides each, allowing for the 
discrimination of candidate epitopes when responses to both unique pools are positive.  
Candidate peptides are then testing individually to confirm reactivity [308].  Animal M1701 
displayed a strong response to two regions in Gag represented as p35/p36 and p68/p69, likely 
representing two specific epitopes found in sets of 15mer peptides containing common 11aa 
sequences (Fig. 2a).  Ad35-Gag vaccination did not alter the specificity of the response.  
Similarly, M7801 displayed reactivity against the p14/p15 and p35/p36 regions of Gag, 
demonstrating potent enhancement of identical responses following Ad5-Gag prime and Ad35-
Gag boost.  Animal M2301 responded to eight different peptides over the course of vaccination, 
representing six regions of Gag protein.  As expected, animals M2201 and M9700 expressing the 
Mamu-A*01 allele developed dominant responses to the p45 and p46 peptides, containing the 
MHC class I-restricted, immunodominant CD8+ T cell epitope CM9 (Gag181-189) (Fig. 2a, data 
not shown) [344].   
We next sought to define whether the identified peptides were MHC class I- or class II-
restricted epitopes, representing responses mediated by CD8+ or CD4+ T cells, respectively.  To 
this end, we used magnetic bead Ab depletion to remove either CD4+ or CD8+ T cells from 
PBMC prior to testing peptide epitopes by IFN-γ ELISPOT analysis.  Analysis revealed that 
IFN-γ responses to p68 and p69 in M1701 and M2301, respectively, were completely abrogated 
upon removal of CD8+ but not CD4+ T cells, illustrating that these epitopes are MHC class I-
restricted (Fig. 2b).  Similarly, IFN-γ release from p35 stimulation of M7801 was lost in the 
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absence of CD8+ T cells.  Additionally, CM9 responses in M2201 and M9700 were found to be 
MHC class I-restricted, CD8+ T cell-dependant as previously reported (data not shown).  In 
contrast, the p14/p15 Gag region recognized by M7801 was found to be MHC class II-restricted, 
as IFN-γ production was eliminated upon the removal of CD4+ T cells.  Taken together, these 
findings demonstrate that Ad-based vaccination is capable of enhancing the breadth of both 
CD4+ and CD8+ T cell responses. 
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Figure 2:  Vaccination induces broad Gag-specific cellular immunity. 
(A) PBMC were incubated with diluents or individual Gag peptides at various times after immunization as indicated, and IFN-γ-producing cells were
quantified 24 h later.  Positive responses as defined in Materials and Methods are indicated by asterisks.  Shown are mean ± SEM of triplicate
determinations.  (B) PBMC from animals M1701, M7801, and M2301 before and after Ab-mediated depletion of CD4+ or CD8+ T cells were incubated
with individual 15mer peptides as indicated and IFN-γ-producing cells were quantified 24 h later.  Shown are mean ± SEM of triplicate determinations based
on absolute number of cells in the assay with or without depletion.  C, diluent control; dep, depleted.     
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3.5.4 Vaccine induced cellular immunity is recalled upon viral challenge 
Given the stark diversity of HIV, a non-autologous vaccination must direct immunity 
against viral regions of high structural conformity and thus evolutionary constraint.  To this end, 
eight immunized and three treatment naïve control animals were mucosally challenged by 
intrarectal inoculation of the pathogenic biologic isolate SIV/DeltaB670 11-12 wks after final 
boost.  Vaccine targeted SIVmac239 and challenge SIV/DeltaB670 are distantly related viral 
strains, sharing an 8% Gag sequence dissimilarity (data not shown), providing a stringent and 
realistic exposure modeling natural HIV infection [337, 339].  The two animals receiving 
repetitive Ad5-Gag immunizations produced recall responses following SIV challenge, although 
of varying dynamics.  M1601 developed a strong and transient Gag-specific recall response, with 
Ag-specific T cell frequencies reaching 1:500 per uncloned PBMC (Fig. 3a) before disappearing 
for the remainder of the study.  M1501 displayed a low frequency response to SIV challenge that 
was sustained.  Unfortunately, M1501 died due to anesthetic related complications unrelated to 
SIV infection at 15 wks post-challenge, precluding further observations.  Animals receiving the 
Ad5/Ad35 prime-boost immunization regimen generally developed robust cellular immunity 
following SIV challenge, although considerable variation between animals was seen (Fig. 3a).  
Notably, post-challenge Gag-specific recall responses were strongly associated with the 
magnitude of peak vaccine induced immunity during vaccinations.  In contrast, the IFN-γ 
response to infection among non-vaccinated control animals was minimal, with only two control 
animals developing moderate responses (Fig. 3b).  When the mean Gag-specific IFN-γ response 
was compared between Ad5/Ad35 immunized and control animals, Gag-specific immunity was 
significantly greater in vaccinees for at least 25 wks post-infection (Fig. 3c).  To demonstrate 
that augmentation in post-challenge immunity was due to Gag-specific vaccination, we examined 
T cell responses to the SIV Env, Nef and Pol proteins before and after SIV challenge.  We found 
no differences in Ag-specific cellular immunity targeting peptide pools comprising the Env, Nef 
or Pol Ags when Ad5/Ad35 immunized animals were compared with control infected animals at 
during establishment of set-point viremia (wks 5-10) and during chronic infection (wks 23-25) 
(Fig. 3d). 
 46 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 47 
 Figure 3:  Vaccination induces durable recall responses following SIV infection. 
Vaccinated (A) or control (B) monkeys were challenged with SIV/DeltaB670 by atraumatic intrarectal inoculation.
PBMC were incubated with diluents or Gag peptide pools at various times after challenge and IFN-γ-producing cells
were quantified 24 h later.  Shown are mean ± SEM of triplicate determinations for all Gag peptides after
subtraction of background.  Thresholds for significance are shown by horizontal lines denoting mean background
responses over all time points for each animal.  (C) Mean Gag-specific IFN-γ responses of Ad5/Ad35-vaccinated
and control groups at intervals after virus challenge.  Responses over time were compared using a binomial test.  (D)
Responses of Ad5/Ad35-vaccinated and control animals to Env, Pol, and Nef peptide pools at intervals after virus
challenge.  Shown are mean responses of triplicate determinations after subtraction of background for each animal,
with the mean for the group represented by a horizontal line.  If more than one sample was analyzed during the
interval indicated, the stronger response is shown.  Vac, vaccinated; con, control. 
3.5.5 Novel and recalled Gag-specific epitopes identified following SIV infection 
Given the degree of genetic variation between the SIVmac239 immunization strain and 
SIV/DeltaB670 challenge virus, we examined whether epitope specific responses developed 
upon vaccination were conserved upon heterologous viral challenge.  To this end, we employed 
peptide matrices and IFN-γ ELISPOT analysis.  M1701 responded vigorously to infection, 
developing recall responses to the identical p35/p36 and p68/p69 regions induced through 
vaccination (Fig. 4).  Notably, M1701 developed rapid and potent recall responses to SIV 
challenge, demonstrating superior IFN-γ production to the immunodominant p68 epitope at 5 
wks post-infection to that seen previously following vaccination.  Upon infection, M2301 
responded to six of eight vaccine induced epitopes, failing to develop recall IFN-γ production to 
p23 or p47 stimulation (Fig. 4).  Peptide mapping revealed M7801 developed recall responses to 
all previously identified epitopes, but interestingly, responded to two novel epitopes, p1 and p67-
p69, following SIV challenge (Fig. 4).  Weak IFN-γ production was transiently identified to the 
CD4+ T cell restricted p14/p15 epitope following viral infection, suggesting rapid elimination of 
virally targeted, SIV-specific CD4+ Tem cells.  As expected, Ag-specific recall responses from 
the Mamu-A*01-expressing M2201 were directed against the immunodominant and conserved 
CM9 coding sequence as identified previously, approaching a frequency of 0.2% in unseparated 
PBMC.  This is in contrast to the failure to develop de novo CM9-specific immunity from the 
Mamu-A*01-expressing control animals M14301 and M15001 (Fig. 3, data not shown), 
illustrating the utility of preventative vaccine-induced CTL memory expansion.  Finally, primary 
epitope-specific responses to SIV infection from M3398, the only control animals for which a 
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robust post-challenge Gag-specific response was detected, were directed against the p68/p69 
region (Fig. 4).  Taken together, these data indicate that epitope-specific vaccine-mediated 
responses were capable of rapid and potent recall upon heterologous infection with 
SIV/DeltaB670.                 
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Figure 4:  Epitope response following SIV/DeltaB670 challenge. 
PBMC were incubated with diluents or individual Gag peptides at various times after SIV infection as indicated, and 
IFN-γ-producing cells were quantified 24 h later.  Positive responses as defined in Materials and Methods are 
indicated by asterisks.  Shown are mean ± SEM of triplicate determinations.  C, diluents control.  
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3.5.6 Limited viral control following heterologous SIV challenge 
We then utilized a sensitive RT-PCR assay to measure alterations in post-challenge 
SIV/DeltaB670 viremia, and the potential impact of Gag-specific Ad-based vaccination.  
Regrettably, analysis of the two Ad5/Ad5 immunized animals was prevented by the anesthesia 
related death of M1501.  Interestingly, M1501 was capable of restricting set-point viremia to 
roughly 2x103 RNA copies per ml in the presence of only moderate Gag-specific IFN-γ 
production, suggesting a qualitative advantage that went undetected in this study (Fig. 5a).  Upon 
SIV challenge, Ad5/Ad35 immunized animals displayed a trend towards lowered viral load when 
compared to controls (Fig. 5a).  Although a great deal of variation was seen among Ad5/Ad35 
immunized animals, two of six, M17010 and M2301 attained undetectable viral loads for 
multiple timepoints until wk 44 post-infection (Fig. 5a).  When mean viral loads over pre-
determined intervals were compared between the Ad5/Ad35 immunized and control groups, we 
found a statistically significant temporal reduction in viremia with Ad5/Ad35 immunized group 
presenting lower viral loads at 11 of 12 timepoints (p=0.003) (Fig. 5b).  Comparison of survival 
between control and Ad5/Ad35-vaccinated groups showed a trend towards longer survival 
periods among immunized animals (P=0.094), with groups achieving median times to death from 
AIDS at 41.0 and 49.3 wks respectively (Fig. 5c).  Animal M2301 remained alive at 70 wks 
post-infection, and the duration of the study.  These data demonstrate the measurable effect of 
vaccination, even of limited antigenic scope, upon viral control.        
 
 
 
 
 51 
 
 
Figure 5:  Post-challenge SIV/DeltaB670 viral load and survival.  
(A) Plasma virus load of control animals and animals vaccinated with Ad5-based or Ad5- and Ad35-based vectors.  
Final measurements are at the time of sacrifice due to AIDS except for animal M1501 which died of unrelated 
causes at wk 15, and animal M2301 which remains alive and free from disease at wk 70 post-infection.  (B) Mean 
virus loads of Ad5/Ad35-vaccinated and control groups at predetermined intervals after challenge.  (C) Kaplan-
Meier survival curves for Ad5/Ad35-vaccinated and control groups.   
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3.5.7 Fine mapping of novel CD8+ and CD4+ T cell-mediated epitopes 
To define precise viral targets, we utilized walking 9mer or 15mer peptides overlapping 
by a single amino acid to span previously targeted regions containing MHC class I- or class II-
restricted epitopes, respectively.  Four animals expressing the MHC Mamu-A*01-expressing 
allele, M2201, M9700, M14301, and M15001 all had immunodominant responses to the CM9 
epitope (Gag181-189) as previously acknowledged (data not shown).  Fine mapping of the p35/p36 
region within the capsid protein revealed that the responses of M1701 and M7801 were directed 
towards peptides GL9 (Gag141-149) and GS9 (Gag142-150), suggesting the optimal epitope is an 8 
amino acid sequence common to both peptides (Fig. 6).  IFN-γ release mediated by the p68/p69 
region was found to be directed against two distinct 9mer sequences, GY9 (Gag270-278) and QP9 
(Gag272-280) within capsid in PBMC from M7801 following SIV challenge (Fig. 6).  By contrast, 
the epitopes within the same region, p68/p69, recognized by M1701, M2301, and M3398 could 
not be identified using 9mer peptides, suggesting a larger peptide sequence may be targeted.  
Using walking 15mers, we identified the CD4+ T cell-mediated p14/p15 matrix protein response 
of M7801 to be directed primarily against GT15 (Gag56-70) (Fig. 6).    
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Figure 6:  Fine mapping of vaccine induced epitopes. 
PBMC from animals M1701 and M7801 were incubated with walking 9mer (p35/p36 and p68/p69) and 15mer 
(p14/p15) Gag peptides overlapping by one amino acid or diluents control at times of optimal immunity following 
SIV infection, and IFN-γ-producing cells were quantified 24 h later.  Shown are mean ± SEM of triplicate 
determinations.  C, diluents control.  
 
 54 
3.5.8 CD8+ T cell-mediated epitope escape mutations and SIV/DeltaB670 
variability 
To examine the effect of CD8+ T cell-mediated immune pressure on viral mutation, we 
longitudinally compared viral sequences in the known immunodominant CM9 epitope and 
regions containing the previously unidentified epitopes listed in this study.  Although isolates 
from the SIV/DeltaB670 challenge virus were heterogeneous at flanking regions compared to 
SIVmac239, known to effect CM9 recognition during SIVmac251 infection, all sequences 
expressed the intact CM9 epitope.  In the presence of potent Gag-specific CD8+ T cell-mediated 
immunity composed exclusively of CM9-specific responses, animal M2201 had a rapid increase 
in plasma viremia at wk 15 post-infection leading to death at wk 32, suggesting cellular 
immunity towards this epitope was no longer effective.  Sequence analysis revealed 
characteristic 2nd anchor residue CM9-specific CD8+ T cell-mediated escape mutations were 
present in the circulating virus of M2201 by wk 15 and wk 23, consisting of 63 and 100% of 
isolates (Fig. 7a) [345].  Of the four animals expressing the Mamu-A*01 allele (Table 1), all had 
measurable CM9-specific IFN-γ responses, and three subsequently developed CM9-specfic 
CD8+ T cell-mediated escape mutations coincident with increases in viral load (Fig. 7a).  
M15001 had 100% viral escape at within CM9 by wk 19 post-infection.  Similarly, M9700 
displayed viral escape in 85% of isolates by wk 39 post-infection.  Notably, the only Mamu-
A*01-expressing animal to not show evidence of CM9 viral escape, M14301, mounted inferior 
Gag-specific immunity following viral infection (Fig. 3b), illustrating the association between 
effective immune pressure and viral escape.  Interestingly, mutations within the CM9 sequence 
but outside positions known to affect peptide binding, were also identified in viruses isolated 
from animals M1701 and M7801, which did not express the Mamu-A*01 allele (Fig. 7b).  
Altered CM9 sequences failed to induce de novo CD8+ T cell-mediated IFN-γ responses (Fig. 
7b), suggesting that SIV/DeltaB670 is capable of limited viral mutation within traditionally 
constricted regions in the absence of immune pressure.  No consistent extraepitopic mutations 
associated with any CM9 mutations could be identified throughout this investigation.  
We next examined if T cell-mediated immunity could direct viral escape mutations in the 
novel GL9, GY9, QP9 and GT15 epitopes.  Sequence analysis of the SIV/DeltaB670 viral 
inoculum showed minimal variation in the MHC class II-mediated GT15 epitope region, which 
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was later found to consistently include the unaltered epitope in plasma viral isolates collected 
from M7801 at wks 2 and 15 post-infection (Fig. 7c).  As IFN-γ response to GT15 stimulation 
was lost by wk 15 post-infection, this suggests elimination of virally targeted SIV-specific CD4+ 
T cells instead of epitope escape.  The SIV/DeltaB670 inoculum was found to contain a position 
5 valine to threonine (V145T) alteration in the MHC class-I restricted GL9 epitope compared to 
the consensus SIVmac239 vaccination strain that was preserved throughout the course of 
infection in M7801 (Fig. 7c).  Peptides corresponding to GL9 with either the valine or threonine 
at Gag145 were found to induce equivalent IFN-γ responses upon stimulation of uncultured 
PBMC from M7801 (Fig. 7c).  Additionally, the immunogenic region containing the GY9 and 
QP9 MHC class I-restricted peptides targeted by M1701 was shown to be identical in both 
vaccine and challenge strains, and was conserved without mutation at wk15 post-infection in this 
animal (Fig. 7d).          
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Figure 7:  CD8+ T cell-mediated epitope escape mutations and SIV/DeltaB670 variability. 
Sequence comparison between SIVmac239 vaccine strain, SIV/DeltaB670 inoculum, and viruses isolated from 
plasma from animals expressing (A) Mamu-A*01, M2201, M9700, M15001, and M14301, (B) non-Mamu-A*01-
expressing animal M1701, (C) animal M7801, and (D) animal M1701 at times post-challenge.  (A, B) The Mamu-
A*01 restricted CM9 epitope is depicted by the shaded region.  (B) IFN-γ responses to the CM9-flanking sequences 
in SIV/DeltaB607 in PBMC by ELISPOT shown at times post-infection as indicated in M1701.  (C) SIV/DeltaB670 
mutations in immunodominant T cell epitopes, depicted as shaded boxes, and concurrent IFN-γ responses to the 
GL9 mutation in PBMC by ELISPOT in animal M7801 at times post-infection.  (D) SIV/DeltaB670 mutations in 
immunodominant T cell epitopes, depicted as shaded boxes, in the p68/p69 region from times post-infection of 
M1701.         
3.6 DISCUSSION 
At the inception of this investigation, second generation adenoviral vectors based on non-
Ad5 serotypes were being extensively pursued as immunogens for vaccination against HIV and 
other infectious diseases [304, 346-348].  Ad35 has risen to the forefront of heterologous Ad 
development based on a relatively low global seroprevalence compared to Ad5, and its ability, as 
a group B virus, to evade cross-neutralization by Ad5-specific humoral immunity [297, 305, 306, 
310, 336].  Previous studies in the murine model have demonstrated the immunogenicity of 
Ad35 vectors to boost transgene-specific cellular immunity in the presence of pre-existing Ad5-
specific NAb responses [319].  Our current study extends these findings, providing the first 
evidence that Ad5/Ad35-based vaccination is immunogenic in the non-human primate model.  
Furthermore, these results support those of similar sequential vaccination regimens utilizing 
recombinant heterologous simian Ad species which have proven to induce robust cellular 
immunity [311].  We found Ad35-based immunization boosted existing Gag-specific T cell-
mediated responses induced through Ad5-based priming without expanding their repertoire, 
suggesting that transgene delivery and processing is consistent between vectors.  In contrast, 
SIV/DeltaB670 infection produced both anamnestic as well as novel Gag-specific epitope 
responses, potentially due to sequence variation or differences in Ag processing and presentation.  
Although the data presented were attained using replication competent Ad35-based vectors, we 
have subsequently developed E1/E3-deleted, replication-defective Ad35-based vectors further 
enhancing the safety of immunization [310].              
 This study demonstrates that vaccination targeting conserved epitopes can induce 
preserved cellular immunity capable of targeting a heterologous challenge strain, providing acute 
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and chronic viral inhibition.  Published sequence analysis confirmed that the vaccine targeted 
molecular clone SIVmac239 and SIV/DeltaB670 quasispecies are truly heterologous, based on 
14% dissimilarity in the predicted amino acid sequence of the viral envelop proteins.  Despite 
significant overall variability, we immunized animals utilizing vectors expressing the relatively 
conserved Gag protein which retains 94% sequence homology between SIVmac239 and 
SIV/DeltaB670 (data not shown).  We found remarkable consistency between the recognized 
epitope repertoires induced through vaccination and upon infection, suggesting anamnestic 
responses capable of viral detection and containment.  Previous findings by Vogel et. al., have 
demonstrated differences in Ag-specific epitope recognition upon DNA/MVA immunization 
against nearly all viral proteins from SIV17E-Fred and SIVmacJ5 and subsequent challenge with 
the closely related pathogenic SIVmac239, characterizing significant addition and loss of 
targeted epitopes during acute and chronic infection [349].  Our current findings utilizing 
SIV/DeltaB670 challenge are similar in nature to the DNA/MVA model, with modest inhibition 
of acute viremia without pronounced containment of disease progression [350].  Notably, viral 
inhibition in our model was achieved following Gag-based immunization alone, as recent reports 
have implicated the breadth of cellular immunity targeting multiple viral proteins, both structural 
and regulatory proteins, in the control of SHIV and SIVmac251 infection following 
immunization [351, 352].     
 Detailed epitope characterization identified an immunogenic region of the capsid protein 
(Gag269-291) that was conserved and targeted within both SIVmac239 and SIV/DeltaB670.  CD8+ 
T cell-mediated responses directed against this region were identified in four unrelated animals.  
The novel 9mer epitopes GY9 (Gag270-278) and QP9 (Gag272-280) were identified in one vaccinee, 
yet specific epitope responses from the remaining three animals could not be defined.  As the 
animals responding to this region lack a consensus MHC genotype, it is possible that Gag269-291-
directed immunity is conferred by a single undefined allele common among the study 
responders.  Regardless of epitope definition and MHC restriction, IFN-γ response to this region 
was associated with heightened control of post-challenge viremia, as two of three Gag269-291-
responsive animals maintained undetectable viral loads for several months.  Interestingly, we did 
not detect stable CD8+ T cell-mediated epitope escape mutations within the Gag269-291 region,  
M1701 who had previously contained viremia died of AIDS at wk 62 post-infection with the 
wild-type Gag269-291 sequence preserved in all viral clones isolated at the time of death, 
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suggesting that although immunogenic, the Gag269-291 region may be of lesser importance in 
virologic control.  It is evident that broad vaccine induced cellular immunity targeting multiple 
structurally conserved Ags and evolutionarily restricted viral epitopes will be necessary to 
establish durable control of heterologous viral infection as supported by the current and similar 
investigations [326, 341, 351, 353].             
 CD8+ T cell-mediated epitope escape occurs continually throughout SIV/HIV infection, 
with immunologic T cell-mediated pressure driving viral mutations inhibiting Ag processing, 
presentation or recognition, often accompanied by reduced viral fitness [224, 240, 354].  The 
capsid-embedded, Mamu-A*01-restricted CM9 epitope is widely conserved among SIV stains 
and other lentiviruses, including SIV/DeltaB670 as shown here, and is highly immunogenic 
among SIV species [355].  CM9 is generally resistant to escape mutation due to accompanying 
defects in virion maturation and Gag protein production [239, 356-358], and CM9 escape is 
associated with loss of virologic control and the development of AIDS [345, 357, 359].  Two 
valine-for-isoleucine compensatory mutations flanking the CM9 sequence at positions 161 and 
206 of Gag (I161V and I206V) have been shown to restore proper virion production and in vitro 
fitness during SIVmac239 and SHIV-89.6P infection [360, 361], and can be stably transmitted to 
susceptible hosts in the absence CD8+ T cell-mediated targeting [362].  Here we show that 
SIV/DeltaB670 is capable of undergoing classic position two anchor residue escape mutation in 
the absence of temporally associated compensatory flanking mutations in the presence of potent 
CM9-specific CD8+ T cell-mediated responses.  CM9 escape occurred relatively early in this 
model, suggesting mutation had only minor effects on viral fitness.  Furthermore, in non-Mamu-
A*01-expressing animals the CM9 epitope voluntarily sustained mutations in the absence of 
measurable epitope-specific T cell response.  Interestingly, the protein sequence of 
SIV/DeltaB670 flanking CM9 is hypervariable when compared to SIVmac239, including a stable 
I161V substitution, with a dissimilarity of 12% compared to just 6% for the entire Gag protein.  
Our findings suggest that structural flexibility and stable mutations in the SIV/DeltaB670 capsid 
impart the ability to undergo early CM9 escape without dramatic fitness loss.  In support, Mamu-
A*01-expressing macaques lack a survival advantage over animals expressing other genotypes 
during SIV/DeltaB670 infection (data not shown), in contrast to SIVmac239 or SIVmac251 
infection [363, 364].          
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 HIV/SIV targeting by CD4+ T cells is a crucial factor in controlling viral replication and 
maintaining CD8+ T cell-mediated responses [133, 212], and is primary goal of effective 
vaccination.  We currently show that dual-serotype Ad-based vaccination induced predominantly 
CD8+ T cell-mediated responses, consisted with earlier reports [288].  Yet, we have identified a 
novel CD4+ T cell-dependant epitope, GT15 (Gag156-170), in the matrix protein induced by Ad5-
priming and sustained through Ad35-based boosting.  Although the GT15 epitope sequence is 
conserved between SIVmac239 and SIV/DeltaB670, detectable IFN-γ responses against this 
region were of low frequency and transient duration following viral challenge.  These findings 
are consistent with previous reports by Vogel, et. al., showing lack of vaccine-induced CD4+ T 
cell-mediated recall responses upon challenge with a closely related viral strain [349].  
Potentially, CD4+ T cell-dependant immunity may be lost due to rapid elimination of SIV-
specific CD4+ T cells following viral challenge, as findings have indicated that HIV/SIV 
preferentially replicate in activated, virus-specific CD4+ T cells [39].  Together these findings 
illustrate the difficulty in inducing sustained Ag-specific CD4+ T helper immunity following 
viral infection, and suggest intervention to salvage CD4+ T cells post-infection may restore 
vaccine primed immunity.    
3.7 CONCLUSIONS 
The presented findings demonstrate the ability of Ad35-based vaccination to be utilized 
in conjunction with Ad5-based immunization, due to the lack of cross-neutralizing vector-
specific Ab responses.  Furthermore, ability of dual-serotype Ad-based vaccination targeting the 
Gag protein alone to limit viremia upon pathogenic SIV challenge highlights the superior 
immunogenicity of Ad-based vectors.  Together, these findings strongly support the further 
examination and optimization of Ad-based vaccination regimens for the treatment of HIV 
infection.             
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4.0  CHAPTER TWO: IMMUNOTHERAPEUTIC ADENOVIRUS-BASED 
VACCINATION INDUCES ROBUST CD8+ T CELL-BIASED IMMUNITY BUT FAILS 
TO CONTROL VIREMIA IN CHRONICALLY SIVMAC251 INFECTED MACAQUES 
4.1 PREFACE 
The following chapter is in fulfillment of specific aim 2 and has been submitted for peer-
reviewed publication.  The described therapeutic vaccination study was a collaborative effort 
within the University of Pittsburgh involving the Barratt-Boyes lab for immunologic analysis, 
the Viral Vector Core for creation of Ad vectors, and the Department of Laboratory Animal 
Research at the Primate Facility for Infectious Disease Research for animal procedures and 
maintenance.  Specifically, Adam C. Soloff performed all experiments excluding RT-PCR viral 
load determinations which were run by Xiangdong Liu.  A. Soloff completed all data analysis 
and statistical evaluation, and was the primary author of the submitted manuscript with 
assistance from Dr. Barratt-Boyes.  A. Soloff assisted in study design.  Wentao Gao and Andrea 
Gambotto manufactured all Ad vectors utilized in the study.  Richard D. Day was consulted on 
statistical analysis. 
4.2 ABSTRACT 
Effective approaches to immunotherapy for HIV infection are being sought with the goal 
of increasing immune control of virus in infected individuals.  We tested a prime-boost 
immunotherapy strategy using recombinant adenovirus serotype 5 (Ad5) and Ad35-based 
vaccines given during two cycles of antiretroviral therapy in monkeys with chronic SIVmac251 
infection.  Vectors independently expressed SIV gag, env, and nef genes as well as bioactive 
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rhesus IL-15, used here as a potential vaccine adjuvant. Vaccination increased the frequency of 
circulating T cells specific for all three targeted viral Ag although this effect was lost with IL-15 
delivery.  Ag-specific CD8+ T cells produced combinations of IFN-γ, TNF-α and/or IL-2, 
whereas Ag-specific CD4+ T cells exclusively produced IFN-γ, with responses represented 
within both central and effector memory CD4+ and CD8+ T cell populations.  Notably, 
vaccination did not change the proportion of CD8+ or CD4+ T cells producing one or more 
cytokines relative to control animals.  Immunization transiently and incompletely restored 
peripheral blood CD4+ Tcm numbers but failed to reverse CD4+ Tem cell decline.  
Immunotherapy did not reverse profound mucosal CD4+ T cell loss but induced Ag-specific 
CD8+ T cell responses of a primarily monofunctional nature at the lung mucosa. Nevertheless, 
Ad-based vaccination had no impact on virus load. When analyzed independent of treatment 
group, virus control was correlated with polyfunctional blood CD4+ and CD8+ T cell responses 
and maintenance of blood CD4+ Tcm cells and mucosal CD4+ T cells. These data demonstrate 
that Ad-based immunotherapy given during chronic SIV infection, after loss of blood and 
mucosal CD4+ T cells, induces robust but largely monofunctional CD8+ T cell-biased responses 
that are incapable of controlling virus load.  
4.3 INTRODUCTION 
Advancements in the therapy of HIV infection have lead to a dramatic reduction in 
disease-associated morbidity and mortality, but have not been successful in preventing disease 
progression due to the emergence of viral drug resistance [365].  Although ART serves to restrict 
viral replication, providing a window of immunologic salvation and opportunity for restoration 
of CD4+ T lymphocyte populations, it fails to eliminate latent viral reservoirs capable of 
regenerating infection upon treatment cessation [60, 366, 367].  Paradoxically, effective ART 
reduces the antigenic exposure necessary to drive virus-specific host immunity, leading to a loss 
of de novo immunologic response and a reduction in effector capabilities [368, 369].  Therefore, 
novel therapeutic strategies aimed at bolstering antiviral immunity and restoring immunologic 
balance during ART-treated HIV infection are urgently needed [370].     
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Therapeutic vaccination should aim to augment antiviral T cell-mediated immune 
responses and maintain CD4+ Tcm populations, both strongly associated with control of 
infection.  Virus-specific cellular immunity has been implicated as a dominant factor in the 
initial control of primary viremia [105, 106], maintenance of lowered chronic set-point viral 
loads [197, 199], and control of rebound viremia during STI [200, 201].  CTLs that target a 
breadth of viral epitopes, particularly in the Gag region, have been associated with reduced 
viremia in untreated HIV infection [214, 371].  Maintenance of cellular immune responses in 
mucosal tissues is also likely to be important in control of infection [372].  Additionally, recent 
studies have demonstrated that durable containment of HIV is predominantly a function of the 
qualitative polyfunctional characteristics of the cellular immune response rather than simply the 
magnitude of response [219, 221, 292].  Working in conjunction with the antiviral effector 
response, CD4+ Tcm lymphocytes aid in the preservation and regeneration of T lymphocyte Tem 
populations during the course of HIV infection of humans and SIV infection of non-human 
primates [36].  In addition, augmentation of CD4+ Tcm cells has been associated with vaccine-
mediated protection against SIV infection [214].   
There has been significant interest in the use of cytokines to augment vaccine-induced 
immune responses to infection, particularly focused on IL-15.  Loss of IL-15 has been observed 
in progressive HIV infection [166, 373], potentially leading to homeostatic disruption of T 
lymphocyte memory populations.  Conversely, elevated plasma IL-15 concentrations are 
associated with control of viremia during STI within chronic HIV infection [167].  Cytokine 
chemotherapy utilizing IL-15 has been shown to augment CD4+ and CD8+ T cell memory 
populations in viral infection [177, 374] and enhance antiviral cellular immunity [172, 179-181].  
In addition, IL-15 treatment has been found to rescue Ag-specific T cell effector and 
proliferative responses from dysfunctional HIV-infected PBMC in vitro [168, 175, 375].  
However, recent reports have observed increases in acute SIV viremia and ablation of 
therapeutic vaccine-mediated reductions in SIV viral loads following systemic administration of 
high-dose IL-15 [376, 377].  As a result of these contradictory reports, the therapeutic benefits of 
IL-15 in promoting antiviral immunity remain unclear. 
Therapeutic vaccine trials have employed inactivated virus, poxvirus vectors, DNA, and 
Ag-pulsed dendritic cells among many other approaches with varying degrees of success in 
controlling HIV and SIV infection [200, 280, 378, 379].  Due to their potent ability to induce 
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transgene-specific cellular immunity, adenoviral (Ad)-based vectors have emerged as one of the 
most promising candidates for HIV vaccine development [288, 304], although enthusiasm has 
been tempered recently following disappointing results from a large vaccine trial [380].  Ad-
based approaches to immunotherapy for HIV infection have not been reported to date. To 
circumvent vector-specific immunity, Ad vectors based on rare human and nonhuman primate 
serotypes have been developed, providing vectors impervious to cross-neutralization and 
appropriate for prime-boost immunization regimens [310-312, 320, 381].  In the current study, 
we employed a heterologous immunization regimen utilizing Ad serotype 5 (Ad5) - and Ad35-
based vectors [289] to enhance antiviral cellular immunity against the Gag, Env, and Nef 
proteins during infection of rhesus macaques with pathogenic SIV.  To address the potential for 
therapeutic efficacy of IL-15, a subset of animals additionally received Ad-based vaccines 
expressing the rhesus IL-15 gene.  To provide a realistic model of clinical HIV infection, we 
delayed intervention until establishment of chronic infection and administered vaccines during 
two periods of ART interspersed by a STI. 
4.4 MATERIALS AND METHODS 
4.4.1 Animals and SIV infection 
Twenty-one colony-bred Indian rhesus macaques (Macaca mulatta) were housed at the 
University of Pittsburgh Primate Facility for Infectious Disease Research and maintained in 
accordance with institutional regulations.  Molecular MHC class I typing for the rhesus macaque 
alleles Mamu-A*01, A*02, A*08, A*11, B*01, B*03, B*04 and B*17 was carried out through a 
contract with the Wisconsin National Primate Research Center.  Animals were i.v. infected with 
1,000 TCID50 of uncloned, pathogenic SIVmac251 provided by Chris Miller (University of 
California, Davis).  The principal criterion for inclusion in the study, for which fifteen animals 
qualified, was a median set-point SIV plasma viral load > 105 RNA copies/ml and < 107 RNA 
copies/ml from wk 6 to wk 12 when ART was initiated.  These animals were stratified based on 
gender and expression of Mamu-A*01 (R479, R480, R487), and subsequently randomized into 
three groups receiving Adψ vectors lacking expression of transgene (control, n=4), Ad-based 
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vectors expressing SIV gag, env, and nef genes (Ad-SIV, n=5), or Ad-based vectors expressing 
SIV gag, env, and nef and rhesus IL-15 (Ad-SIV/IL-15, n=6). 
4.4.2 ART and therapeutic vaccination 
All animals received ART consisting of 9-[2-(phosphonylmethoxy)propyl]adenine (PMPA; 
20mg/kg/day, s.c. injection) and 2’-deoxy-5-fluoro-3’-thiacytidine (FTC; 30mg/kg/day, s.c. 
injection), from wk 12 to wk 24 post-infection (PI, ART cycle-1) and again from wk 32 to wk 44 
PI (ART cycle-2).  PMPA and FTC were provided by Michael Miller (Gilead Sciences, Inc).  
Ad5-based vectors were given by i.m. injection during ART cycle-1 at wk 16 (5x1010 viral 
particles per vector) and at wk 22 (1x1011 viral particles per vector), and Ad35-based vectors 
were given by the same route and dose during ART cycle-2 at wk 36 and wk 42 PI.  Control-
treated animals received injections of similar amounts of the Adψ5 and Ad ψ35 vectors, 
respectively.  
4.4.3 Recombinant Ad vectors 
Ad5- and Ad35-based vectors expressing egfp or codon-optimized SIVmac239 gag, env, or nef 
or lacking transgene were developed as previously described [289, 310].  IL-15 was RT-PCR 
amplified from total RNA extracted from healthy macaque PBMC following 24 h stimulation 
with IL-2 and SEB using the sense 
(5'CGTCGACGGATCCGCCACCATGAGAATTTCGAAACCACATTTGAG3') and anti-sense 
(5'GCGAATTCTCAAGAAGTGTTGATGAACATTTGGACAATATGTAC3') primers and 
subcloned into the pAdlox shuttle plasmid.  Incorporation of the IL-2 signaling peptide sequence 
(SP2) and C-terminal stop codon and FLAG epitope into the IL-15 expression plasmid was 
performed through successive rounds of PCR utilizing the listed primer sequences based on 
previous reports [140].  The stop codon was inserted upstream of the FLAG sequence to prevent 
expression of the FLAG epitope and remove the potential for production of anti-FLAG Ab in 
vivo.  Ad5- and Ad35-based vectors containing the optimized SP2.IL-15.FLAG sequence were 
created using established methods [289, 310].  All Ad vectors were E1/E3-deleted with the 
exception of Ad35 containing the env transgene, which was E3-deleted due to technical 
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difficulties in generating E1/E3-deleted Ad35-env.  Protein expression by Ad5- and A35-based 
vectors expressing SIV genes was confirmed by Western blot analysis of infected HEK293 cells 
as described [289] (data not shown). 
4.4.4 IL-15 production and bioactivity 
Cytokine production was measure by human IL-15-specific ELISA kit using the rhesus cross-
reactive capture (G243-935) and detection (G243-886) Abs (BD PharMingen, San Jose, CA).  
ELISAs were performed on supernatants harvested 48 h after transfection of HEK293T cells 
with pAdlox plasmids or infection with Ad5- or Ad35-based vectors at an MOI of 100.  MTT 
cell proliferation assays were performed to measure the capacity of Ad-produced IL-15 to 
propagate the IL-2/IL-15 dependant CTLL-2 cell line [172].  Briefly, CTLL-2 cells were 
incubated for 24 h with either exogenous IL-2 or culture supernatants and then incubated for 6 h 
in the presence of 10μl MTT reagent prior to lysis and detection of absorbance at 570 nm 
wavelength.  
4.4.5 Measurement of SIV RNA in plasma 
Viral RNA was isolated from cell-free plasma of SIV-infected monkeys and SIV RNA levels 
quantified by real-time PCR as described previously [289].  Plasma SIV RNA levels were 
detected to a sensitivity of 103 copies/ml with lesser values reported at a baseline of 104 
copies/ml.  
4.4.6 IFN-γ ELISPOT 
Effector T cell responses to SIV Ag were analyzed in previously cryopreserved PBMC by IFN-γ 
ELISPOT assay using pools of overlapping peptides representing the Gag, Env, and Nef proteins 
of SIVmac239 as previously described [289].  Responses that were two times that of DMSO 
background with a minimum number of 50 spots per 106 PBMC were scored as positive.   
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4.4.7 T cell phenotype and intracellular cytokine staining  
Phenotypic characterization and detection of Ag-specific cytokine production from T cells within 
cryopreserved PBMCs were performed simultaneously as previously described with minor 
modifications [382].  All Abs listed in this study were procured from BD Biosciences (BD 
Biosciences, San Jose, CA) unless otherwise specified.  Briefly, cells were stimulated at 1x106 to 
5x106 cells per test with final concentrations of 1.0μg/ml anti-CD49d (9F10) and Gag, Env, or 
Nef peptide pools, or 50ng/ml PMA and 1.0μg/ml ionomycin (Sigma, St. Louis, MO) for 6 h 
with brefeldin A (10μg/ml, Sigma) present for the last 5 h.  Fresh bronchoalveolar lavage (BAL) 
samples were treated similarly using the dominant Ag pool identified through IFN-γ ELISPOT.  
Samples were labeled to exclude dead cells by incubation with amine reactive UV Live/Dead 
dye (Molecular Probes, Carlsbad, CA) or 0.5μg/ml ethidium monoazide (Sigma) followed by 
fluorescent light fixation for 15 min, and  then stained for surface Ag using mAbs specific for 
CD3 conjugated to Alexa488 (CD3-Alexa488; SP34-2), CD4-AmCyan (L200, NIH AIDS 
Research and Reference Reagent Program), CD8-APC-Cy7 (RPA-T8), CD28-PE-Cy5 (28.2), 
and CD95-Alexa647 (DX2).  Cells were then fixed and permeabilized by treatment with BD 
Cytofix/Cytoperm solution followed by labeling with mAbs specific for IFN-γ-PE-Cy7 (4S.B3), 
TNF-α-Pacific Blue (Mab11, eBioscience, San Diego, CA), and IL-2-PE (MQ1-17H12) for 30 
min at 4oC in the presence of permeabilizing staining buffer.  Cells were collected immediately 
on a BD LSRII flow cytometer (Beckman Dickenson) using FACSDiva software for analysis.  A 
minimum of 300,000 events were collected with values greater than three times DMSO 
background scored as positive.                       
4.4.8 T lymphocyte quantitation 
Absolute quantitation of peripheral blood T lymphocytes was performed using TruCount beads 
(BD Biosciences) based on manufacturer’s suggestions.  Briefly, 50μl of peripheral whole blood 
collected in EDTA was added to TruCount tubes containing CD3-PE, CD4-FITC, and CD8-PE-
Cy5 specific mAbs, and incubated at room temperature for 20 min prior to the addition of 
BDfix/lyse solution (Beckman Dickenson).  Cells were collected the same day on a BD LSRII 
with 2,500-10,000 CD3+ T cell events analyzed using FACSDiva software.  Absolute numbers of 
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memory T cells were calculated from the known quantity of CD3+CD4+ or CD3+CD8+ T cells 
per μl whole blood.  Baseline values were determined by averaging 2-3 pre-infection timepoints.  
4.4.9 Statistical analysis 
Given the small sample sizes used in this study, nonparametric analysis was performed 
throughout this investigation.  Comparisons between treatment groups were carried out using the 
Mann-Whitney U test, while assessments of variation within each group were made using the 
Wilcoxon ranked-sum test.  SPSS 14.0 software (SPSS Inc., Chicago, IL) was utilized for these 
calculations.  Correlation coefficients were calculated using the Spearman rank-order test and 
performed using Graphpad PRISM 5 (Graphpad Software, Inc., La Jolla, CA).  All P values are 
two-sided with significance considered to be P < 0.05.     
4.5 RESULTS 
4.5.1 Ad-mediated delivery of bioactive rhesus IL-15 
To incorporate IL-15 administration into our immunotherapy regimen, we first developed 
and tested Ad-based vectors expressing rhesus macaque IL-15.  Transfection by pAdlox 
encoding rhesus IL-15 resulted in notable cytokine production compared to control transfection 
with pAdlox-egfp (Fig. 8a).  Removal of C-terminal translational inhibition through inclusion of 
a FLAG epitope provided a 4-fold increase in IL-15 production to 208±7 pg/ml, consistent with 
previous reports [140].  Insertion of the IL-2 signal sequence, facilitating cytokine secretion, on 
its own into the pAdlox-IL-15 plasmid had minimal effect, whereas addition of the IL-2 signal 
sequence together with the FLAG epitope resulted in a 5-fold increase in IL-15 production over 
the unaltered IL-15-expressing plasmid to 260±36 pg/ml (Fig. 8a).  Ad5- and Ad35-based 
vectors expressing SP2.IL-15.FLAG (Ad5-IL-15 and Ad35-IL-15, respectively) were 
subsequently tested for the capacity to induce IL-15 expression following 48 h infection of 
HEK293T cells.  Ad5-IL-15 and Ad35-IL-15 transduction resulted in high-level expression of 
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IL-15, with levels of 1,988±11 pg/ml and 1,008±6 pg/ml, respectively (Fig. 8b).  Control 
transduction with Ad5-EGFP and Ad35- EGFP or mock transduction of cells produced 
undetectable levels of IL-15 (Fig. 8b).  The reduced levels of cytokine production by Ad35- as 
compared to Ad5-based vectors are due to differences in post-infection replicative capacity and 
subsequent protein production within HEK293T cells, and are not observed in cells of 
hematopoietic origin (data not shown).  Finally, we examined the bioactivity of Ad-derived IL-
15 using the IL-2/IL-15 dependant CTLL-2 cell line.  Viable and proliferating CTLL-2 cells 
cultured for 24 h in the presence of exogenous IL-2 were standardized to 100% (Fig. 8c).  When 
CTLL-2 cells were cultured in the presence of supernatants from HEK293T cells transduced 
with Ad5-IL-15 or Ad35-IL-15, we observed five and three fold enhancement of cellular 
proliferation, respectively, over that induced by IL-2, demonstrating functional bioactivity.  Non-
transduced supernatants lacking IL-2 or IL-15 failed to sustain CTLL-2 cells, leading to rapid 
cell death and undetectable MTT measurement (Fig. 8c).  These data indicate that Ad-based 
vectors encoding an optimized rhesus macaque IL-15 expression construct are highly effective at 
generating bioactive IL-15 in infected cells.  
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Figure 8:  Expression and bioactivity of rhesus IL-15 following plasmid transfection and recombinant Ad 
infection. 
(A) Presence of rhesus IL-15 in HEK293T cell supernatants following transfection with pAdlox expressing egfp, IL-
15, or IL-15 including the IL-2 signaling peptide sequence and/or c-terminal FLAG epitope as determined by 
ELISA.  (B) Presence of rhesus IL-15 in HEK293 T cell supernatants following infection with Ad5- or Ad35-IL-15, 
Ad5- or Ad35-EGFP, or mock transduction as determined by ELISA.  (C) Bioactivity of rhesus IL-15 in HEK293 T 
cell supernatants following Ad5- or Ad35-IL-15 infection or mock transduction as determined by CTLL-2 cell 
propagation using the MTT assay.  Propagation was standardized against CTLL-2 cell activity in response to IL-2.  
Shown are means of triplicate determinations with SEM.  ND = not detected. 
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4.5.2 Therapeutic vaccination enhances the strength and breadth of Ag-specific 
immunity 
To determine the capacity of Ad-based immunotherapy, with and without IL-15, to 
enhance Ag-specific immune responses in nonhuman primates with established SIV infection, 
infected macaques received Ad5- and Ad35-based immunizations during two cycles of ART as 
described in Materials and Methods (Table 2).  IFN-γ ELISPOT analysis was performed bi-
weekly to measure the magnitude of SIV-specific cellular immune responses over time.  Animals 
that received Ad5-gag, Ad5-env, and Ad5-nef (collectively called Ad5-SIV) alone at wk 16 and 
wk 22 during ART cycle-1 had significantly increased cumulative IFN-γ responses to all three 
viral proteins at wk 22 and wk 24 as compared to control animals, with an average frequency of 
around 1 Ag-specific cell per 1,000 PBMC (Fig. 9a, c).  In contrast, animals receiving Ad5-SIV 
with Ad5-IL-15 had limited responses to vaccination as compared to controls (Fig. 9a, c), 
although when all vaccinated animals were evaluated irrespective of Ad-IL-15 delivery 
statistically significant differences were maintained (Fig. 9b).  IFN-γ ELISPOT responses 
returned to baseline levels in vaccinated animals during the first STI, but boosting with Ad35-
SIV at wk 36 and wk 42 during ART cycle-2 rapidly expanded the frequency of virus-specific 
IFN-γ producing cells as compared to controls, with significant differences at wk 38 and wk 42 
reaching an average frequency of around 1 Ag-specific cell per 300 PBMC (Fig. 9a, c).  As in 
the first treatment cycle, animals that received the combination of Ad35-SIV/IL-15 had modest 
increases that were not significantly different than control animals (Fig. 9a, c), whereas all 
vaccinated animals analyzed collectively, irrespective of IL-15 delivery, maintained significant 
increases in IFN-γ ELISPOT responses over controls (Fig. 9b).  During the second STI, IFN-γ 
ELISPOT responses in both SIV and SIV/IL-15-vaccinated groups were greater than those of 
mock-treated animals, but did not attain significance (Fig. 9a, b).  Notably, intermittent cycles of 
ART followed by STI in the absence of immunotherapy failed to enhanced T cell responses to 
virus, as animals in the control group maintained relatively stable frequencies of Ag-specific T 
cells over the entire course of the study (Fig. 9a-c).   
To examine whether vaccination influenced the breadth of T cell responses against 
targeted viral Ags, we evaluated the IFN-γ ELISPOT responses against Gag, Env, and Nef 
proteins individually.  Immunization with both Ad5-SIV and Ad35-SIV, irrespective of IL-15 
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immunotherapy, significantly increased peak IFN-γ responses against each viral protein from 
those identified at the initiation of ART cycle-1 (wk 12) and ART cycle-2 (wk32), respectively 
(Fig. 9d).  In contrast, mock immunized animals failed to develop significant enhancement of 
peak Gag-, Env-, or Nef-specific immunity during either ART cycle (Fig. 9d).  These data 
indicate that vaccination with Ad-SIV vectors was effective at enhancing the magnitude and 
antigenic breadth of the IFN-γ response to SIV, but that addition of IL-15 in the vaccine regimen 
provided no detectable benefit. 
 Table 2: Animal characteristics and immunotherapy schedule. 
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Figure 9:  Robust enhancement of cellular immunity following Ad5- and Ad35- based immunotherapy in SIV 
infected monkeys. 
PBMC were harvested from SIV-infected monkeys at intervals after initiation of ART at wk 12 and tested for Ag-
specific IFN-γ production by ELISPOT assay.  (A-C) All animals received two cycles of ART as depicted by shaded 
regions and therapeutic or mock-vaccination with Ad5- and Ad35-based vaccines at times indicated by closed and 
open arrows, respectively.  (A) Cumulative IFN-γ responses against Gag, Env, and Nef peptide pools for animals 
receiving Ad-ψ5 control vectors (open circles), Ad-SIV (closed circles), or Ad-SIV together with Ad-IL-15 (closed 
squares). Shown are mean + SEM.  (B) Cumulative IFN-γ responses against Gag, Env, and Nef peptide pools for 
animals receiving Ad-ψ5 control vectors (open circles) or Ad-SIV vaccination irrespective of Ad-IL-15 delivery 
(closed diamonds).  Shown are mean + SEM.  (C) Individual cumulative IFN-γ responses against Gag, Env, and Nef 
peptide pools for immunized animals (left) receiving Ad-SIV (solid lines) or Ad-SIV plus Ad-IL-15 (dotted lines) or 
control animals receiving Ad5ψ and Ad35ψ (right).  (D) IFN-γ responses to Gag, Env, and Nef peptide pools in 
PBMC from vaccinated (top) and control (bottom) animals, comparing responses at the initiation of ART cycle-1 
(wk 12) and ART cycle-2 (wk 32) with peak responses following Ad5- and Ad35-based immunotherapy, 
respectively.  Animals receiving Ad-SIV alone or in combination with Ad-IL-15 (top graphs) are depicted as solid 
and dotted lines, respectively. *=P<.05, **=P<.01.    
4.5.3 Ad-based immunotherapy induces polyfunctional CD8+ but monofunctional 
CD4+ T cell responses to SIV during established infection 
We next analyzed the functional character of vaccine-induced T cells, focusing on 
production of the Th1 cytokines IFN-γ, IL-2, and TNF-α, as coexpression of these cytokines by 
CD4+ and CD8+ T cells is associated with virologic control in HIV-1-infected individuals [219, 
222, 383].  Utilizing multiparameter flow cytometry, we compared systemic T cell responses at 
the initiation of ART cycles-1 and 2 with peak responses following Ad5- and Ad35-based 
immunotherapy, respectively, as previously determined by IFN-γ ELISPOT (Fig. 10a).  For 
simplicity, vaccinated animals were assessed collectively, irrespective of Ad-IL-15 delivery, for 
responses induced by individual Gag, Env, and Nef peptide pools combined.  Ad5-SIV 
immunotherapy increased the frequency of monofunctional Ag-specific CD8+ T cells producing 
either IFN-γ or TNF-α but not IL-2 (Fig. 10b).  In addition, the magnitude of polyfunctional 
CD8+ T cells producing combinations of IL-2 and IFN-γ, IFN-γ and TNF-α or all three cytokines 
was increased in response to Ad5-based immunization (Fig. 10b).  However, the proportion of 
total Ag-specific CD8+ T cells producing two or three cytokines in response to Ag stimulation 
was not increased in vaccinated animals relative to controls and remained minor, with a mean of 
19% and 1%, respectively, for all vaccinated animals (Fig. 10d). Boosting with Ad35-SIV 
further expanded the frequency of virus-specific CD8+ T cells producing IFN-γ alone but had no 
impact on polyfunctional T cell responses (Fig. 10b).  In the case of Ag-specific CD4+ T cells, 
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Ad5-based vaccination increased only the frequency of cells producing IFN-γ alone and had no 
impact on CD4+ T cells producing more than one cytokine (Fig. 10c, d).  This effect was lost 
upon Ad35 boosting, as the peak frequency of Ag-specific CD4+ T cells producing any 
combination of cytokines was not significantly different from the baseline frequency at wk 32 
(Fig. 10c).  Moreover, the proportion of CD8+ and CD4+ T cells producing one, two, or three 
cytokines as a result of Ad5 and Ad35 vaccinations was essentially the same as control animals 
receiving mock Ad-based vaccination (Fig. 10d).  As expected, no increase in the frequency of 
Ag-specific CD8+ or CD4+ T cells was observed in control animals during either ART cycle for 
any cytokine (Fig. 10b, c).  These data indicate that Ad-based immunization bolstered the 
strength of antiviral cell-mediated immunity, but vaccination had limited impact on the 
qualitative nature of this response, particularly with respect to the CD4+ T cell response.   
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Figure 10:  Polyfunctional CD8+ and monofunctional CD4+ T cell responses induced by Ad-based 
immunization of SIV-infection monkeys. 
(A) Representative flow cytometry dot plots depicting the gating strategy for the identification of live CD4+ and 
CD8+ T cell subsets (top) and CD8+ T cells expressing combinations of  IFN-γ, TNF-α, and IL-2 following 
stimulation with Gag peptides or mock-stimulation (DMSO, bottom).  (B, C) Frequency of CD8+ (B) and CD4+ (C) 
T cells in PBMC expressing IFN-γ, IL-2, or TNF-α either alone or in combination from animals receiving Ad-SIV 
immunization, irrespective of Ad-IL-15 administration, or mock immunized controls (Adψ).  Shown are mean 
values ± cumulative responses to Gag, Env, and Nef peptide pools at the initiation of ART cycle-1 (wk 12) and ART 
cycle-2 (wk 32) compared to peak responses following Ad5- and Ad35-based immunization, respectively.  (D) 
Proportion of Ag-specific CD8+ (Left) and CD4+ (Right) T cells producing 1, 2, or 3 cytokines at the peak response 
following immunization with Ad5-SIV and Ad35-SIV (Immunized) or Ad-ψ5 and Ad-ψ35 (Control).  *=P<.05, 
**=P<.01.    
4.5.4 Differential effects of Ad-based immunotherapy on CD4+ and CD8+ T cell 
memory subsets in the peripheral blood 
We next determined whether CD8+ and CD4+ T cell responses induced by vaccination in 
chronic infection were mediated by central memory or effector memory subsets or both. 
CD3+CD8+ and CD3+CD4+ T cells were identified as Tcm (CD28+CD95+) or Tem (CD28-
CD95+) [384] and SIV-specific cytokine production was measured in these cells at the time of 
peak response following Ad-based immunization, irrespective of IL-15 administration, using 
multiparametric flow cytometry (Fig. 10a).  Both CD8+ Tcm and CD8+ Tem cells were rapidly 
and significantly increased in number in the peripheral blood by wk 12 of infection relative to 
pre-infection levels, and vaccination beginning at wk 16 did not impact this response (Fig. 11a, 
c).  However, Ad5-SIV immunization significantly increased the peak frequency of Ag-specific 
CD8+ Tcm cells producing one cytokine relative to control animals, and this effect was extended 
to CD8+ Tcm cells producing two cytokines following the Ad35 boost (Fig. 11b, d). Similar 
enhancement of peak Ag-specific responses following Ad5- and Ad35-based vaccination from 
CD8+ Tem cells producing one or more cytokine combinations was observed, but failed to attain 
statistically significant variation relative to mock immunized control animals (Fig. 11b, d). These 
findings indicate that immunization with Ad5 and Ad35 induces durable CD8+ T cell responses 
from both central and effector memory compartments during established infection. 
 Figure 11:  Ad-based immunization induces primarily Ag-specific CD8+ Tcm in the peripheral blood of SIV-infected monkeys.  
(A, C) Changes in the number of circulating CD8+ Tcm cells (A) and CD8+ Tem cells (C) in animals at various intervals after immunization with Ad-SIV with 
and without Ad-IL-15 (left, closed) or control vectors (right, open) depicted as percent change from baseline.  Shown are box-whisker plots depicting median and 
interquartile ranges with SEM.  (B, D) Frequency of cumulative SIV-specific CD8+ Tcm (B) and CD8+ Tem (D) responses consisting of 1, 2 or 3 cytokine 
profiles following Ad5- (left) and Ad35- (right) administration for Ad-SIV immunized animals, irrespective of IL-15 administration, and mock immunized 
controls.  Shown are mean ± SEM.  (*=P<.05, **=P<.01).         
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In contrast to CD8+ T cell subsets, there was a rapid loss of circulating CD4+ T cells in all 
study animals prior to ART at wk 12 that corresponded to a precipitous decline in Tcm cells (Fig. 
12a), consistent with previous reports [36].  Notably, Ad5 prime and Ad35 boost vaccinations 
resulted in transient increases in the number of CD4+ Tcm cells between wk 12 and 24 and wk 32 
and 44, respectively, which translated into a partial normalization of total CD4+ T cells to 80% of 
pre-infection levels.  No recovery of CD4+ Tcm cells was observed in control animals over this 
period, indicating that this effect was due to vaccination and not antiretroviral therapy alone (Fig. 
12a). There was a trend towards an increase in the peak frequency of Ag-specific CD4+ Tcm 
cells producing 1 or 2 cytokines in response to Ad5 and Ad35 vaccination although this did not 
reach significance (Fig. 12b). CD4+ Tem populations increased between the time of infection and 
initiation of antiretroviral therapy at wk 12 but were gradually eliminated from the peripheral 
blood of all study animals over time (Fig. 12c).  Ad5-based immunization resulted in high peak 
frequencies of Ag-specific CD4+ Tem cells relative to controls, with 12% and 4% of the 
population producing 1 and 2 cytokines, respectively; however boosting with Ad35 was 
incapable of sustaining this response (Fig. 12d).  Notably, peak Ag-specific CD4+ Tem responses 
following Ad35-based vaccination were reduced by 5 fold compared to those attained during 
Ad5 administration within both immunized and control groups (Fig. 12d).  These results indicate 
that Ad-based immunotherapy initiated during chronic SIV infection was effective at transiently 
correcting CD4+ Tcm loss and boosting the frequency of Ag-specific CD4+ Tcm cells. However, 
CD4+ Tem cell numbers were progressively lost over time, and increases in Ag-specific cells in 
this subset were limited to Ad5 priming and were lost upon boosting with Ad35.   
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Figure 12:  Ad-based immunization transiently restores CD4+ Tcm but not CD4+ Tem cells in SIV-infected monkeys.   
(A, C) Changes in the number of circulating CD4+ Tcm cells (A) and CD4+ Tem cells (C) in animals at various intervals after immunization with Ad-SIV with 
and without Ad-IL-15 (left, closed) or control vectors (right, open) depicted as percent change from baseline.  Shown are box-whisker plots depicting median and 
interquartile ranges with SEM.  (B/D) Frequency of cumulative SIV-specific CD4+ Tcm (B) and CD4+ Tem (D) responses consisting of one, two, or three 
cytokine profiles following Ad5- (left) and Ad35- (right) administration for Ad-SIV immunized animals, irrespective of IL-15 administration, and mock 
immunized controls.  Shown are mean ± SEM.  (*=P<.05, **=P<.01).      
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4.5.5 Ad-based immunotherapy enhances primarily monofunctional Ag-specific 
CD8+ T cell responses in mucosa 
Using BAL samples as a readily available source of mucosal T cells, we examined the 
effects of therapeutic immunization within mucosal tissues.  We detected a near complete 
elimination of CD4+ T lymphocytes in all animals prior to ART which was maintained for the 
duration of the study (Fig. 13a, b), consistent with previous reports [215].  We next examined 
whether Ad-based immunotherapy, irrespective of Ad-IL-15 administration, enhanced Ag-
specific mucosal T cell responses.  We focused on the production of IFN-γ and IL-2 by CD8+ T 
cells directed against the dominant Ag identified by IFN-γ ELISPOT PBMC analysis.  
Intracellular cytokine analysis was performed prior to and 2 wks following Ad5- and Ad35-
based immunizations.  Animals immunized with Ad5-SIV had increased peak frequencies of Ag-
specific mucosal CD8+ T cells producing IL-2 but not IFN-γ or both cytokines compared to 
responses measured at ART cycle-1 initiation (Fig. 13c).  Interestingly, Ad35-SIV immunization 
expanded peak frequency of polyfunctional IL-2+ IFN-γ+ CD8+ T cells responding to viral Ag 
without further enhancement of monofunctional IL-2 or IFN-γ production, although the 
proportion of dual cytokine-producing cells relative to cells producing either cytokine alone was 
minor (Fig. 13c).  These data indicate that systemic Ad-based immunotherapy has the potential 
to enhance Ag-specific CD8+ T cell immunity at mucosal tissues during chronic SIV infection 
despite the massive loss of CD4+ T cells from that compartment.   
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Figure 13:  Ad-based immunotherapy enhances cellular immunity at the lung mucosa. 
(A) Representative flow cytometry dot plots showing T cell subsets in BAL from a SIV-naïve monkey and a SIV-
infected monkey (wk 11 PI) highlighting profound CD4+ T cell loss following infection.  Numbers represent the 
percentage of CD4+ T cells in each sample.  (B) The percentage of CD4+ T cells in BAL isolated from SIV-naïve 
animals (n=6) and SIV-infected animals receiving Ad-SIV immunotherapy with and without Ad-IL-15 (closed) or 
mock immunotherapy (open) at the initiation and termination of ART cycle-1 (wk 12 and wk 24, respectively) and 
the initiation and termination of ART cycle-2 (wk 32 and wk 44, respectively).  Shown are box-whisker plots 
depicting median and interquartile ranges with SEM.  (C) Proportion of CD8+ T cells in BAL expressing IFN-γ, IL-
2, or both from animals receiving immunotherapy with Ad-SIV with and without Ad-IL-15 (dotted and solid lines, 
respectively) or mock immunotherapy (Adψ).  Shown are responses to Gag, Env, or Nef peptide pools at the 
initiation of ART cycle-1 (wk 12) and ART cycle-2 (wk 32) compared to peak responses measured 2 wks after 
immunization with Ad5- and Ad35-based vectors, respectively. *=P<.05.   
4.5.6 Ad-based immunotherapy fails to contain virus load during chronic SIV 
infection 
To determine whether the enhanced systemic and mucosal cellular immune responses 
induced through Ad-based immunotherapy had an effect on viral containment in SIV-infected 
monkeys, we quantified cell-free virus in plasma at intervals after infection.  Upon the initiation 
of ART cycle-1, all animals had around a 2-log reduction in virus load indicating responsiveness 
to ART, although the extent of virologic control varied between animals over the course of 
therapy (Fig. 14).  Interestingly, animals receiving Ad5-SIV immunotherapy either alone or with 
Ad5-IL-15 had no evidence of virus control relative to animals not receiving immunotherapy 
(Fig. 14a).  Following ART cycle-1 cessation, the majority of animals experienced a transient 
reduction in virus load that was rapidly reversed regardless of whether animals had received Ad-
based immunotherapy during the preceding period (Fig. 14).  Initiation of ART cycle-2 resulted 
in an average reduction in virus load of 1 to 1.5 logs for each group, and there was no detectable 
influence of Ad35-based immunotherapy on plasma viremia during this period (Fig. 14).  
Following cessation of ART at wk 44, the average plasma virus load remained relatively low in 
control animals and animals receiving Ad5- and Ad35-based SIV immunotherapy alone, being 
roughly 2-logs lower than at the initiation of ART at wk 12 (Fig. 14).  In contrast, animals 
treated with Ad5- and Ad35-SIV together with the respective Ad-based IL-15 delivery tended to 
have increased virus loads subsequent to the second STI (Fig. 14).  These findings indicate that 
Ad-based immunotherapy administered in the context of ART was not effective at controlling 
SIV virus loads in chronically-infected animals.  
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Figure 14:  Ad-based immunotherapy fails to control viremia in chronically infected animals on ART. 
(A) Median plasma virus loads at intervals after SIV infection for animals receiving Ad-SIV (closed circles), Ad-
SIV with Ad-IL-15 (closed square) or mock (open circle)  immunotherapy.  (B) Individual virus loads at intervals 
after SIV infection for animals receiving Ad-SIV with and without Ad-IL-15 (dotted and solid lines, respectively, 
top) or mock immunotherapy (bottom).  The periods of ART are depicted by shaded regions and the times of 
immunotherapy with Ad5- and Ad35-based vaccines are indicated by closed and open arrows, respectively. 
4.5.7 Strength of T cell response, T cell function, and CD4+ Tcm cells correlate 
with virus control 
To better understand why the robust cellular immune responses to SIV induced through 
immunotherapy failed to control viremia, we evaluated data from all animals irrespective of 
treatment for potential factors that correlated with virus control.  The strength of peak Gag- and 
Env-specific IFN-γ ELISPOT responses each correlated inversely with virus load during ART, 
and the magnitude of the cumulative IFN-γ ELISPOT response at 12 wks PI prior to therapeutic 
intervention was inversely correlated with sustained virus control measured at 52 wks PI, 
indicating the importance of the strength and breadth of the cellular immune response (Fig. 15a).  
However, the quality of cellular immunity was also important in controlling virus in infected 
animals.  The peak frequency of CD8+ T cells producing both IFN-γ and TNF-α during the first 
ART cycle was strongly correlated with reduced viremia at that time and at 56 wks PI (Fig. 15b).  
Similarly, the proportion of polyfunctional Ag-specific CD4+ T cells expressing two or three 
cytokines was inversely correlated with virus load during the first ART cycle (Fig. 15b).  The 
maintenance of CD4+ Tcm cells both early (wk 12) and late (wk 24 or 44) in infection was 
negatively correlated with virus load and positively correlated with Ag-specific dual cytokine-
producing CD8+ Tcm cells in blood, supporting the role of CD4+ T cell help in the preservation 
of effective memory CD8+ T cell responses (Fig. 15c) [385].  Finally, the number of mucosal 
CD4+ T cells during chronic infection was inversely correlated with virus load (Fig. 15d).  
Interestingly, this association was not observed when comparing CD4+ T cell levels in the 
peripheral blood with viral loads (data not shown), illustrating the sensitivity of BAL CD4+ T 
cell measurements as a predictive indicator of disease outcome [215].  Expression of the Mamu-
A*01 allele (in animals R478, R480 and R487) did not correlate with virus control, and no other 
detected MHC allele was observed to influence viral load in this model (data not shown).  These 
correlative data indicate that both quantitative and qualitative CD8+ and CD4+ T cell responses 
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along with maintenance of peripheral and mucosal CD4+ T cells are associated with control of 
viremia in chronic SIV infection.  
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Figure 15:  Control of chronic SIV infection is correlated with the magnitude and quality of cellular 
immunity and maintenance of peripheral CD4+ Tcm and mucosal CD4+ T cells. 
(A) The peak IFN-γ ELISPOT response in PBMC to Gag or Env during ART cycle-1 and 2 inversely correlated 
with virus load at the same time PI, and the cumulative IFN-γ ELISPOT response to Gag, Env, and Nef combined at 
wk 12 PI inversely correlated with virus load at wk 52 PI.  (B) The peak frequency of CD8+ T cells in PBMC 
expressing IFN-γ and TNF-α in response to Gag, Env, and Nef stimulation during ART cycle-1 correlated inversely 
with virus load at the same time PI and at wk 56 PI, and the peak frequency of CD4+ T cells in PBMC expressing 
either IL-2 and TNF-α, IFN-γ and TNF-α, or IFN-γ, IL-2, and TNF-α in response to Gag, Env, and Nef stimulation 
during ART cycle-1 correlated inversely with virus load at the same time PI.  (C) The number of CD4+ Tcm cells in 
blood at wk 12 and wk 44 PI, respectively, correlated inversely with virus load at the same time PI, and the number 
of CD4+ Tcm in blood at wk 24 PI correlated positively with the peak frequency of blood CD8+ Tcm cells producing 
IFN-γ and TNF-α in response to Gag, Env, and Nef stimulation during ART cycle-1.  (D) The proportion of CD4+ T 
cells in BAL at wk 22 and wk 44 PI, respectively, correlated inversely with virus load measured at the same time PI.  
Each symbol represents an individual animal either receiving Ad-SIV with and without Ad-IL-15 (closed symbols) 
or mock (open symbols) immunotherapy.  P-values and Spearman’s rank-order correlation coefficient (r) values are 
presented.   
4.6 DISCUSSION 
Our findings demonstrate the potent ability of Ad-based vectors to elicit virus-specific 
cellular immune responses during ART-treated, chronic SIV infection in rhesus macaques, 
extending the use of Ad-based vectors for the first time beyond prophylactic vaccination in this 
model [211, 289, 294, 304, 381, 386].  Therapeutic vaccination readily enhanced the magnitude 
of IFN-γ-mediated cellular immunity against all targeted viral Ags, promoted CTL responses 
both in the circulation and mucosa, and increased an array of TH1 cytokines produced by Ag-
specific CD8+ T cells, all factors that have been shown to aid in the containment of disease 
progression [372, 387, 388].  Yet, Ad-based immunotherapy was not effective at controlling 
virus load during ART or the period of rebound viremia following STI.  While these findings 
were limited by the relatively small number of animals used, the results are in agreement with 
previous studies showing that therapeutic immunization utilizing poxvirus-based vectors during 
ART-treated HIV infection had only minor influences on rebound viremia following ART 
cessation [389, 390].  Furthermore, the data are also consistent with recent findings that 
vaccination with replication-defective Ad5-based vectors failed to prevent HIV-1 infection in a 
large cohort of human volunteers [380].  
Recent studies have associated the maintenance of polyfunctional CD4+ and CD8+ T cells 
producing multiple cytokine and chemokine combinations with long-term non-progression, viral 
containment during STI, and effective cytotoxic control of viral replication during HIV infection 
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[219-222, 383].  Similarly, we observed a strong relationship between polyfunctional CD4+ and 
CD8+ T cell-mediated immunity and control of chronic SIV viremia.  However, therapeutic 
vaccination with Ad-based vectors mainly induced CD8+ T cell responses in blood and mucosa 
and these were characterized primarily as monofunctional, with less than 20% of cells producing 
two cytokines and less than 1% producing three cytokines. In addition, while the proportion of 
blood CD4+ T cells producing IFN-γ increased in response to Ad5-based immunotherapy the 
total number of CD4+ T cells steadily declined over time, resulting in a decrease in the number of 
Ag-specific CD4+ T cells during ART cycle-2. Moreover, the fraction of each CD4+ or CD8+ T 
cell subset producing 1, 2 or 3 cytokines subsequent to vaccination did not differ from those 
observed in control animals, suggesting that immunization served to merely enhance the 
magnitude of the innate response already established against SIV infection without altering its 
polyfunctional character. Consistent with our data is the finding that Ad5-mediated immunity 
invokes skewed CD8+ to CD4+ T cell responses and restricted polyfunctional cytokine 
expression as compared to alternative vectors based on Ad26 or Ad48 serotypes in a prophylactic 
vaccine model [294].  Therapeutic Ad5-based priming vaccination in our model may have 
established qualitatively deficient antiviral immunity, ameliorating the potential of Ad35-based 
boosting as seen in mice [294].  These findings are corroborated by a recent report showing that 
high-dose Ad5 exposure induced qualitatively inferior cellular immunity and protection against 
Leishmania major infection of mice [291].     
CD4+ Tem cells provide crucial support against opportunistic infections in HIV and SIV 
infected individuals and are an essential mediator in reducing disease pathogenesis [215, 391].  A 
recent study indicated that the ability to repopulate the CD4+ Tem compartment during 
progressive SIV infection of monkeys is associated with the regenerative capacity of CD4+ Tcm 
cells to expand and differentiate [46].  Our data showed that maintenance of CD4+ Tcm cells 
both early and late in infection was directly correlated with the frequency of polyfunctional 
CD8+ T cells and inversely correlated with virus load.  Encouragingly, we found a significant 
expansion of CD4+ Tcm cells present in peripheral blood following Ad-based immunotherapy 
during ART.  However, this recovery was relatively short-lived and was not associated with any 
detectable recovery of CD4+ Tem cells.  It is possible that the relatively brief duration of ART 
administered in our study, together with incomplete control of virus load while on therapy, may 
have limited the full development of long-lived memory CD4+ T lymphocyte populations.  
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Additional rounds of heterologous vaccination under the protection of ART, ideally directed 
against multiple drug targets, may allow for further reconstitution of CD4+ T cell cellular 
memory and enhanced cellular immunity leading to greater restriction of rebound viremia.   
Currently, cytokine chemotherapy utilizing IL-15 is being explored as an alternative 
treatment for HIV and SIV infections due to the potent immunoregulatory functions of this 
cytokine [165].  Studies have shown that the addition of exogenous IL-15 is capable of restoring 
functionality to anergic T lymphocytes, concurrent with IL-15 deficiencies present during 
chronic HIV infection [156, 168, 175, 176, 178].  We used an Ad-based delivery method for IL-
15 immunotherapy, which was highly effective in vitro at inducing production of bioactive IL-15 
in infected cells.  Yet, we observed no significant differences in the induction of SIV-specific 
cellular immunity, the character of the cytokine profile, or the absolute numbers of CD4+ or 
CD8+ T memory cells as result of Ad-based IL-15 immunotherapy.  In fact, although not 
statistically significant, we observed a trend towards reduced response to immunization and 
heightened viremia in animals receiving Ad-based IL-15.  These negative results are consistent 
with recent findings by others using systemic IL-15 in a similar therapeutic setting in SIV-
infected monkeys [376], and raise further doubts about the utility and safety of IL-15 as a 
therapeutic modality in HIV infection.      
Our results highlight the relationship between maintaining immune function prior to ART 
initiation and having durable control of viremia.  Perhaps not surprisingly, animals that had 
greater mucosal CD4+ T cell counts and quantitatively and qualitatively stronger Ag-specific 
immunity in blood and mucosa during chronic infection were able to more effectively and 
durably suppress SIV viremia.  This trend has been observed in individuals expressing various 
HLA molecules allowing for superior control of HIV infection [203, 392, 393].  Similarly, 
individuals receiving early ART have been shown to maintain healthy immunity and control HIV 
viremia [394].  It is likely that in our study the profound level of immunologic damage accrued 
during the first 12 wks, as evidenced by massive loss of mucosal CD4+ T cells and peripheral 
blood CD4+ Tcm cells, crippled host immunity to a point beyond transient therapeutic salvation.  
These findings would suggest that therapeutic intervention initiated early in infection while the 
host immune system is relatively intact may be more effective at controlling infection. In 
addition, combining different vaccine approaches such as DNA prime with Ad boost may 
enhance the quality of T cell response to infection, as has been shown in prophylactic SIV 
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vaccines [278], although the capacity to generate qualitatively superior cellular responses 
through combination immunotherapy remains to be tested.  
4.7 CONCLUSIONS 
Our findings illustrate the potent ability of Ad-based vaccination to enhance robust 
antiviral cellular immunity during chronic SIV infection.  Immunization induced durable, high 
frequency TH1 responses, and augmented CD4+ Tcm populations, both implicated in viral 
containment.  Regrettably, therapeutic vaccination failed to control rebound viremia following 
ART cessation, in spite of demonstrated immunogenicity.  Previous studies have suggested that 
effective therapeutic augmentation of T cell-mediated immunity and T lymphocyte dynamics by 
vaccination is unfeasible in the absence of complete virologic containment during ART [181, 
376, 395] (B. Felber, personal communication).  This study demonstrates the potential for Ad-
based immunization to enhance SIV-specific immunity in the presence of underlying viremia, 
without exacerbating disease state.  Together these findings strongly support the further 
evaluation of Ad-based therapeutic vaccination in conjunction with improved ART treatment 
regimens.        
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5.0  CHAPTER THREE:  EFFECTS OF IMMUNOTHERAPEUTIC VACCINATION 
UPON T LYMPHOCYTE DYNAMICS DURING CHRONIC SIVMAC251 INFECTION 
5.1 PREFACE 
The following chapter is in fulfillment of specific aim 3.  These findings represent a 
portion of the data currently being incorporated into a manuscript addressing pre-treatment SIV 
pathogenesis and responsiveness to therapeutic Ad-based vaccination.  These findings will be 
submitted for publication by a peer-reviewed journal.  Adam C. Soloff performed all 
experiments, data analysis, and statistical evaluation under the guidance of Simon M. Barratt-
Boyes. 
5.2 ABSTRACT 
HIV pathogenesis is characterized by a massive elimination of CD4+ T lymphocytes from 
the extralymphoid tissues, leading to deleterious T cell turnover and disruption of T lymphocyte 
homeostasis.  Although ART inhibits CD4+ T cell loss, ART alone is insufficient to continually 
restore mucosal and systemic T cell populations, naturally replenished through thymopoiesis and 
Ag-driven peripheral expansion.  Therapeutic treatment with immunoregulatory IL-15 has been 
shown to enhance CD4+ and CD8+ Tem cell proliferation, and concurrent emigration to mucosal 
tissues.  Using a rigorous model of chronic SIV infection in rhesus macaques, we evaluated 
whether therapeutic vaccination utilizing heterologous Ad5- and Ad35-based vectors 
administered during two separate cycles of ART was capable of enhancing cellular proliferation 
and promoting peripheral expansion of T cell populations.  Vectors independently expressed SIV 
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gag, env, and nef genes, as well as bioactive rhesus IL-15, used here as a potential vaccine 
adjuvant.  Ad-based vaccination, with or without IL-15 administration, was found to have 
negligible effects upon T cell phenotype or proliferative response either systemically or at the 
lung mucosa.  Although progressive CD4+ T cell depletion was seen in the peripheral blood in all 
animals, proportionate increases in both CD4+ Tcm and Tem populations concomitant with 
steady loss of naïve CD4+ T cells were observed.  Alternatively, total peripheral blood CD8+ T 
cells were dramatically augmented throughout infection, experiencing enhanced proportions of 
CD8+ Tcm and Tem populations with gradual reductions of naïve CD8+ T cells in all treatment 
groups.  ART provided suppression of cellular proliferation, inhibiting dramatic expansion in 
PBMC.  Additionally, ART transiently restored mucosal T cell balance, leading to increased 
CD4+ T cell proportions and reduced proliferation.  These findings suggest that therapeutic Ad-
based vaccination, with or without IL-15, was incapable of further enhancing Ad-driven memory 
expansion, naïve T cell salvation, or proliferative responses above the effects mediated by ART 
during chronic SIV infection.                             
5.3 INTRODUCTION 
The defining characteristic of HIV/SIV pathogenesis is the elimination of CD4+ T cells 
within extralymphoid tissues leading to disruption of T cell function and homeostasis.  In healthy 
individuals, T cell pools are established initially through thymic output of naïve pluripotent T 
lymphocytes capable of responding to neoantigens [396].  Thymopoiesis naturally declines with 
age, coinciding with a corrective increase in peripheral Ag-driven expansion of long-lived 
memory T cell populations necessary to maintain stable cellular immunity [397].  Although 
peripheral expansion supports all memory T cell populations, CD4+ T cells are more reliant upon 
continual low-level thymopoeitic regeneration then their CD8+ T cell counterparts [396].  During 
HIV infection, cellular immune exhaustion occurs only after years of disease progression, as 
progressive illness causes thymic atrophy, associated with inflammatory-induced increases in 
inhibitory cytokines and cellularity, particularly CTL infiltrates, within the perivascular space 
[398].  Further suppression of thymopoiesis during HIV infection may occur through direct viral-
mediated killing of thymocytes or thymic dendritic cells, viral-induced damage to thymic 
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epithelial cells, or localized signaling inhibition [397, 399, 400].  In conjunction with viral-
mediated reductions in the already age-limited capacity for thymopoiesis, viral- and 
inflammatory-mediated hyperactivation leads to rapid turnover of peripheral T cells, further 
burdening the ability to replenish systemic and mucosal T lymphocyte pools [92].   
Inhibiting HIV/SIV pathogenesis, therapeutic intervention utilizing ART salvages the 
capacity for thymic and peripheral T cell regeneration.  ART treatment during HIV infection has 
been shown to enhance de novo production of TREC+, naïve T cells associated with increased 
thymic size and functional output as compared to untreated controls [91].  Effective ART 
restores the capacity of Ag-specific CD4+ and CD8+ T cells to proliferate in response to cognate 
Ag, essential to replenishing T lymphocyte pools [113, 126, 401].  In addition, ART has been 
shown to reduce the level of generalized systemic and mucosal cellular activation during 
infection, and is associated with reduced inflammation and bacterial translocation, inhibiting T 
cell pool turnover and alleviating supply pressure [100, 402].  Nevertheless, immune 
reconstitution following ART is incomplete, necessitating the development of immunoregulatory 
therapeutics capable of cellular regeneration.   
Novel therapeutic approaches utilizing the common γ-chain cytokines IL-2, IL-7, IL-15, 
and IL-21 have been shown to expand CD4+ and CD8+ memory T cell populations both in vitro 
and in vivo in murine and nonhuman primate models [396, 403].  The most extensively tested 
cytokine, IL-2, has been utilized clinically to promote T cell regeneration and decrease latent 
viral reservoirs during HIV infection, but has been recently shown to establish regulatory T cell 
populations and peripheral tolerance through specific, non-redundant cytokine functioning [67, 
404].  In contrast, IL-15 treatment reduces activation induced cell death, inhibits apoptosis, and 
expands and sustains CD4+ and CD8+ memory populations [374].  Although reports are 
conflicting as to the extent that IL-15 drives central and effector memory T cell proliferation, IL-
15 definitively augments CD4+ and CD8+ T cells populations either through direct stimulated 
expansion or alleviating regenerative inhibition.  In addition, systemic IL-15 delivery during 
ART-treated chronic SIV infection has been shown to potently induce CD4+ and CD8+ effector 
memory T cell expansion and emigration to extralymphoid tissues, strongly correlated with 
immunocompetence and delayed disease progression [177].  In the current study, we evaluated 
the potential of therapeutic vaccination, with or without Ad-mediated IL-15 support, to effect the 
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phenotype, proliferative capacity, and magnitude of T lymphocyte populations during ART-
treated, chronic SIVmac251 infection in rhesus macaques.      
5.4 MATERIALS AND METHODS 
5.4.1 SIV infection and immunotherapy 
The adult Indian rhesus macaques utilized presently were described in detail in Chapter 2.  
SIVmac251 infection, ART treatment with PMPA and FTC, and subsequent immunization 
utilizing Ad5- and Ad35-based vectors were performed as previously described in Materials and 
Methods sections 4.4.1, 4.4.2, and 4.4.3.  Inclusion criteria were identical with fifteen macaques 
subsequently analyzed.   
5.4.2 Absolute T lymphocyte determinations 
Absolute counting of CD4+ and CD8+ T cell populations in the peripheral blood of rhesus 
macaques was performed as specified previously in Materials and Methods section 4.4.8. 
5.4.3 FACS analysis of T cell phenotype and proliferation 
Multiparametric FACS analysis was performed as described in Materials and Methods section 
4.4.7 with minor alterations.  Live T cells were identified through successive gating strategies 
based on size and viability using the blue LiveDead apoptotic stain (Molecular Probes/Invitrogen 
Life Technologies). Immunophenotyping was performed on frozen PBMC or fresh BAL samples 
using the following Abs (purchased from BD Pharmingen, unless otherwise noted): Pacific Blue 
(CD3-Pacblue; SP34-2), CD4-AmCyan (L200, NIH AIDS Research and Reference Reagent 
Program), CD8-PE-Cy7 (RPA-T8), CD28-APC (28.2), and CD95-PE (DX2).  Cryopreserved 
cells were thawed, washed, and stained for surface markers for 1 h at 4oC. Fixation and 
intracellular staining was performed with BD Biosciences Fix/Perm reagent kits according to the 
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BD Biosciences protocol. Upon permeabilization, cells were stained intracellularly for Ki-67-
FITC (B56) for 30 min at 4oC. Appropriate isotype controls were included in all experiments.  
Data acquisition was performed on a LSRII cytometer with a minimum of 200,000 events 
collected from each sample. Data were analyzed using BD FACSDiva software (BD 
Biosciences).  To examine alterations in cellular profiles, the change in absolute cell number of 
individual phenotypic and proliferating cells was compared to values measured at pre-infection 
baseline within each animal, except for naïve CD4+ and CD8+ T cell proliferation represented 
cell count/μl whole blood due to insufficient cell numbers.   
5.4.4 Statistical analysis 
Comparisons between treatment groups were carried out using the Mann-Whitney U test 
performed using SPSS 14.0 software (SPSS Inc., Chicago, IL).  All P values are two-sided with 
significance considered to be P < 0.05. 
5.5 RESULTS  
5.5.1 Immunotherapy enhances CD4+ T cell memory but not naïve CD4+ T cell 
populations in peripheral blood 
To determine the effects of ART and immunotherapeutic vaccination upon the size and 
proliferative capacity of peripheral blood T cell populations, we longitudinally measured CD4+ T 
cells in PBMC utilizing multiparameter FACS analysis in conjunction with absolute cell 
quantitation.  As depicted previously (Fig. 10a), live, size-gated CD4+ and CD8+ T cells were 
identified as Tcm, Tem, or naïve as described [384] and cellular proliferation was measured 
through intracellular detection of nuclear Ki-67 protein, present during all active phases of the 
cell cycle.  Notably, no statistically significant differences were detected between immunized 
and controls groups for alterations in CD4+ T cell phenotype or proliferative response.  
Immediately upon SIV infection (wk 1), all animals underwent a dramatic loss of absolute CD4+ 
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T cells from the peripheral blood, followed by varying degrees of restoration prior to ART 
initiation at wk 12 (Fig. 16a).  Although CD4+ T cell counts remained stable during periods of 
ART, modest decreases were observed during each of two STIs among all study animals.  
Interestingly, animals receiving Ad5-SIV with IL-15 had significantly increased CD4+ T cell 
counts at wk 26 compared with animals immunized with Ad5-SIV alone, which were not 
different from controls (Fig. 16a).  By wk 52 post-infection, all groups retained less than half of 
their original CD4+ T cell numbers in peripheral blood. 
We next determined the influence of immunotherapeutic vaccination upon the proportion 
of memory and naïve CD4+ T cell populations in PBMC, measured as change from baseline, pre-
infection levels.  Interestingly, as the proportion of CD4+ Tcm cells decreased during the first 12 
wks post-infection, the percentage of Tem and naïve CD4+ T cells increased dramatically in all 
treatment groups (Fig. 16b, c, d).  Subsequent ART administration was found to inversely effect 
CD4+ T cell memory populations, increasing the proportion of Tcm while decreasing Tem 
representation in PBMC during both treatment cycles (Fig. 16b, c).  In contrast, naïve CD4+ T 
cells were gradually lost from Ad-SIV and control groups, while animals receiving Ad-SIV/IL-
15 immunizations maintained elevated naïve CD4+ T cell proportions throughout the 
investigation (Fig. 16d).  Notably, substantial expansion of the proportion of both CD4+ Tcm and 
Tem memory populations occurred progressively over the course of investigation, with wk 52 
levels of 157% and 391% of baseline values seen among all animals, respectively, whereas naïve 
CD4+ T cells were reduced to 64% of baseline among all animals at this time. 
To monitor Ag-driven peripheral expansion and potential naïve repopulation of CD4+ T 
cells, Ki-67 levels were measured at timepoints of therapeutic intervention.  Collectively, Tcm, 
Tem, and naïve CD4+ T cells demonstrated consistent responses among groups to ART 
intervention, with or without Ad-based vaccination, in their level of proliferative activity.  All 
CD4+ T cell phenotypes underwent a burst of replication upon infection, sustained until ART 
initiation at wk 12, with Tcm and Tem cells doubling initial baseline proliferation levels (Fig. 
16a).  During ART cycle-1, all animals displayed inhibited rates of proliferation, abrogating 
increases or sustaining the pre-ART level of proliferation in total, Tcm, and naïve CD4+ T cells 
(Fig. 16a, b, d).  In contrast, CD4+ Tem cells experienced reduced proliferation during the first 
ART cycle, suggesting inhibited generalized peripheral immune activation (Fig. 16c).  
Subsequently, during the first STI, all groups had a pronounced decrease in proliferation for all 
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phenotypes, potentially due to preferential elimination of activated CD4+ T cells during 
heightened viremia.  Reinstating ART plateaued CD4+ T cell proliferation, with slight increases 
observed among Tem and total CD4+ T cells (Fig. 16a, c).  Interestingly, upon cessation of ART 
during the second STI, all treatment groups experienced increased a dramatic burst of 
proliferating CD4+ T cells, irrespective of phenotype.  Notably, at wk 52 post-infection, Ad-SIV 
and control groups, but not Ad-SIV/IL-15 immunized animals, had a greater proportion of total 
CD4+ T cell proliferation than at pre-infection, baseline levels (Fig 16). 
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Figure 16:  Peripheral expansion of memory but not naïve CD4+ T cells throughout therapeutic intervention. 
Change in absolute CD4+ T cells/μl whole blood (A, left and D, right) or proportion of CD4+ T cells per pre-
infection baseline values in PBMC for CD4+ T cells at intervals after SIV infection in animals receiving Ad-SIV 
(closed diamonds), Ad-SIV with Ad-IL-15 (closed square) or mock (open circle) immunotherapy.  Periods of ART 
are depicted as shaded boxes, and with Ad5- and Ad35-based immunizations shown as black and open arrows, 
respectively.  Phenotype (Left) and proliferation (Right) illustrated for (A) total counts, (B) Tcm, (C) Tem, and (D) 
naïve CD4+ T cells.*=P<.05.  
5.5.2 Robust expansion of CD8+ T cell memory with naïve CD8+ T cell decline 
following therapeutic intervention in peripheral blood 
To evaluate the ability of therapeutic vaccination to expand systemic CD8+ T cell 
numbers, we monitored cellular phenotype and proliferation by FACS analysis of PBMC as 
described previously.  Similar to observations of CD4+ T cell populations, negligible differences 
were found between immunized and controls groups for any CD8+ T cell phenotype or 
proliferative response.  By 1 wk post-infection, peripheral blood CD8+ T cell numbers had 
dramatically declined among all animals, likely representing the relocation and homing of these 
cells to extralymphoid tissues (Fig. 17a).  This was followed by a robust expansion of the CD8+ 
T cell population in all groups, reaching levels of roughly 200% baseline values.  In contrast to 
the fluctuations of the CD4+ T cell population, CD8+ T cells were consistently elevated 
throughout the investigation, with negligible response to either ART or STI.  Notably, animals 
receiving Ad5-SIV with IL-15 augmentation displayed a trend towards higher CD8+ T cell 
counts than those of control or Ad5-SIV immunized groups during the first ART cycle.  When 
immunized animals were evaluated irrespective of IL-15 administration, they had statistically 
significant increases in total CD8+ T cell counts at wk 24 as compared to non-immunized 
controls (Fig 17a). 
Next we sought to analyze the ability of immunotherapeutic vaccination to promote the 
Ad-driven peripheral expansion of naïve and memory CD8+ T cell populations of the peripheral 
blood.  Unlike the therapeutic augmentation seen in the CD4+ Tcm population, CD8+ Tcm 
proportions were largely unaffected by ART or vaccination, with control and Ad-SIV groups 
showing marginal increases and Ad-SIV/IL-15 animals remaining at baseline levels (Fig 17b).  
In contrast, a marked increase in the percentage of CD8+ Tem cells represented was seen in all 
treatment groups, with wk 52 values reaching 238% of baseline levels among all study animals 
(Fig. 17c).  Notably, as the proportion of CD8+ memory T cells remained stable or elevated, all 
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treatment groups sustained a dramatic decrease in the proportion of naïve CD8+ T cells in the 
peripheral blood, with immunized animals, irrespective of IL-15 administration, experiencing 
statistically reduced naïve CD8+ T cells at wk32 compared to controls (Fig. 17d).  Interestingly, 
ART intervention was capable of ameliorating naïve CD8+ T cell declines during both treatment 
cycles. 
To examine the ability of immunotherapeutic vaccination to augment the proliferative 
capacity of CD8+ T cells in peripheral blood, we measured intracellular Ki-67 production at 
timepoints of therapeutic intervention.  As seen in CD4+ T cell populations, cellular proliferation 
profiles remained consistent between total CD8+ T cells and individual memory and naïve 
phenotypes, regardless of immunization status.  From pre-infection to ART initiation at wk 12, a 
proliferative burst was observed among all CD8+ T cell phenotypes within the peripheral blood 
(Fig. 17).  Subsequently, proliferation of CD8+ T cell phenotypes from all treatment groups was 
found to gradually decline from wk 12 to wk 44, with values at the end of the second ART cycle 
approaching baseline levels (Fig. 17).  During the second STI, robust increases in memory and 
naïve CD8+ T cells were identified from wk 44 to wk 52 among all treatment groups (Fig. 17).  
Interestingly, in light of the continual reduction of naïve CD8+ T cells proportions from pre-
infection to wk 52 post-infection, naïve CD8+ T cells experienced a roughly 15 fold increase in 
proliferation among all animals, suggesting functional differentiation, bystander killing, or 
heightened apoptotic susceptibility in eliminating naïve CD8+ T cells (Fig. 17).            
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Figure 17:  Therapeutic intervention enhances Tem but not naïve CD8+ T cell populations in the peripheral 
blood.  
Change in absolute CD8+ T cells/μl whole blood (A, left and D, right) or proportion of CD8+ T cells per pre-
infection baseline values in PBMC for CD8+ T cells at intervals after SIV infection in animals receiving Ad-SIV 
(closed diamonds), Ad-SIV with Ad-IL-15 (closed square) or mock (open circle) immunotherapy.  Periods of ART 
are depicted as shaded boxes, and with Ad5- and Ad35-based immunizations shown as black and open arrows, 
respectively.  Phenotype (Left) and proliferation (Right) illustrated for (A) total counts, (B) Tcm, (C) Tem, and (D) 
naïve CD8+ T cells.*=P<.05. 
5.5.3 Immunotherapy transiently restores mucosal T cell balance and reduces 
hyperactivation 
To examine the capacity for immunotherapeutic vaccination to salvage mucosal 
immunity, we longitudinally monitored the phenotype and proliferative ability of CD4+ and 
CD8+ T cells present in BAL samples.  Although CD4+ T cell numbers were insufficient for 
detailed characterization, we examined the proportion of CD8+ to CD4+ T cells in BAL samples 
at timepoints throughout the investigation.  Normal CD8+ to CD4+ ratios in uninfected macaques 
were found to be 2.57±0.37, providing a frame of reference to healthy cellular profiles in the 
lung.  A substantial increase in CD8+ to CD4+ T cell proportion was observed following 
infection, prior to ART intervention at wk 12, attaining 22 and 23 fold increases for collective 
immunized and control groups, respectively, suggesting effector CD8+ T cell homing to the lung 
in response to immune activation and inflammation (Fig. 18a).  The first cycle of ART 
transiently restored cellular balance, potently increasing the percentage of CD4+ T cells present 
compared to CD8+ T cells among all treatment groups for the duration of ART administration 
(Fig. 18a).  Upon ART cessation, during the first STI, all treatment groups again experienced a 
dramatic increase of mucosal CD8+ to CD4+ T cells.  Subsequently, the second ART cycle was 
minimally effective at restricting skewed CD8+ T cell levels, improving the mucosal CD4+ ratio 
from initiation of ART in Ad-SIV immunized animals alone.  Notably, CD8+ to CD4+ ratios at 
the end of the second ART cycle, wk 44, were considerably elevated compared to healthy levels, 
with Ad-SIV, Ad-SIV/IL-15, and mock immunized control groups displaying roughly 10, 30, 
and 30 fold increases in CD8+ to CD4+ cells compared to non-infected control animals, 
respectively (Fig. 18a).   
To decipher the effects of therapeutic vaccination on CD8+ T cell phenotype at the 
mucosa, we utilized FACS analysis to longitudinally measure cellular profiles.  BAL samples 
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were nearly devoid of naïve CD8+ T cells, consisting of predominantly CD8+ Tem cells (Fig 18a, 
b, data not shown).  As CD8+ Tcm and Tem memory populations represented nearly 100% of 
CD8+ T cells at the lung, the proportions of these populations were inversely related.  Upon 
establishment of chronic infection at wk 12, CD8+ Tcm percentages increased as Tem 
percentages decreased relative to values attained from uninfected controls (Fig. 18b, c).  During 
the first ART cycle, CD8+ Tem cell numbers were restored to those of pre-infection, healthy 
controls by wk 24, with concomitant decreases in Tcm seen in all treatment groups (Fig. 18b, c).  
CD8+ T cell phenotypes were unaffected during STI regardless of treatment groups.  Finally, 
slight decreases in CD8+ Tem, with subsequent increases in Tcm were observed during the 
second ART cycle, leaving CD8+ T cell profiles nearly identical to those identified in non-
infected control animals (Fig. 18b, c).   
To determine whether vaccination enhanced the proliferative activity and subsequent 
hyperactivation status of CD8+ T cells at the lung mucosa, we measured intracellular Ki-67 
production.  As seen in peripheral blood T cell populations, cellular proliferative responses, 
regardless of immunization status, were consistent between total CD8+ T cells and individual 
memory phenotypes.  We observed marked increases in Ki-67+ CD8+ T cells over those seen in 
non-infected controls by wk 12 post-infection in all treatment groups (Fig. 18).  Initiation of 
ART cycle-1 effectively reduced mucosal CD8+ T cell proliferation during drug treatment, 
potentially due to decreased viral-induced activation and associated inflammation in the lung.  
Animals receiving Ad-based vaccination collectively, with or without IL-15, had significantly 
increased Ki-67+ CD8+ T cells at wk 17, one week post-Ad5-SIV vaccination, compared with 
controls, an effect mediated predominantly by the CD8+ Tem population (Fig. 18a, c).  Upon 
STI, all animals had gradual increases in CD8+ T cell proliferation that were not restricted by re-
initiation of ART.   
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Figure 18:  Immunotherapy transiently restores T cell balance and reduces hyperactivation at the lung 
mucosa. 
Shown are the percentage change over time for animals receiving Ad-SIV (closed diamonds), Ad-SIV with Ad-IL-
15 (closed square) or mock (open circle) immunotherapy from non-infected control animals used for baseline 
representations.  Periods of ART are depicted as shaded boxes, and with Ad5- and Ad35-based immunizations 
shown as black and open arrows, respectively.  Phenotypic (Left) and proliferative (Right) percentage changes are 
illustrated for (A) representative ratio of total CD8+ to CD4+ T cell counts, (B) CD8+ Tcm, and (C) CD8+ Tem 
cells.*=P<.05.  
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5.6 DISCUSSION 
For the countless benefits afforded by ART, pharmacologic intervention against HIV is 
incapable of completely restoring the cellular immune system to an extent sufficient for 
perpetual self-regeneration and maintenance.  Thus, we have evaluated the potential for 
therapeutic vaccination, with or without immunoregulatory IL-15 administration, to induce 
peripheral expansion of CD4+ and CD8+ memory T cell numbers both systemically and at the 
lung mucosa during ART-treated, chronic SIV infection.  In addition, we proposed that effective 
immunization would support naïve T cell replenishment through alleviating virologic pressure, 
allowing for unmolested thymopoeitic supply of de novo CD4+ T cells while inhibiting the 
heightened susceptibility of peripheral naïve T cell populations to apoptosis.  Although Ad-based 
vaccination was previously shown to induce robust Ag-specific effector responses both 
peripherally and mucosally in our model, immunization failed to augment either T cell memory 
populations or enhance proliferation above levels seen in non-immunized controls.  These 
findings suggest that although potently immunogenic, Ad-based vaccination has limited 
influence on global T cell dynamics in the presence of underlying SIV viremia during therapeutic 
intervention.  Cellular maintenance and reductions in proliferation can be attributed primarily to 
ART, as no biologically significant differences were observed between animals immunized, with 
or without IL-15, and control animals throughout this investigation.  Therefore, without attaining 
complete suppression of viral replication in our model, the results of Ad-based 
immunotherapeutic immunization were negligible and inconclusive.    
As we have previously identified the role of early SIV-specific immunity and prolonged 
control of viremia in our model (Fig. 15), it is likely that the acute pathogenic insult sustained 
prior to immunotherapeutic intervention was insurmountable to completely restore T cell 
homeostasis.  At the initiation of ART, all study animals presented gross CD4+ T cell loss, 
consisting of reductions in both Tcm and naïve populations, factors strongly associated with 
response to immunization and virologic control [214, 388].  Concurrent with the significant loss 
of CD4+ T cells, is the dramatic expansion of CD8+ T cells, representing a near doubling of the 
effector arm of the CD8+ T cell population.  The dramatic expansion of systemic and mucosal 
CD8+ T cells, sustained throughout the course of investigation, is indicative of a state of 
hyperactivation, potentially induced by continual exposure to viral Ag, bacterial translocation, 
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and cytokine deregulation [100, 401].  Finally, as ART failed to ubiquitously contain viral 
replication in our model (Fig. 13), gradual but progressive disruption of T lymphocyte dynamics 
ensued, leading to unrestricted and suboptimal CD8+ effector T cell responses in the absence of 
CD4+ T cell helper function, compounded by pathologic T cell turnover and lack of naïve T cell 
regeneration.           
Given as an immunoregulatory adjuvant, animals receiving IL-15 administration 
demonstrated a trend towards enhanced absolute CD4+ and CD8+ T cell numbers throughout the 
first ART treatment cycle.  Yet, in contrast to previous reports, animals receiving IL-15 had 
neither significantly increased CD4+ or CD8+ Tcm or Tem memory populations nor enhanced 
effector memory proliferation when compared to Ad-SIV or non-immunized control groups 
[177].  These results also conflict with studies suggesting that IL-15 is capable of peripheral 
memory CD8+ T cell expansion, even in the absence of CD4+ T cell helper functioning.  Notably, 
animals receiving Ad-SIV with IL-15 demonstrated increased naïve CD4+ T cell proportions, 
retaining roughly equivalent proportions, albeit with reduced absolute numbers, as seen prior to 
infection (Fig. 16).  Although we previously demonstrated potent Ad-mediated production of IL-
15 in vitro (Fig. 8), it is likely that the levels of vector-delivered cytokine are insufficient to 
effect systemic T cell dynamics, with IL-15 remaining largely localized to the site of vaccination.  
Further investigation into the use of high-dose, systemic IL-15 administration during Ad-based 
immunotherapeutic vaccination will be required to assess the global effects of cytokine 
augmentation in this model.     
To the best of my knowledge, our findings represent the first report to examine cellular 
proliferation dynamics following therapeutic Ad-based vaccination of chronic SIV infection.  
Over the course of investigation, we observed a biphasic response to immunotherapeutic 
intervention, resulting in initial reductions of viral-induced hyperactivation both mucosally and 
in the peripheral blood, followed by enhanced proliferative rates during and immediately after 
ART cycle-2 in BAL and PBMC, respectively.  Furthermore, it is possible that even as 
vaccination failed to enhance generalized, overall proliferation, Ag-specific stimulation and 
expansion of T cells may have occurred as seen following poxvirus-based therapeutic 
vaccination, but was not directly addressed in this investigation [282].    
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5.7 CONCLUSIONS 
In the present study, immunotherapeutic vaccination had negligible influence upon the 
state of global T cell dynamics.  As previously suggested, potential effects of immunization may 
be occluded by the persistent response to continual, low-level viremia present during suboptimal 
antiretroviral-mediated control of infection.  Notably, trends in the expansion of CD8+ T cell and 
CD4+ Tcm cell populations were observed following immunotherapeutic vaccination.  These 
findings support the further evaluation of therapeutic Ad-based vaccination in the presence of 
more compete antiretroviral-mediated control of viremia.        
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6.0  DISSERTATION RELEVANCE 
HIV persists as one of the most devastating pathogens to coincide with modern humanity, 
representing a global challenge to not only biomedical researchers, clinicians, and public health 
experts, but individuals of compassion and conscience worldwide.  Fortunately, with the 
knowledge of generations past and dedication of those at present, science has never been more 
prepared for such a challenge.  The work presented in this document describes the utilization of 
novel, recombinant adenoviral vector-based vaccination regimens for the prevention and 
therapeutic intervention against –immunodeficiency virus infection in the nonhuman primate 
model.  This work represents an incremental advancement in understanding the character of T 
cell-mediated immunity induced through the Ad-based vaccination platform, and the subsequent 
potential to inhibit SIV pathogenesis.                
6.1 AIM 1:  CHAPTER ONE - NOVEL VACCINE REGIMEN UTILIZING 
ADENOVIRUS SEROTYPE 5- AND 35-BASED VECTORS 
At the turn of the 21st century, the field of HIV vaccine development had shifted its 
attention towards the development of vaccines capable of inducing robust CTL-mediated 
immunity in an attempt to curtail the HIV pandemic.  Failures to create conformationally 
representative antigenic targets for humoral immune induction, in conjunction with a growing 
body of evidence supporting the role of cellular immunity in restricting disease progression, led 
to interest and development of viral vectors as immunogens.  In 2002, a hallmark study by Shiver 
et al. demonstrated the ability of Ad5-based vectors to control SHIV89.6 infection in nonhuman 
primates, albeit utilizing genetically optimal Mamu-A*01-expressing animals and a challenge 
virus of attenuated pathogenesis, encouraging further investigation of Ad-based vectors and 
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infusing optimism into a demoralized field that vaccine-induced control of HIV infection was 
possible [211].  With the revelation that vector-specific humoral immunity limited the potential 
of homologous Ad-based vaccination regimens, development of Ad vectors based on rare human 
or nonhuman species was advanced.  Studies by our group were among the first to develop and 
explore the utility of Ad35-based vectors as potential HIV vaccine candidates due to their low 
seroprevalence in the United States and regions of Africa [305, 310].  Furthermore, the data 
presented in Chapter 1 represents the first reported study utilizing heterologous Ad5- and Ad35-
based vaccination of nonhuman primates against SIV infection [405].  This study provided the 
preliminary immunogenicity results necessary to support the continued development of 
heterologous Ad-based vaccination regimens for the prevention and therapeutic inhibition of 
HIV infection.         
6.1.1 Immunogenicity of Prophylactic Dual-Serotype Adenoviral-Based 
Vaccination 
Our laboratory’s demonstration that novel Ad35-based vectors effectively enhanced 
immunity previously induced through Ad5-based immunization of nonhuman primates expanded 
the field of analysis of heterologous Ad-based prime/boost vaccine regimens, building upon 
previous reports illustrating the effective use of the Ad5/Ad35 prime-boost combination in mice, 
or Ad5/AdC6 interspecies prime-boost models in nonhuman primates [311, 319].  Notably, as a 
proof-of-concept, we demonstrated the ability of sequential heterologous Ad5/Ad35-based 
immunization to augment the magnitude of Gag-specific IFN-γ production over that induced 
following homologous Ad5-based vaccination, coinciding with lack of Ad5-specific NAb to 
cross-neutralize Ad35-based vectors in nonhuman primates (Fig. 1).  Following pathogenic SIV 
challenge, we showed that vaccine induced IFN-γ-mediated responses were rapidly recalled, 
demonstrating the ability of this novel immunization regimen to promote durable Ag-specific 
memory responses, a goal of any effective preventative immunization strategy.  Detailed 
characterization of vaccine-induced and post-challenge cellular immunity revealed a plethora of 
epitope targets with slightly varied profiles, suggesting that efforts to maximize T cell targeting 
such as the inclusion of heterologous vaccine Ags may be necessary to optimize protective 
immunity.  The discovery of the novel CD4+- and CD8+-restricted T cell epitopes described in 
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this work adds to the burgeoning library of known nonhuman primate epitopes within SIV, and 
will allow for a more precise characterization of the ability of vaccine induced immunity to 
translate into effective anamnestic responses.  Taken together, these findings have confirmed the 
ability of the Ad5/Ad35-based vaccine regimen to induced robust Ag-specific cellular immunity 
in a pre-clinical nonhuman primate trial against SIV infection and support the advancement of 
heterologous over homologous Ad-based vaccine regimens for further investigation as 
immunogens against HIV infection.      
6.1.2 Viral Escape from Cellular Immune Pressure 
Although clinical observation of HIV viral escape following the development of cellular 
immunity have been reported, the nonhuman primate model of infection provides the opportunity 
to study the mechanisms and consequences, for both host and virus, of T cell-driven viral escape 
through the use of molecularly cloned viral strains, specific timing of infection, and defined 
genetic models.  In chapter 1, we utilized IFN-γ ELISPOT matrices to provide detailed 
characterization of the precise T cell-mediated Gag-specific responses following Ad-based 
immunization against the molecular isolate SIVmac239 and recalled upon heterologous viral 
challenge utilizing SIV/DeltaB670.  As cellular immune responses conserved between 
vaccination and challenge should be capable of applying immunologic pressure and influencing 
viral escape, we elucidated precise T cell epitopes and their associated viral sequences to 
evaluate sustained viral immune evasion.  Notably, the SIV/DeltaB670 challenge virus consists 
of an uncloned, pathogenic viral swarm and has seldom been examined in infection models, 
allowing for the primary characterization of T cell-driven immune evasion mechanisms.  Our 
findings demonstrated that CD8+ T cell-mediated responses directed against the Mamu-A*01-
restricted CM9 epitope were capable of driving viral escape, with rapid selection of position 2 
anchor residue viral variants following SIV/DeltaB670 challenge, consistent with previous 
reports [357].  Yet, further investigation revealed that SIV/DeltaB670 developed sustained CM9 
escape variants in the absence of extraepitopic flanking mutations, shown to be necessary for 
persistent CM9 escape in SIVmac239 and SIVmac251 [361, 362].  Notably, we found the 
extraepitopic regions of the CM9 epitope to be hypervariable in SIV/DeltaB670, suggesting a 
flexible Gag structure, unique to SIV/DeltaB670, which may allow for viral escape without 
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concurrent reductions in viral fitness, posing a new mechanism for SIV CTL escape.  In contrast 
to the rapid viral escape identified from CM9-driven CTL pressure, potent vaccine induced, 
CD8+ T cell-mediated responses targeting the novel GL9/GS9 (Gag141-150), GY9 (Gag270-278), and 
QP9 (Gag272-280) in the SIV capsid, as well as CD4+ T cell-mediated targeting of the novel GT15 
(Gag56-70) epitope found in the viral matrix protein failed to induce sustained alterations in 
concomitant viral sequences (Fig. 7).  Interestingly, two of three animals who developed CD8+ T 
cell-mediated responses to the novel GY9/QP9 epitope regions (p68/p69) following vaccination 
demonstrated superior control of viremia upon SIV/DeltaB670 challenge for over 30 wks post-
infection.  These findings suggest the presence of an evolutionarily conserved viral sequence 
within the SIV/DeltaB670 capsid protein that is under severe structural or functional constraints, 
thus limiting its capacity to sustain mutations and inhibiting viral escape, as demonstrated by in 
vitro analysis of HIV capsid and population wide assessments of HLA effect and HIV evolution 
[406, 407].  Although the MHC allele or alleles responsible for binding these peptide epitopes 
could not be identified at this time, further investigation into the mechanisms of the viral 
restriction associated with cellular immune responses directed against this region would advance 
our current understanding of the qualitative role of immunologic targeting, potentially 
elucidating the most effective targets for vaccination. 
6.1.3 Vaccine-mediated Restriction of Heterologous SIV Challenge 
The recent failure of the phase IIb STEP trial performed by Merck and the NIH of a 
homologous Ad5-based vaccine candidate including HIV clade B Gag, Nef, and Pol genes to 
either prevent HIV infection or suppress post-infection viremia has raised the questions of what 
vaccine-induced antiviral cellular immune responses will be efficacious, and how much can we 
extrapolate from current nonhuman primate models of HIV infection [408].  The STEP Ad5-
based vaccine demonstrated limited immunogenicity among a human population heterogeneous 
in pre-existing Ad5-specific NAb titres, with responses per Ag determined by IFN-γ ELISPOT 
detected in roughly 38-76% of subjects depending upon their anti-Ad5 NAb titres [409].  By 
comparison, the magnitude of these cellular immune responses represent roughly 10-20% of 
those seen in HIV infected individuals who innately control infection [410].  In contrast, our 
study (Chapter 1) showed that macaques ubiquitously developed IFN-γ-mediated responses 
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following Ad5-Gag priming immunization that were further augmented in those animals 
receiving Ad35-Gag administration (Fig 1).  Although animals were initially devoid of anti-Ad5 
NAb titres, we observed potent enhancement of Gag-specific IFN-γ production during four 
rounds of homologous Ad5-based immunization in all animals following the development of 
Ad5-specific NAb titres >100 and in 7/8 animals with Ad5-specific NAb titres >200, the STEP 
delineation level for elevated NAb titre.  Notably, animals receiving Ad5/Ad35-Gag vaccination 
demonstrated significantly lower viral loads over the course of investigation and extended 
survival rates compared with controls, with two vaccinees attaining undetectable viremia 
following challenge with heterologous and pathogenic SIV/DeltaB670 (Fig. 5).  Remarkably, our 
immunization targeted the related but distinct Gag protein of SIVmac239 alone, suggesting that 
the failure of the STEP trial may under represent the potential utility of Ad-based vaccination 
against HIV.  Unfortunately, Ad5/Ad35-based vaccination in our model failed to achieve the 1.5 
log reduction in post-infection chronic viremia that is the current benchmark for an altruistic 
vaccination to inhibit HIV transmission and disease progression [322, 323, 411-413].  
Potentially, a higher dosage of Ad-based vaccine or continued rounds of heterologous Ad-based 
immunization may have been necessary for the optimal induction of de novo cellular immunity 
and subsequent expansion of antiviral cellular memory.   
6.1.4 Insights into Nonhuman Primate Models of HIV Infection 
The SIV challenge model of rhesus macaques remains inadequately characterized, 
prohibiting comparison of preclinical vaccine modalities and obscuring the potential for direct 
clinical translation of results.  Once the gold-standard for pathogenic challenge, SHIV-89.6P 
viruses have been shown to inaccurately reflect disease course in humans, demonstrating nearly 
ubiquitous and aberrant depletion of both memory and naïve peripheral CD4+ T cells through 
CXCR4-mediated entry [414].  In contrast to natural HIV or pathogenic SIV infection, SHIV-
89.6P viruses are exquisitely sensitive to Ab-mediated neutralization, and have been controlled 
repeatedly through a multitude of immunization strategies.  This discrepancy was highlighted by 
the results of the STEP trial, failing to demonstrate clinical efficacy following protection against 
SHIV-89.6P challenge [211].  Our findings examining the ability of Ad5/Ad35-based 
vaccination to elicit T cell-mediated protection against the relatively unutilized SIV/DeltaB670 
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quasispecies support the use of uncloned, pathogenic SIV species as a stringent model of HIV 
infection.  Although vaccinated animals sustained lower viral loads compared to control animals, 
statistically significant reductions in viremia were not observed at any specific timepoint after 
heterologous SIV/DeltaB670 infection (Fig. 5).  As the standardization of challenge models will 
be necessary for the preclinical evaluation of next-generation vaccines, our findings are a notable 
addition to the field, supporting the use of uncloned, pathogenic SIV to realistically model HIV 
infection.            
6.2 AIM 2:  CHAPTER 2 - THERAPEUTIC ADENOVIRUS-BASED VACCINATION 
DURING ART-TREATED CHRONIC SIVMAC251 INFECTION 
6.2.1 Therapeutic Ad-Based Vaccination Enhances the Breadth and Magnitude of 
Antiviral Cellular Immunity  
With an estimated 33.2 million people living with HIV in 2007, therapeutic intervention 
strategies aimed at augmenting dormant antiviral immunity, decreasing latent viral reservoirs, 
and salvaging crucial CD4+ T cell memory populations are being examined to alleviate the 
pathogenic effects of ongoing HIV infection and potentially promote a state of immunologic 
balance capable of durable containment of viremia in the absence of continuous pharmacologic 
treatment.  Building upon the success of preventative Ad-based vaccination regimens, we 
utilized Ad5- and Ad35-based vectors encoding the SIVmac239 gag, env, and nef genes, with or 
without Ad-mediated IL-15 delivery, in a therapeutic vaccination strategy during ART-treated, 
chronic SIVmac251 infection of rhesus macaques, extending the use of Ad-based vectors for the 
first time beyond prophylactic vaccination in this model.  As hypothesized, Ad5/Ad35-based 
vaccination was capable of augmenting cumulative antiviral cellular immunity over innate 
responses seen in mock immunized control animals during chronic SIVmac251 infection, as 
determined through IFN-γ ELISPOT (Fig. 9).  Furthermore, vaccination expanded peak Ag-
specific cellular immunity during immunotherapy against the individual Gag, Env, and Nef 
proteins to a significant degree (Fig. 9).  Notably, two rounds of ART followed by STI failed to 
induce heighted T cell-mediated immunity in mock immunized control animals, demonstrating 
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that immune induction was due to vaccination.  As conventional theories supported by years of 
preclinical observations suggest that enhancing the overall magnitude of Ag-specific IFN-γ-
mediated cellular immunity is necessary for effective control of all stages of HIV/SIV viremia, 
our findings support the development of Ad-based vaccination strategies for the treatment of 
chronic –immunodeficiency virus infection.                  
6.2.2 Therapeutic Vaccination Induces CD8+ T cell-Biased Monofunctional 
Immunity 
Prior to the development of multiparametric FACS analysis, T cell functionality and 
presumptive antiviral immunity at the single cell level was predicted by the quantitation of IFN-
γ, TNF-α or IL-2 individually in responses to viral Ag.  As the sensitivity and scope of cellular 
cytokine detection has expanded, so too has our understanding of the effective antiviral 
mediators associated with protection from disease [292].  Studies comparing the T cell effector 
profiles of individuals who control HIV infection, with or without ART, compared to those with 
progressive infection have suggested that functional heterogeneity consisting of polyfunctional 
IFN-γ, TNF-α, IL-2, MIP-1β, and CD107a/b responses are essential in disease containment [219, 
222].  Therefore, we utilized multiparameter FACS analysis to characterize the CD4+ and CD8+ 
T cell-mediated production of IFN-γ, TNF-α, and IL-2 simultaneously during peak responses 
subsequent to Ad-based vaccination.  Within the peripheral blood CD8+ T cell population, 
therapeutic Ad5-based vaccination enhanced predominantly monofunctional production of both 
IFN-γ and TNF-α, as well as IL-2+ IFN-γ+, IFN-γ+ TNF-α+, and triple positive cytokine profiles 
to a lesser degree (Fig. 10).  Additionally, increased Ag-specific IL-2 was detected from CD8+ T 
cells in BAL samples following Ad5-SIV administration (Fig. 13).  In contrast, Ad5-SIV 
immunization induced limited CD4+ T cell responses, consisting of Ag-specific IFN-γ 
production alone (Fig. 10).  Subsequent boosting with heterologous Ad35-SIV maintained IFN-
γ-mediated production from CD8+ T cells in PBMC and enhanced IL-2+ IFN-γ+ in BAL samples 
in responses to peptide stimulation, failing to support previously induced CD4+ effector 
responses.  The predominance of monofunctional CD8+ T cell-mediated immunity following 
vaccination suggests that Ad-based immunization serves to establish terminal differentiation of 
Ag-specific effector T cells, leading to cytokine dysfunction.  The conspicuous absence of IL-2 
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production from either CD4+ or CD8+ T cells of the peripheral blood further supports the idea 
that therapeutic Ad-based immunization fails to induce a regenerative cytokine profile.  These 
findings are in agreement with recent immunization studies suggesting that Ad5-based 
vaccination induces a CD8+ T cell-skewed, qualitatively restricted immune profile when 
compared to less overtly immunogenic serotyped vectors such as Ad26 and Ad48 [294].  
Collectively, these findings suggest that the unique immunogenicity of Ad5-based vectors may 
promote less efficacious immunity against complex intracellular pathogens such as HIV.     
6.2.3 Vaccination Transiently Restores CD4+ Tcm Populations  
  Therapeutic interventions capable of restoring depleted CD4+ Tcm populations will 
allow for the regeneration of CD4+ Tem cells and provide support for memory CD8+ T cells 
necessary to maintain effective antiviral cellular immunity.  In addition, the maintenance of 
CD4+ Tcm cells in animals receiving DNA-prime/Ad-boost immunizations strongly correlated 
with survival following pathogenic SIVmac251 challenge [214].  We currently demonstrate that 
administration of Ad5/Ad35-SIV administration significantly augmented peripheral blood CD4+ 
Tcm populations from levels detected at ART initiation (Fig. 12).  Unfortunately, increases in 
CD4+ Tcm cells were not reflected in the CD4+ Tem cell populations or the overall CD4+ T cell 
populations of the peripheral blood or lung mucosa (Fig. 12 and 13).  Augmentation of 
peripheral CD4+ Tcm populations may be indicative of peripheral Ag-driven memory expansion, 
suggesting that further immunization under restricted viremic conditions afforded by effective 
ART may serve to fully restore homeostasis within the CD4+ T cell memory compartment. 
6.2.4 Therapeutic Vaccination Fails to Control Rebound Viremia upon ART 
Cessation 
The primary goal of the Ad-based immunotherapy described in chapter 2 was to promote 
a SIV-specific cellular immune response of sufficient quality and magnitude that would be 
capable of containing rebound viremia upon cessation of ART.  Although therapeutic Ad5/Ad35-
SIV administration induced robust CD8+ and moderate CD4+ T cell responses, immunization 
failed to further contain SIVmac251 viremia beyond the effects seen with ART alone (Fig. 14).  
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Although disappointing, these results are not surprising given that the combination of PMPA and 
FTC utilized in our study failed to suppress chronic viremia in 11 of 15 animals selected for 
median control of chronic viral load (Fig. 14).  Previous therapeutic intervention trials and 
personal communications (B. Felber, National Cancer Institute) strongly suggest that in the 
absence of ART-controlled SIV viremia the effects of therapeutic vaccination will be 
undetectable due to continual low-level antigenic stimulation of effector responses [376, 395].  
Taken together, the full potential of the current heterologous Ad-based vaccine regimen may yet 
to be recognized, as the underlying viremia present in our study confounds interpretation, 
providing SIV-mediated Ag-stimulation, homeostatic T cell disruption, and ongoing disease 
pathogenesis. 
6.2.5 Effects of IL-15 Augmentation 
Within Aim 2, we addressed whether Ad-mediated delivery of the immunoregulatory 
cytokine IL-15 as a vaccine adjuvant would augment SIV-specific immunity allowing for further 
suppression of viremia throughout the investigation.  Co-administration of Ad-IL-15 with Ad-
SIV vectors failed to enhance cumulative or individual Ag-specific cellular immune responses, 
with animals receiving Ad-IL-15 adjuvantation displaying reduced reaction to immunization 
during both ART cycles (Fig. 9).  In addition, no distinguishable differences were identified 
between animals, with or without IL-15 augmentation, in the Ag-specific CD4+ and CD8+ T cell 
TH1 cytokine profiles induced through vaccination (Fig. 10).  Furthermore, although not 
statistically significant, animals receiving Ad-SIV with Ad-IL-15 had median viral loads 1 log 
greater than either Ad-SIV or control groups at 52 wks post-infection.  While not detected 
systemically, IL-15-induced activation and proliferation of SIV-specific CD4+ Tem at the local 
site of vaccination and compartmentally in lymph nodes may enhance the susceptibility of these 
cells to SIV-mediated elimination, subsequently removing essential Ag-specific CD4+ T cell 
support functions necessary to propagate antiviral cellular immunity while increasing SIV 
replication.   
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6.2.6 Immunologic Correlates to SIV Control 
The diverse range of viral control demonstrated by study animals in Chapter 2 in 
conjunction with the detailed analysis of cellular immunity performed during this investigation 
provided the opportunity to identify the immunologic factors that correlate with pathogenic 
inhibition throughout therapeutic intervention.  When animals were analyzed, irrespective of 
treatment group, we found significant correlations between the magnitude of peak Gag- and Env-
specific IFN-γ ELISPOT responses in PBMC during both ART cycles and reduced viral load 
(Fig. 15).  Additionally, systemic IFN-γ+ TNF-α+ producing CD8+ T cells and polyfunctional 
CD4+ T cells in PBMC producing two or three cytokines were negatively correlated with viremia 
(Fig. 15).  As moderators of cellular dynamics, the absolute number of CD4+ Tcm cells in 
peripheral blood were negatively associated with both early (wk 12) and late (wk 44) viremia, 
and positively associated with the maintenance of polyfunctional Ag-specific CD8+ Tcm 
populations in the periphery.  Maintenance of gross CD4+ T cell populations at the lung mucosa 
were found to correlate with reduced plasma viral loads both early and late during infection, an 
association which was not identified with peripheral blood CD4+ T cells, illustrating the 
sensitivity of mucosal CD4+ T cell analysis.  As the precise correlates of protective immunity 
against HIV infection have yet to be defined, our findings provide insight into the mechanisms of 
immunologic control of chronic SIVmac251 infection, and corroborate the role of polyfunctional 
Ag-specific T cell-mediated immunity, peripheral CD4+ Tcm, and mucosal CD4+ T cells in the 
inhibition of SIVmac251 pathogenesis.         
6.3 AIM 3:  CHAPTER 3 - EFFECTS OF IMMUNOTHERAPEUTIC VACCINATION 
ON SYSTEMIC AND MUCOSAL T CELL DYNAMICS 
6.3.1 Limitations of Ad-Based Vaccination During Chronic SIV Infection 
The results presented in chapter 3 detailing the effects of immunotherapeutic Ad-based 
vaccination during ART-treated, chronic SIVmac251 infection suggest the inability of 
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parenterally administered Ad-based vectors, with or without IL-15, to influence T cell population 
phenotypes or proliferative activity.  Regrettably, statistically significant differences between 
treatment groups were practically absent, leaving general trends of phenotypic evolution and 
proliferative response throughout the course of investigation.  In contrast, administration of ART 
altered both systemic and mucosal T cell phenotypes and proliferative response, and was the 
primary influence on T cell dynamics within our treatment model.  Moreover, as ART failed to 
suppress viremia, the sustained viral loads of greater than 104 RNA copies per ml seen in all 
treatment groups throughout investigation may have been capable of inducing homeostatic T cell 
dysfunction, as evidenced by loss of peripheral and mucosal CD4+ T cells, naïve T cell 
populations, and lack of proliferation.   
6.3.2 Immunotherapy Promotes CD4+ T Cell Memory But Not Naïve Populations 
in PBMC 
Throughout the course of infection, we observed a stark contrast between the dramatic 
expansion of memory CD4+ T cell populations and the gradual and near complete elimination of 
naïve CD4+ T cells in the peripheral blood (Fig. 16).  Initial declines in CD4+ Tcm cells, 
potentially due to Ag-driven differentiation into Tem cells, were reversed with the initiation of 
ART at wk 12, subsequently demonstrating continued expansion throughout observation.  
Similarly, CD4+ Tem populations experienced a roughly 400% increase among all treatment 
groups from pre-infection baseline levels.  Interestingly, ART had contradictory effects upon 
CD4+ T cell memory populations, promoting Tcm cell numbers while causing moderate declines 
in Tem populations, potentially due to suppressed peripheral activation.  Conversely, naïve CD4+ 
T cells underwent a limited increase prior to the initiation of ART at wk 12, which was followed 
by progressive depletion of these cells in the peripheral blood.  Interestingly, although not 
statistically significant, animals receiving Ad-IL-15 administration maintained heighted naïve 
and lower memory CD4+ T cell numbers throughout investigation.  Collectively, immunotherapy 
had limited effects on CD4+ T cell phenotype, as ART-mediated control of viremia was 
incomplete, and therapeutic vaccination failed to expand memory CD4+ T cells at any timepoint 
over controls.            
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6.3.3 Expansion of CD8+ Tem Cells and Loss of Naïve CD8+ T Cells Throughout 
Progressive Infection 
Upon the establishment of chronic infection, we observed a rapid expansion of absolute 
CD8+ T cell numbers in peripheral blood, characteristic of pathogenic SIV infection.  Phenotypic 
analysis identified the majority of this burgeoning CD8+ T cell compartment to be composed 
CD8+ Tem cells, indicative of the adaptive response to viral infection and activation induced 
through systemic hyperactivation.  In addition, a marginal collective increase in CD8+ Tcm cells 
was identified among all groups over the course of infection (Fig. 17).  Interestingly, expansion 
of the CD8+ T cell memory populations coincided with a progressive loss of peripheral naïve 
CD8+ T cell population over the period of observation.  As neither ART nor Ad-based 
vaccination were found to significantly effect the CD8+ T cell compartment, it can be presumed 
that the observed T cell dynamics represent a close to natural state of progressive viral 
pathogenesis.  These findings suggest that overrepresentation of CD8+ Tem populations and 
depletion of naïve CD8+ T cells in the peripheral blood were due to continual Ag-driven 
peripheral expansion of CD8+ T cells in the presence of ongoing viremia.   
6.3.4 Immunotherapy Transiently Restores Mucosal CD8+ to CD4+ T cell balance  
The effects of HIV/SIV infection upon the T cell dynamics of mucosal surfaces are the 
most predictive indicators of systemic pathogenesis and disease progression.  In as much, we 
evaluated the potential for therapeutic vaccination to promote functional cell-mediated immunity 
in the lung mucosa either through alleviating virologic pressure or through the expansion and 
recruitment of CD4+ Tem cells to the extralymphoid tissue [177, 215].  As normal macaque T 
lymphocytes in BAL samples are predominantly CD8+ T cells, we monitored the ratio of CD8+ 
to CD4+ T cells, providing baseline values of healthy mucosal T cell homeostasis.  SIV infection 
resulted in a rapid augmentation of CD8+ to CD4+ T cells percentages, likely due to both Ag-
specific effector CD8+ T cell recruitment and mucosal CD4+ Tem depletion (Fig. 17).  Notably, 
initiation of ART restored CD8+ T cell-skewed populations to levels approaching pre-infection 
baseline, maintaining this ratio for the duration of ART.  A CD8+ T cell-skewed profile was 
again established during the first STI.  Interestingly, although the second ART cycle transiently 
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supported cellular balance within all treatment groups, only animals receiving Ad-SIV achieved 
cellular ratios comparable to those established during the first ART cycle.  While the effects of 
therapeutic vaccination, with or without Ad-mediated IL-15 delivery were negligible, our 
findings illustrate the clinical benefit of ART upon T cell dynamics at sites of the mucosa, and 
provide insight into the cellular pathogenesis of SIVmac251 infection at the lung.   
6.3.5 Immunotherapy Suppresses Systemic and Mucosal Proliferation 
As ART has been shown to reduce cellular activation, we characterized non-specific 
cellular proliferation through the detection of Ki-67 in T lymphocyte populations of the 
peripheral blood and lung mucosa.  Regrettably, therapeutic vaccination was ineffective at 
promoting peripheral or mucosal proliferation of T cell memory populations, as no statistically 
significant differences were observed between treatment groups (Fig. 16-18).  Interestingly, 
memory and naïve phenotypes of both CD4+ and CD8+ T cell populations in PBMC and BAL 
samples demonstrated a consistent pattern of cellular proliferation following SIV infection, ART 
treatments, and STIs (Fig. 16-18).  Although T cell proliferation was suppressed for the duration 
of ART intervention, proliferative rates were elevated above pre-infection baseline values for all 
T cell phenotypes found in the peripheral blood or lung mucosa at study endpoint, wk 52 and wk 
44, respectively.  Collectively, these findings suggest that although ART was capable of 
transiently suppressing the hyperactivation associated with chronic SIV infection through 
inhibiting viral replication, transient immunotherapeutic intervention was incapable of durably 
controlling rapid T cell turnover and subsequent cellular exhaustion.                                  
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7.0  CURRENT STATE OF HIV VACCINE DEVELOPMENT 
7.1 THE FAILURE OF THE STEP TRIAL 
 To date, only two vaccine candidates have completed human efficacy trials for the 
prevention of HIV infection.  The first, VaxGen’s gp120-specific, subunit protein-based vaccine 
failed to elicit NAb responses and subsequently protect from infection.  The inability of this 
vaccine to elicit Ab-mediated sterilizing immunity was among several factors leading to a shift in 
research emphasis towards the pursuit of vaccines capable of promoting antiviral cellular 
immunity.  Theoretically, T cell-mediated immunity may limit peak HIV viral loads, resulting in 
reduced acute pathogenesis, as well as inhibit chronic viremia through eliminating infected cells, 
allowing for durable immune control in the absence of sterilizing immunity.  Over ten years after 
the failure of VaxGen’s vaccine, clinical evaluation of the first T cell-mediated vaccine candidate 
was performed by Merck and the US National Institutes of Health with the testing of a 
recombinant replication-defective Ad5-based immunogen in the STEP trial.  Regrettably, this 
study was abruptly terminated when interim analysis showed that vaccination failed to prevent 
HIV infection or reduce post-infection, set-point viral loads at three months following HIV 
seroconversion.  The results of this phase IIb clinical efficacy trial represent an invaluable tool to 
shape the future of HIV vaccine development, and provide insight into the small successes that 
accompany this unfortunate failure.   
The Step trial consisted of a double-blind, phase IIb, test-of-concept vaccine study 
involving 3000 HIV seronegative volunteers within North America, South America, the 
Caribbean, and Australia who were at high risk of HIV acquisition.  Participants received three 
immunizations at 0, 1, and 6.5 months of replication-defective Ad5-based vectors individually 
encoding the gag, nef, and pol genes from HIV clade B strains [328].  Notably, HIV env 
transgenes were not included within vaccination vectors, tailoring immunization for the 
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induction of T cell-mediated immunity specifically.  Study participants were randomized to 
receive Ad5-based vaccination or immunization diluent as a placebo based on gender, pre-
existing Ad5-specific Ab titres, and testing site.  Interim analysis of individuals who acquired 
HIV infection, all but one male, revealed that immunization was incapable of preventing HIV 
infection, as 49 of 914 male vaccine recipients became infected as compared to 33 of 922 men 
receiving placebo controls [415].  Furthermore, no reduction in mean set-point viral-loads 
following seroconversion were observed among vaccine recipients as compared to placebo-
treated control subjects [415].  Unexpectedly, the STEP trial identified higher rates of HIV 
acquisition among men who had either greater Ad5-specific NAb titres, who were 
uncircumcised, or both [415].  In addition to the absence of a protective effect afforded by 
vaccination, the increased rates of HIV acquisition among vaccine recipients are alarming, 
raising concerns over the safety as well as utility of Ad-based and other viral vector-based 
immunizations against HIV infection.  Collectively, these results highlight the need to further 
expand basic research into the specific mechanisms of viral-vector induced immunity and 
potential vaccine-induced immunologic phenomenon capable of enhancing sensitivity to HIV 
infection.   
Historically touted for their ability to induce robust IFN-γ-mediated cellular immune 
responses, the STEP trial demonstrated that the Ad5-based vaccine candidate utilized induced T 
cell-mediated responses which were incapable of containing acute or chronic HIV viremia.  First, 
IFN-γ-mediated responses to HIV Ags targeted by immunization were detected by ELISPOT in 
only 77% of vaccine recipients after completing the full vaccination regimen, demonstrating 
limited immunogenicity in a genetically diverse population with variable pre-existing Ad5-
specific NAb titres [416].  The STEP Ad5-based vaccination resulted in a narrow breadth of 
response to targeted Ags, as a mere 62% of vaccinees mounted IFN-γ responses against two or 
more of the three targeted proteins [416].  As expected, the level of pre-existing Ad5-specific 
NAb titres were correlated with reduced vaccine immunogenicity.  Furthermore, Ad5-based 
vaccination resulted in predominantly CD8+ T cell-mediated responses consisting of primarily 
IFN-γ and TNF-α with limited polyfunctional capacity.  Finally, Ad5-based vaccination 
established a CD8+ T cell-biased Ag-specific response, with only 41% of vaccine recipients 
mounting CD4+ T cell-mediated responses and 31% of vaccinees developing both CD4+ and 
CD8+ T cell response against HIV antigens [416].  Notably, there were no differences in the 
 125 
magnitude, breadth, or character of HIV-specific vaccine-induced immunity identified between 
vaccine recipients who remained HIV negative or subsequently contracted HIV, suggesting that 
the Ad5-based STEP immunization promoted a functionally deficient immune response [416].  
With only preliminary data available for interpretation, it is difficult to explain the failure 
of the Ad5-based STEP vaccination to effect HIV transmission rates or the dynamics of early 
infection.  Potentially, Ad5-induced immunity was of insufficient magnitude, as only three 
fourths of vaccine recipients developed significant ELISPOT responses, measured between 
1:1500 and 1:6000 IFN-γ-producing cells within PBMC [416].  The magnitude of this response 
is dramatically lower than T cell-mediated responses attained through similar homologous Ad5-
based immunizations, heterologous Ad-based regimens, or vaccination strategies employing 
DNA priming prior to Ad- or vaccinia-based boosting in both preclinical and clinical trials [211, 
212, 267, 276, 288, 289, 321].  Additionally, STEP researchers noted that vaccine-induced CD8+ 
T cell-mediated cytokine responses were 43% lower than those observed in HIV long-term non-
progressors in a North American cohort [416].  Although not empirically evaluated in the STEP 
trial, pre-existing Ad5-specific humoral immunity may have limited vector immunogenicity, 
rendering immunization ineffective at the administered dose.  Furthermore, detailed 
characterization of Ad5-mediated cellular immunity demonstrated that vaccination resulted in 
predominantly CD8+ T cell-biased responses of restricted breadth and polyfunctional capacity.  
Thus, in addition to the quantitative shortcomings of vaccination, a qualitative deficiency may 
have been present, as immunization failed to promote HIV-specific T cell-mediated responses 
against all targeted viral Ags, CD4+ T cell responses of a significant nature, and functional 
heterogeneity within the antiviral cytokine response.  As the precise correlates of T cell-mediated 
inhibition of HIV disease progression are yet undefined, it is imperative that novel vaccination 
strategies are rigorously tested in the preclinical setting to further elucidate the functional 
characteristics and subsequent mechanisms of T cell-mediated control of HIV infection prior to 
their advancement into clinical trials.  
It has been proposed that individuals with pre-existing Ad5-specific immunity would 
undergo Ag-specific expansion of T cell populations following Ad5-based vaccination with 
subsequent redistribution of Ad5-specific effector memory CD4+ T cells to the mucosa, resulting 
in an increased availability of cellular targets susceptible to HIV infection.  This would 
effectively increase the vulnerability of a vaccine recipient to HIV infection, due to the elevated 
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density of permissive target cells within the reproductive and gastrointestinal mucosa.  Recent 
analysis from STEP trial participants has demonstrated that pre-existing Ad5-specific NAb titers 
were not correlated with increased Ad5-specific CD4+ and CD8+ T cell responses [417].  In fact, 
the opposite has been shown, with trends of lower Ad5-specific CD4+ and CD8+ T cell responses 
detected among STEP vaccine recipients with higher Ad5-specific NAb titers, presumably due to 
Ab-mediated opsonization and innate immune clearance of Ad5 vectors prior to the induction of 
T cell-mediated immunity [417].  Notably, vaccine recipients who contracted HIV during the 
STEP trial had lower Ad5-specific CD4+ T cell-mediated responses when compared to vaccinees 
who remained seronegative, indicating that the frequency of Ad5-specific CD4+ T cell in the 
peripheral blood did not correlate with infection.  However, these studies examined Ad5-specific 
cellular immunity in the peripheral blood alone.  As HIV is largely transmitted across the 
mucosal tissues, systemic analysis may not accurately represent the dynamics of Ad5-specific 
effector memory CD4+ T cell infection, as has been previously shown in HIV-specific effector 
memory T cells of the GALT and lymph nodes [39, 50].  Therefore, further analysis is necessary 
to define the mechanism, if any, through which Ad5-based vaccination enhanced the 
susceptibility to HIV infection among STEP vaccine recipients.  Remarkably, STEP participants 
in the placebo group did not receive empty (Ad-ψ5) vectors to control for the delivery of Ad 
particles, eliminating the potential to compare the effects of Ad5-specific CD4+ T cell-mediated 
immune responses with enhanced susceptibility to HIV infection.  Therefore, future evaluation of 
viral vector-based vaccination strategies against HIV must account for the induction of 
deleterious cellular or humoral immune responses through the inclusion of appropriate mock 
controls.  
7.2 FUTURE DIRECTIONS IN HIV VACCINE DEVELOPMENT 
In the brief period I have been involved in the field of HIV vaccine development, I have 
been continually surprised by the ideologic dichotomy between those investigators who 
emphasize humoral immunity and the believers of T cell-mediated responses for the control of 
HIV infection.  The apparent resistance of researchers and funding institutions to empirically 
evaluate intervention strategies encompassing innate, humoral, as well as cellular immune 
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responses may needlessly postpone the discovery of effective correlates of immune protection 
against progressive HIV infection.  This is exemplified by the two major vaccine failures to date 
testing gp120- and Ad5-based vaccine candidates aimed at inducing isolated humoral and 
cellular immunity, respectively.  Additionally, the association of Ad5-specific NAb responses 
with higher rates of HIV acquisition in STEP trial vaccine recipients further emphasizes the need 
to critically evaluate the complex interactions of innate and adaptive immunity to non-
conventional immunogens to fully assess vaccine safety and the mechanisms of immunologic 
protection.  This is not to suggest that immunogens inducing humoral or T cell-mediated 
immunity alone are without merit; merely that their utility lies in the preclinical identification of 
the correlates of protection against HIV infection, furthering our understanding of the precise 
nature of adaptive immunity necessary to prevent or durably contain disease progression.       
In as much, it seems imperative that future HIV vaccine development focuses on 
immunogens or regimens capable of promoting a combined HIV-specific humoral as well as T 
cell-mediated immune response.  Within hours to days following infection, HIV has seeded the 
cells of the mucosa and lymph nodes, creating a cell-associated reservoir sufficient for continued 
viral generation and immune evasion.  As anamnestic T cell responses will take several days to 
develop following HIV exposure, the presence of vaccine-induced mucosal Ab would confer the 
most effective means of preventing or limiting the initial establishment of viral infection.  
Conversely, if a pre-existing humoral immune barrier fails to provide sterilizing immunity, Ab-
mediated responses will likely be incapable of eliminating quickly established cell-associated 
viral reservoirs due to the lack of exposed antigenic targets during latency.  At this point, T cell-
mediated responses capable of eliminating virally-infected host cells and thus limiting cellular 
pathogenesis and viral replication will be of greater benefit.  Furthermore, humoral and cellular 
immune responses will function in concert during chronic HIV infection, effectively inhibiting 
the de novo infection of susceptible host targets while clearing latent cell-associated reservoirs, 
respectively.  In conjunction, activated innate immunity will enhance Ag-specific adaptive 
responses, supplementing antiviral function through non-specific viral inhibition and clearance 
of opsonized viral particles and infected host cells, and facilitating the induction of optimized 
adaptive immunity.  Although individual Ab- or T cell-mediated responses have been shown to 
prevent or inhibit SIV replication alone under optimal experimental conditions, a dynamic 
 128 
immune response combining both compartments of the adaptive immune system will likely be 
necessary to contain clinical HIV infection.          
As a preventative intervention remains unavailable, immunotherapeutic strategies to 
prolong asymptomatic infection and augment antiviral immunity must be explored.  Advances in 
our understanding of the CD4+ T cells dynamics within cellular homeostasis and HIV 
pathogenesis suggest that methods to therapeutically regenerate CD4+ T helper lymphocyte 
populations during chronic HIV infection may lead to durable containment of disease.  As the 
gold standard clinical indicator for progression to AIDS, CD4+ T cells have long been 
acknowledged to play the crucial role in the development of immunodeficiency.  Superior ART 
regimens reduce the rate of disease pathogenesis, but are unable to completely prevent viral 
replication and subsequent exhaustion and destruction of the CD4+ T cell compartment.  
Although 32 drugs have been approved to interrupt the HIV life cycle, no pharmacologic agent 
has been developed which effectively promotes CD4+ T cell regeneration.  In support of this 
idea, findings in the nonhuman primate have demonstrated that adoptive transfer of autologous 
CD4+ T cells during established SIV infection is sufficient to promote immunocompetence and 
long-term nonprogressor status in the absence of ART [418].  Furthermore, techniques for the 
efficient ex vivo propagation of autologous CD4+ T cells are currently being explored, as 
therapeutic CD4+ T cell delivery may provide the support necessary to continually 
immunologically suppress disease regardless of the development of viral immune and drug 
evasion mutations [419].  In conjunction, preclinical immunogenicity studies have demonstrated 
that during experimental CD4+ T cell depletion, immunization utilizing a DNA-prime, MVA-
boost fails to promote dynamic, polyfunctional cellular immunity as compared to vaccination in 
the presence of T lymphocyte assistance, suggesting that any therapeutic vaccination may be 
insufficient in the absence of appropriate CD4+ T cell-mediated support [420].  Therefore, 
pharmacologic or immunologic strategies aimed at enhancing thymopoiesis and the peripheral 
expansion of the CD4+ T cell compartment must be actively pursued, as restoring cellular T cell 
homeostasis may provide greater clinical benefit then augmenting HIV-specific immunity alone.         
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7.3 CONCLUDING REMARKS 
For over a quarter of a century, dedicated researchers of unmatched creativity have 
struggled tirelessly to develop a cure for HIV infection.  The current lack of a preventative or 
therapeutic vaccine reflects greatly upon the monumental challenge presented by the biology and   
pathology of the human immunodeficiency virus itself.  Nevertheless, adversity has inspired 
ingenuity, as the pursuit of a cure has lead to remarkable advancements in the fields of 
immunology, virology, and vaccine development.  In the wake of agonizing vaccine failures and 
collective disappointments, incremental progress continues to being made in our understanding 
of the nature of HIV-associated disease and our technical ability to intervene therein.  It is upon 
this foundation of knowledge established by those investigators past and present that the cure 
will eventually be found.                 
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